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ABSTRACT
The adrenal steroids are known collectively as corticosteroids and consist of
mineralocorticoids and glucocorticoids. They are synthesised in the adrenal cortex,
and exert effects on metabolism and biosynthesis in virtually every organ and tissue
in the body. The enzyme 1lB-hydroxysteroid dehydrogenase (11G-HSD) catalyses
the interconversion of the active glucocorticoids (Cortisol and corticosterone) with
their inactive metabolites (cortisone and 11-dehydrocorticosterone), thus regulating
glucocorticoid access to intracellular corticosteroid receptors. 11B-HSD type 1 is a
bi-directional NADP(H)-dependent enzyme in vitro, and is expressed in many
tissues throughout the body. It is highly expressed in liver, where it is regulated by
glucocorticoids, thyroid hormones, oestrogen and growth hormone in vivo.
However, very little is known about the role of 11B-HSD-1 in liver, or even its
reaction direction, although it is well placed to modulate the action of hepatic
glucocorticoid receptors. 11B-HSD-1 activity is also present in the hippocampus
where it may modulate the potentially deleterious effects of glucocorticoids on
neuronal survival and function. The purpose of this thesis was to investigate the
regulation and function of 11B-HSD-1 in liver and in the hippocampus.
A culture system was established for rat primary hepatocytes which
maintained high levels of 11G-HSD-1 activity and mRNA expression. I used this
system to examine the role and regulation of hepatic 11B-HSD-1. 11B-HSD-1 was
found to be an exclusive 116-reductase (reactivation of inert metabolites), with
alterations in pH and cellular NADP/NADPH ratios having little or no effect on
reaction direction. Glucocorticoids induced 11B-HSD-1 and insulin antagonised this
effect in primary hepatocytes, indicating their regulation is directly mediated.
Growth hormone, oestradiol and thyroid hormone had no effect on 11B-HSD-1
expression or activity in this system, suggesting their control was either lost in
culture or is indirectly mediated. Examination of 11B-HSD-1 activity in a liver
perfusion system by measurement of glucocorticoid metabolism across the intact
liver confirmed that 1 IB-reduction is the predominant reaction in this organ with
approximately 40% conversion of 11-dehydrocorticosterone to corticosterone on a
single pass through the liver. These data suggest that hepatic 11B-HSD-1 activity in
liver potentially increases intrahepatic active glucocorticoid levels. Many hepatic
enzymes of carbohydrate and fat metabolism are regulated by glucocorticoids,
including phosphoenolpyruvate carboxykinase (PEPCK), the rate-limiting enzyme
in gluconeogenesis, and in humans, 11B-HSD inhibition increases hepatic insulin
sensitivity. Therefore I examined the effect of selective and near complete repression
of hepatic 11B-HSD-1 by oestradiol on glucocorticoid-inducible gene expression in
liver. Oestradiol treatment resulted in reduced expression of glucocorticoid-
inducible genes, including PEPCK. This effect could not be attributed to a direct
action of oestradiol. Furthermore, inhibition of whole body 11B-HSD by a chemical
inhibititor, carbenoxolone, lowered fasting blood glucose. These data suggest that
11B-HSD-1 plays an important role in potentiating glucocorticoid action in the liver
and illustrate the potential to alter gluconeogenesis/insulin sensitivity by
manipulating hepatic 11B-HSD-1 activity.
Examination of the regulation of hippocampal 11B-HSD-1 demonstrated that
intracerebroventricular administration of growth hormone had no effect on 11B-
HSD-1 mRNA expression. This is in direct contrast with the periphery, where
growth hormone is a major regulator. Examination of 118-HSD-l activity in the
hippocampus and liver in a well-documented model of chronic psychosocial stress in
the tree-shrew showed that chronic stress attenuates hippocampal 11B-HSD-1
activity, whereas excess glucocorticoid administration has no effect. In contrast, in
the liver, both chronic stress and glucocorticoid administration decrease activity. In
hippocampus, this attenuation of 11B-HSD-1 appears to be an effect of stress, rather
than glucocorticoid excess per se. Attenuated hippocampal 11B-HSD-1 may reflect
an homeostatic response to minimise the adverse effects of prolonged stress or
glucocorticoid excess. These data demonstrate that the regulation of 11B-HSD-1 in
the hippocampus differs from that in the periphery, thus indicating that the function




LIST OF FIGURES 3
LIST OF TABLES 6
ABBREVIATIONS 7
CHAPTER 1: INTRODUCTION 9
1.1 Adrenocortical Steroids 10
1.1.1 Adrenal Corticosteroid Biosynthesis 10
1.1.2 Control of Glucocorticoid Secretion 11
1.1.3 Corticosteroid Release and Circulation 15
1.1.4 Glucocorticoid Metabolism 15
1.1.5 Glucocorticoid Action 17
1.1.6 Mineralocorticoid Secretion and Action 19
1.2 Steroid Receptors 22
1.2.1 The Steroid Receptor Superfamily 22
1.2.2 Glucocorticoid Receptors 24
1.2.3 Mineralocorticoid Receptors 25
1.3 7 lfi-Hydroxysteroid Dehydrogenase 27
1.3.1 1 lB-Hydroxysteroid Dehydrogenase Type 2 27
1.3.2 1 lB-Hydroxysteroid Dehydrogenase Type 1 - Purification and
Cloning 30
1.3.3 116-Hydroxysteroid Dehydrogenase Type 1 - Tissue-Specific
Modulator of Glucocorticoid Receptor Function? 32
1.3.4 1 lB-Hydroxysteroid Dehydrogenase Type 1 - Hormonal
Regulation 36
1.4 Hepatic Glucose Metabolism 39
1.4.1 Effects of Glucocorticoids on Metabolism 39
1.4.2 The Role of the Liver in Glucose Metabolism 39
1.4.3 Hormonal Regulation of Liver Glucose Metabolism 41
1.4.4 Regulation of Expression of the Genes of Hepatic Glucose
Metabolism 43
1.4.5 Insulin Resistance and Non-Insulin-Dependent Diabetes
Mellitus 47
AIMS OF THE THESIS 52
CHAPTER 2: MATERIALS AND METHODS 53
2.1 Materials 54
2.1.1 Sources 54
2.2.2 Preparation of routinely used buffers and materials 55
2.2 SteroidAnalysis Techniques 58
2.2.1 In Vitro Assay of 116-Dehydrogenase Activity of 11B-HSD 58
2.2.2 In Vitro Assay of 1 lB-Reductase Activity of 11B-HSD 60
2.2.3 Quantitation of 11G-HSD Activity in Intact Cells 61
2.2.4 Quantitation of 11B-HSD Activity in Cell Homogenates 61
2.2.5 Protein Estimation 62
2.2.6 High Pressure Liquid Chromatography 63
2.2.7 Thin Layer Chromatography 63
2.2.8 Preparation of Samples for Gas Chromatography-Mass
Spectrometry 64
2.2.9 Gas Chromatography-Mass Spectrometry 65
2.2.10 Synthesis of [3H]-11-Dehydrocorticosterone 65
2.3 Primary Rat Hepatocyte Cultures 66
2.3.1 Hepatocyte Isolation 66
2.3.2 Primary Hepatocyte Culture Conditions 67
2.3.3 Hormonal Manipulation of Hepatocyte Cultures 67
2.3.4 Measurement of the Effects of Oxidative Stress on Hepatocyte
Cultures 68
2.3.5 Metabolic Studies in Hepatocyte Cultures 69
2.3.6 pH Manipulations of Hepatocyte Medium 69
2.3.7 Inhibition of 11B-HSD-1 Activity by Carbenoxolone Treatment
of Hepatocyte Cultures 70
2.3.8 Analysis of the Products of 11-Dehydrocorticosterone
Metabolism 70
2.3.9 NADP and NADPH Extraction and Quantitation from
Hepatocytes 70
2.3.10 Charcoal Stripping of Nu-serum 71
2.4 11J3-HSD Activity Studies in Y1 Adrenocortical Cells 72
2.4.1 Maintenance of Y1 cells in culture 72
2.4.2 Calcium Phosphate Transfection of Cells 72
2.5 Liver Perfusion Studies 73
2.5.1 The Liver Perfusion System 73
2.5.2 Inhibition of 116-HSD-l Activity by Carbenoxolone in
Perfused Liver 74
2.5.3 Analysis of the Products of 11-Dehydrocorticosterone
Metabolism 74
2.6 In Vivo Studies 75
2.6.1 Animal Maintenance 75
2.6.2 Adrenalectomy ± Oestradiol Treatment 75
2.6.3 Carbenoxolone Administration and Glucose Tolerance Tests 76
2.6.4 Adrenalectomy ± Adrenal Steroid Replacement 76
2.6.5 Intracerebroventricular Administration of Growth Hormone 76
2.7 DNA Preparation 78
2.7.1 Plasmid Vectors 78
2.7.2 Bacterial Transformation 79
2.7.3 Plasmid DNA Preparation 79
2.7.4 Plasmid DNA Minipreparation 80
2.7.5 Restriction Endonuclease Digestion and Electrophoresis of
DNA 81
2.7.6 32P-Labelling ofDNA Fragments 82
2.8 Northern Analysis ofRNA 83
2.8.1 Extraction of RNA from tissues and cells 83
2.8.2 RNA Electrophoresis and Capillary Transfer 84
2.8.3 Hybridisation to 32P-Labelled cDNAs 84
2.9 Statistics 85




3.2.1 Optimisation of Culture Conditions for Maintenance of 116-
HSD Activity and Measurement of Enzyme Direction 88
3.2.2 Products of 11 -Dehydrocorticosterone Metabolism in
Hepatocyte Cultures 91
3.2.3 116-Reductase Activity Predominates Under Conditions of
Oxidative stress, Metabolic Inhibition and Altered pH in
Hepatocyte Cultures 91
3.2.3.1 Oxidative stress of Hepatocyte Cultures 96
3.2.3.2 Effects ofMetabolic Inhibitors on Hepatocyte Cultures 96
3.2.3.3 Effects of pH Manipulations on 116-HSD-l in Hepatocyte
Cultures 97
3.2.4 116-HSD-l Expression in Y1 Adrenocortical Cells 100
3.2.5 Hormonal regulation of 11B-HSD-1 in hepatocytes in culture 100
3.2.5.1 The Effects of Glucocorticoids and Insulin Upon 116-
HSD-1 Activity and mRNA Expression in Hepatocyte
Cultures 103
3.2.5.2 The Effects of Oestradiol, Growth Hormone and Thyroid
Hormone Upon 116-HSD-l Activity and mRNA
Expression in Hepatocyte Cultures 103
3.3 Discussion 106
CHAPTER 4: THE ROLE OF HEPATIC 116-HSD-l: IN VIVO STUDIES 111
4.1 Introduction 112
4.2 Results 114
4.2.1 Effect of Attenuation of Hepatic 116-HSD-l by Chronic
Oestradiol Treatment on Hepatic Glucocorticoid Modulated
Gene Expression 114
4.2.1.1 Effect of Chronic Oestradiol Treatment on 116-HSD-l
Activity and mRNA Expression 114
4.2.1.2 Effect of Oestradiol on Hepatic Glucocorticoid-Inducible
Gene Expression 114
4.2.1.3 Effect of Oestradiol ± Adrenalectomy on Hepatic
Glucocorticoid-Inducible Gene Expression 114
4.2.1.4 Effect of Oestradiol on Endogenous Hepatic Metabolism
of Corticosterone 119
4.2.2 The Effect of Carbenoxolone Administration on 116-HSD-l and
Glucose Tolerance 119
4.2.3 116-HSD-l Activity in the Obese Zucker Rat 131
4.2.4 116-HSD-l Activity in the 116-HSD-l "Knock-Out" Mouse 131
4.3 Discussion 137
CHAPTER 5: THE FUNCTION OF 116-HSD-1 IN PERFUSED LIVER 144
5.1 Introduction 145
5.2 Results 146
5.2.1 116-HSD-l Activity Across the Intact Perfused Liver 146
5.2.2 Effect of Route of Delivery Upon 11B-HSD-1 Activity in the
Perfused Liver 146
5.2.3 Effect of Substrate Concentration on 11B-HSD-1 Activity in the
Perfused Liver 148
5.2.4 Carbenoxolone Inhibition of 11B-HSD-1 Activity in the
Perfused Liver 148
5.2.5 Products of 11-Dehydrocorticosterone Metabolism Across the
Perfused Liver 148
5.2.5 Carbenoxolone Inhibition of 11B-HSD-1 in Hepatocyte
Cultures 153
5.3 Dissussion 157
CHAPTER 6: THE IN VIVO REGULATION OF 11B-HSD-1 163
6.1 Introduction 164
6.2 Results 167
6.2.1 Thyroid Hormone Regulation of Hepatic 11B-HSD-1 in the
Mouse 167
6.2.2 Sexual Dimorphism of 116-HSD-l Activity in the Mouse 167
6.2.3 The Effects of Adrenalectomy and Glucocorticoid Replacement
Upon 11B-HSD-1 170
6.2.4 The Effects of Chronic Stress and Glucocorticoid
Administration Upon 11B-HSD Activity in the Tree-Shrew 172
6.2.5 Effect of Introcerebroventricular Administration of Growth
Hormone on 11B-HSD-1 mRNA Expression in the Brain 177
6.3 Discussion 179
CHAPTER 7: DISCUSSION 185
REFERENCES 189
PUBLICATIONS FROM THIS THESIS 247
DECLARATION
I declare that this thesis was written entirely by me, and that all the work presented
within it is the results of my own efforts, except for the procedures listed below
which are also acknowledged in the text. Where assistance was given with surgical
procedures, this is also acknowledged in the text.
This work has not been and is not concurrently submitted for any other degree.
Glucose and insulin assays and plasma electrolyte analyses were carried out by Dr.
Mark Lindsay of the Metabolic Unit, Western General Hospital.
GCMS operation was carried out by Dr. Ruth Best of the Department of Medicine,
University of Edinburgh, Western General Hospital.
Lactate analyses were carried out by Professor Stephen Chapman of the Department
of Chemistry, University of Edinburgh.
Surgical procedures were carried out with the assistance of Sharon Rossiter and
Keith Chalmers of the Biomedical Research Facility, Western General Hospital, and





I would firstly and especially like to thank my supervisors Jonathan Seckl
and Karen Chapman for their help and support over the last three years. Jonathan for
giving me the opportunity to join his laboratory in the first instance and for his
continuing encouragement and enthusiasm, particularly when things were not
running so smoothly, and Karen for always being there when I needed advice and for
taking time to share some of her vast knowledge of molecular biology with me.
I thank those gave of their valuable time to assist me with laboratory assays
and animal studies, particularly Sharon Rossiter who always managed to
accommodate my demands and June Noble for helping out with all sorts of stuff
when my hands were not enough to meet the task. Also thanks to Keith, Andy and
Vince for their assistance with the animals.
I an indebted to Dr. Brian Walker for his useful discussions on my work, his
help in designing some experiments, and his comments as co-author on my work,
which always furthered my knowledge and understanding.
Thanks for moral, and often practical support from everyone in the Molecular
Endocrinology laboratory, particularly Roger Brown, Michael Voice, Ruth Best, Val
Lyons, and Jill Smith.
Lastly, I would like to gratefully acknowledge the financial support of The
Wellcome Trust which enabled me to complete this PhD.
2
LIST OF FIGURES
Figure 1.1: The basic steroid ring structure 11
Figure 1.2: Corticosteroid biosynthesis in the adrenal cortex 12
Figure 1.3: The hypothalamic-pituitary-adrenal axis: a schematic outline 14
Figure 1.4: The major pathways of Cortisol metabolism in vivo 16
Figure 1.5: The renin-angiotensin-aldosterone system 21
Figure 1.6: The steroid receptor superfamily: Sequence identities 23
Figure 1.7: The major reactions catalysed by 116-HSD in man and rat 27
Figure 1.8: 1 lB-hydroxysteroid dehydrogenase in AME 28
Figure 1.9: Glucocorticoid effects on fuel metabolism in the liver and the
periphery 40
Figure 1.10: Schematic representation of glucose metabolism 42
Figure 1.11: Hepatic glycolytic and gluconeogenic pathways 44
Figure 1.12: Regulation of glucose by insulin and glucagon in the resting
state, starvation and in post-prandial conditions 48
Figure 1.13: Basal glucose regulation in normal conditions, islet
dysfunction insulin resistance and islet dysfunction with insulin
resistance 50
Figure 2.1: 11B-HSD-1 activity with varying protein concentrations 59
Figure 3.1: 11B-HSD-1 mRNA expression in primary hepatocyte cultures 89
Figure 3.2: 11B-HSD-1 activity of cultures maintained in DMEM/F12 or
Williams E medium 90
Figure 3.3: 118-HSD-l activity in primary hepatocyte cultures 92
Figure 3.4: 11B-HSD-1 activity in intact hepatocytes over a range of
substrate concentrations 93
Figure 3.5: Time course of 11B-HSD-1 activity in intact hepatocytes 94
Figure 3.6: Products of 11 -dehydrocorticosterone metabolism in hepatocyte
cultures 95
Figure 3.7: Effect of metabolic manipulations on 11B-HSD-1 activity in
hepatocyte cultures 98
Figure 3.8: Effect ofmetabolic inhibitors on (a) NADP/NADPH levels and
(b) NADP/NADPH ratios in hepatocyte cultures 99
Figure 3.9: Effect of pH on 11B-HSD-1 activity in hepatocyte cultures 101
Figure 3.10: 11B-HSD activity in Y1 adrenocortical cells transiently
transfected with 11B-HSD-1 cDNA 102
3
Figure 3.11: Regulation of 11B-HSD-1 (a) activity and (b) mRNA
expression in hepatocyte cultures by dexamethasone and insulin 104
Figure 3.12: Effects of oestradiol, growth hormone and thyroid hormone on
116-HSD-l activity in hepatocyte cultures 105
Figure 4.1: Effect of oestradiol administration on 11B-HSD-1 activity 115
Figure 4.2: Oestradiol repression of hepatic 11B-HSD-1 mRNA expression
in liver 116
Figure 4.3: Effect of oestradiol on hepatic PEPCK mRNA expression in
liver 117
Figure 4.4: Effect of oestradiol on glucocorticoid-modulated hepatic gene
expression 118
Figure 4.5: Effect of adrenalectomy and oestradiol on hepatic 11B-HSD-1
mRNA expression 120
Figure 4.6: Effect of adrenalectomy and oestradiol on hepatic 11B-HSD-1
activity and mRNA expression 121
Figure 4.7: Effect of adrenalectomy and oestradiol on hepatic PEPCK
mRNA expression 122
Figure 4.8: The effect of oestradiol on hepatic gene expression is dependent
upon adrenal steroids 123
Figure 4.9: Effect of carbenoxolone administration on hepatic 11B-HSD-1
activity 124
Figure 4.10: Effect of carbenoxolone administration on fasting plasma
glucose 126
Figure 4.11: Effect of carbenoxolone administration on glucose tolerance 127
Figure 4.12: Effect of carbenoxolone administration on fasting plasma
insulin 128
Figure 4.13: Effect of carbenoxolone administration on insulin secretion 129
Figure 4.14: Effect of carbenoxolone administration on plasma electrolytes 130
Figure 4.15: 11B-HSD-1 activity in obese Zucker rats 132
Figure 4.16: 11B-HSD activity in the 11B-HSD-1 "knock-out" mouse 136
Figure 5.1: 11B-HSD-1 activity across the intact perfused liver 147
Figure 5.2: Effect of route of delivery upon 1 lB-reductase activity in the
perfused liver 149
Figure 5.3: Effect of route of delivery upon 1 lB-dehydrogenase activity in
the perfused liver 150
Figure 5.4: Effect of substrate concentration upon 1 lB-reductase activity in
the perfused liver 151
4
Figure 5.5: Carbenoxolone inhibition of 1 lii-reductase activity in the
perfused liver 152
Figure 5.6: Products of 11-dehydrocorticosterone metabolism in the
perfused liver 155
Figure 5.7: Carbenoxolone inhibition of 11B-HSD-1 in (a) hepatocyte
cultures and (b) homogenised liver 156
Figure 6.1: Thyroid hormone regulation of hepatic 11B-HSD-1 in the
mouse 168
Figure 6.2: Lack of Sexual dimorphism of 11B-HSD activity in mice 169
Figure 6.3: Time course of the effect of sham adrenalectomy upon hepatic
11B-HSD-1 mRNA expression 171
Figure 6.4: Time course of the effect of adrenalectomy and dexamethasone
replacement upon hepatic 116-HSD-l 173
Figure 6.5: Time course of the effect of adrenalectomy and dexamethasone
replacement upon hippocampal llft-HSD-1 174
Figure 6.6: Time course of the effect of adrenalectomy and dexamethasone
replacement upon renal 11J3-HSD 175
Figure 6.7: The effects of chronic stress and glucocorticoid administration
upon llfi-HSD activity in the tree-shrew 176
Figure 6.8: Effect of introcerebroventricular administration of growth
hormone upon 11B-HSD-1 mRNA in brain 178
5
LIST OF TABLES
Table 2.1: Protein concentrations routinely employed in the 11B-HSD
dehydrogenase assay 60
Table 2.2: HPLC elution times of the major metabolites of corticosterone 64
Table 2.3: Steroid hormone content of Nu-serum before and after charcoal
stripping 71
Table 2.4: Plasmid vectors 78
Table 2.5: Restriction enzymes used to isolate fragments of cDNA from
plasmids 82
Table 3.1: Lactate concentration in the medium overlying the cells and 116-
HSD-1 activity following exposure to varying concentrations of
02 97
Table 4.1: Products of corticosterone metabolism in liver homogenates from
gonadectomised male rats receiving oestradiol for 42 d and
control animals receiving vehicle 125
Table 4.2: Plasma levels of 11-dehydrocorticosterone following 14 d of
carbenoxolone administration as measured by GCMS 131
Table 4.3: 11B-HSD-1 activity in obese Zucker rats and lean controls 133
Table 4.4: 11B-HSD activity in the 11B-HSD-1 "knock-out" mouse 134







































1 lB-hydroxysteroid dehydrogenase type 1



































GR - glucocorticoid receptor
HPA axis - hypothalamic-pituitary-adrenal axis
HPLC - high pressure liquid chromatography
ICV - intracerebroventricular






mmol/L: mM - millimolar
mg - milligram
min - minute
mH20 - millipore water
ml - millilitre
MR - mineralocorticoid receptor
mRNA - messenger ribonucleic acid
pg - microgram
NAD - nicotinamide adenine dinucleotide
NADP - nicotinamide adenine dinucleotide phosphate
NADPH - nicotinamide adenine dinucleotide phosphate - reduced form
NIDDM non-insulin dependent diabetes mellitus
PEPCK - phosphoenolpyruvate carboxykinase
POMC - proopiomelanocortin
RNA - ribonucleic acid
rpm - revolutions per minute
s - second
SAMS - S-adenosylmethionine synthetase
SDS - sodium dodecyl sulphate
SEM - standard error of the mean
SSC - saline-sodium citrate
T3 - triiodothyronine (thyroid hormone)
TAT - tyrosine aminotransferase
TLC - thin layer chromatography
TRIS tris (hydroxymethyl) methyamine
UV - ultraviolet






The steroid hormones are all derivatives of cholesterol and are of two types:
those with an intact steroid nucleus including the gonadal steroids (oestrogens,
progestins and androgens) and the adrenal steroids, and those in which the B ring of
the steroid is broken - these are vitamin D and its derivatives. The adrenal steroids
are known collectively as corticosteroids and consist of mineralocorticoids and
glucocorticoids. They are synthesised in the adrenal cortex, and exert effects on
metabolism and gene expression in virtually every organ and tissue in the body.
Corticosteroids exert their effects through two types of receptors - mineralocorticoid
receptors (MR) and glucocorticoid receptors (GR). Regulation of corticosteroid
levels is achieved at the levels of steroid synthesis and metabolism. Corticosteroids
are metabolised in many tissues by enzymes, including 1 lB-hydroxysteroid
dehydrogenase (11B-HSD), which specifically regulates levels of active
glucocorticoid within the body's tissues.
1.1.1 Adrenal Corticosteroid Biosynthesis
The adrenal cortex is subdivided into three concentric morphologically
distinct zones (Arnold et al., 1866). The zona glomerulosa lies just under the capsule
and constitutes about 15% of the cortex. It is responsible for the production of the
major mineralocorticoid, aldosterone. The zona fasiculata lies inside the
glomerulosa, constitutes about 75% of the cortex and together with the innermost
cortical layer, the zona reticularis, is responsible for the production of the
glucocorticoids Cortisol and/or corticosterone, as well as significant amounts of
adrenal androgens in some species.
The starting point for adrenocortical steroid synthesis is cholesterol, the basic
steroid ring structure of which (Fig. 1.1) is conserved throughout the biosynthetic
pathways operating in the adrenal cortex (Fig. 1.2).
The C19 steroids have a keto group attached to C17 and possess weak
androgenic activity. Dehydroepiandrosterone and its sulphated form are qualitatively
the major products of the human adrenal gland and may function as precursors
which are converted to testosterone and oestrogens, largely in the periphery (Nimrod
& Ryan, 1975).
Progesterone and 17a-hydroxyprogesterone have a two-carbon side-chain
attached to C17, and undergo 21-hydroxylation (Kominami et al., 1980) followed by
1 lB-hydroxylation to yield the C21 steroids corticosterone (B) and Cortisol (F)
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Figure 1.1: The basic steroid ring structure.
The numbering represents the conventional designation of carbon atoms.
respectively. F is the major glucocorticoid in many species including man, but in
rodents B predominates. C21 steroids have both mineralocorticoid and
glucocorticoid properties with small structural differences responsible for
determining which property predominates (Fig. 1.2). Aldosterone - the major
mineralocorticoid - possesses an 11,18-hemiacetal bridge, preventing its use as a
substrate for 116-HSD type 2 (116-HSD-2) (section 1.3.1) (Edwards and Hayman,
1991). The synthesis of aldosterone from deoxycorticosterone is catalysed by P-
450cn (aldosterone synthase) (Chua et al., 1987), which is found only in the zona
glomerulosa and is distinct from the P-450cn involved in the synthesis of
glucocorticoids in the zona fasiculata (Chua et al., 1987). The latter enzyme lacks the
ability to catalyse the 18-methyl oxidation reaction required for the final step in
aldosterone synthesis.
1.1.2 Control of Glucocorticoid Secretion
Glucocorticoid synthesis and release from the adrenal cortex is controlled
almost entirely by adrenocorticotrophic hormone (ACTH) released from the anterior
pituitary which is in turn regulated by corticotrophin releasing hormone (CRH),
arginine vasopressin (AVP) and other agents released from the hypothalamus into
the hypophyseal portal circulation in response to neural stimuli (reviewed by Jones
11
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Figure 1.2: Corticosteroid biosynthesis in the adrenal cortex.
The pathways for synthesis of glucocorticoids, mineralocorticoids, adrenal
androgens are shown. 36-HSD, 313-hydroxysteroid dehydrogenase. Taken from Orth
et al., 1992.
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& Gillham, 1988; Antoni 1993, 1986). The inhibitory effect of glucocorticoids on
CRH, AVP and ACTH synthesis and secretion completes the negative feedback loop
which regulates their plasma concentration (Fig. 1.3). The system is known as the
hypothalamic-pituitary-adrenal axis (HPA axis) and is reviewed in Orth et al., 1992.
ACTH is a 39-amino-acid peptide produced in the anterior pituitary by
cleavage and extensive post-translational processing of a large precursor
polypeptide, pro-opiomelanocortin (POMC) (Eipper & Mains, 1980). CRH is the
major physiological ACTH secretogogue (Vale et al., 1981). It is synthesised by
neurones in the parvicellular division of the hypothalamic paraventricular nucleus
(Bloom et al., 1982) whose axons project to the median eminence where CRH is
secreted into the hypophyseal portal blood. On reaching the anterior pituitary, it
binds to cell surface receptors on the corticotrophes (Millan et al., 1987), stimulating
ACTH secretion within seconds and also increasing synthesis of POMC mRNA
(Lundblad & Roberts, 1988). AVP alone is a weak stimulator of ACTH secretion,
but it potentiates the action of CRH (DeBold et al., 1984).
In addition to the homeostatic negative feedback loop controlling
glucocorticoid secretion described above, there are other factors known to affect
glucocorticoid release. Glucocorticoid and ACTH secretion exhibit a circadian
rhythm in humans and other species (Krieger et al., 1971; Veldhuis et al., 1990).
This is modified by sleep and light patterns such that in humans, pulse amplitude of
ACTH secretion reaches a peak in the few hours before wakening and declines
throughout the day to reach a nadir in the evening. Plasma glucocorticoid levels rise
and fall in response to the pattern of ACTH release, thus reaching maximal levels in
the early morning. The mechanism of this circadian rhythm is unclear. There is
probably an endogenous pacemaker in the suprachiasmatic nucleus of the
hypothalamus (Szafarczyk et al., 1979), but environmental stimuli play an important
role.
Stress stimulates ACTH secretion by increasing hypothalamic secretion of
CRF and AVP. Both physical and psychological stresses such as exercise, trauma,
surgery, cold exposure, fear and depression activate the HPA axis.
Finally, in addition to the negative feedback inhibition of glucocorticoids on
ACTH secretion, they also inhibit POMC gene transcription and hence POMC
synthesis (Lundbland & Roberts, 1988), and decrease CRF and AVP mRNA and
peptide levels in the paraventricular nucleus of the hypothalamus (Itoi et al., 1987).
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Figure 1.3: The hypothalamic-pituitary-adrenal axis: a schematic outline.
Refer to the text for details. +ve = stimulation.
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1.1.3 Corticosteroid Release and Circulation
The primary action of ACTH on the adrenal cortex is to stimulate
steroidogenesis (Hall, 1985), thus increasing glucocorticoid secretion and causing
circulating glucocorticoids to rise within minutes following ACTH release (Simpson
& Waterman, 1983, 1988). In addition, ACTH stimulates adrenal growth, thus
maintaining adrenal weight under normal physiological circumstances but resulting
in adrenal hypertrophy and hyperplasia if levels are supraphysiological as in
pituitary-dependent hyperadrenocorticism, and adrenal atrophy in the absence of
ACTH (Gill, 1972).
Corticosteroid hormones are released immediately following synthesis with
only small amounts stored in the gland (Dickerman et al., 1984). Circulating steroid
hormones are largely bound to plasma proteins. Plasma F and B are largely bound to
corticosteroid-binding globulin (CBG) or transcortin (70-80%) with 3-4% circulating
free, whilst the remainder is bound to albumin (Dunn et al., 1981; Partridge, 1981;
Hammond, 1990). In contrast, only 20% of aldosterone is bound to CBG and 40% to
albumin leaving the remaining 40% non-protein bound or free (Dunn et al., 1981;
Partridge, 1981). However the total concentration of circulating aldosterone (350
pM) is tiny in comparison with that of glucocorticoid (approximately 500 nM)
(Dunn et al., 1981). Steroids are also associated with red blood cells, and
erythrocyte-associated Cortisol actually exceeds that which is albumin bound or free
(Hiramatsu & Nisula, 1987; Hammond et al., 1987). The circulating half-life of F is
50-90 minutes, whilst that of aldosterone is 15-25 minutes.
1.1.4 Glucocorticoid Metabolism
The processes of glucocorticoid metabolism can be divided into hepatic and
extrahepatic. The hepatic metabolism of glucocorticoids involves reduction,
oxidation, hydroxylation and conjugation (Orth et al., 1992) and is outlined in Fig.
1.4 for F. Reduction of the double bond is important for glucocorticoid inactivation,
and it appears this is the most important pathway, and the rate-limiting step in the
metabolism of active glucocorticoids (Peterson, 1981). 56-reduction predominates
over 5a-reduction, although both activities occur resulting in 5a/B-dihydrocortisol.
The 3-keto group is then reduced by 3a/6-hydroxysteroid dehydrogenases to yield
tetrahydrocortisols. 3a-hydroxysteroid dehydrogenase predominates so that the

































CORTOLONIC ACIDS 11 HYOROXYETIOCHOLANOLONE CORTOLIC ACIDS
Figure 1.4: The major pathways of Cortisol metabolism in vivo.
Width of the arrows indicates the relative importance of the pathways under normal
conditions. SCC, side chain cleavage activity; 6B-OHASE, 6B-hydroxylase; 20 HSD,
20a-hydroxysteroid dehydrogenase; 11B-HSD, 1 lB-hydroxysteroid dehydrogenase;
3a-HSD, 3 a-hydroxysteroid dehydrogenase; 21 OX, 21-oxidase. Taken from Orth et
al„ 1992.
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glucocorticoids is mainly carried out by 11B-HSD, which is the subject of this thesis
(see section 1.3).
1.1.5 Glucocorticoid Action
Glucocorticoids have widespread and varied actions. Their more obvious
physiological effects are demonstrated in the disease states of glucocorticoid
deficiency and excess, but it should be remembered that they have permissive and
modulatory action on the ability of tissues to respond to other hormones and so exert
their effects on most, if not every, system in the body.
Glucocorticoid excess, such as occurs in long term exogenous administration
or Cushing's disease, results in redistribution of body fat from the periphery to the
abdomen, hypertension, impaired glucose tolerance, impaired immune responses and
degenerative changes to muscle and connective tissue which are manifest as thin
skin, bruising and muscle weakness. Conversely, in corticosteroid deficiency or
Addison's disease, the weight loss, hypotension, hypoglycaemia and muscular
weakness observed are due in part to lack of glucocorticoids. The effects of
glucocorticoids upon fuel homeostasis are discussed in section 1.3. Their other
actions are described briefly here.
Glucocorticoids have profound immunosuppressive effects (Graham &
Tucker, 1984). They deplete the numbers of lymphocytes in the peripheral
circulation by redistributing them from the intravascular compartment to the spleen,
lymph nodes, thoracic duct and bone marrow (Facui & Dale, 1974; Yu et al., 1974).
They inhibit the phagocytic and cytotoxic functions of macrophages (Rinehart et al.,
1982) and their proliferation, as well as that of T-cells and B-cells (Ishii et al., 1983,
Gillis et al., 1979; Cupps et al., 1985) and of monocytes. Glucocorticoids inhibit the
accumulation of neutrophils at the site of inflammation (Dale et al., 1975) and also
inhibit the release of mediators responsible for the inflammatory response.
Prostaglandin and kinin synthesis are inhibited by glucocorticoids (Kantrowitz et al.,
1975; Hong & Levine, 1976) thus inhibiting the local inflammatory response
(Zweifach et al., 1953).
Glucocorticoids affect bone metabolism and connective tissue function.
Chronic glucocorticoid excess causes osteopenia. Glucocorticoids inhibit osteoblast
function (Frost & Villanueva, 1961; Jowsey & Riggs, 1970) which results in
decreased formation of new bone, and increased osteoclast cell numbers (Hahn et al.,
1979) which may stimulate bone resorbtion. They also decrease intestinal calcium
absorption (Klein et al., 1977) and increase urinary calcium secretion by a decrease
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in renal reabsorption (Laake, 1960). The profound myopathy that can result from
glucocorticoid excess is due to the catabolic effect on muscle protein and
glucocorticoids inhibit fibroblast functions including proliferation (Pratt & Aronow,
1966) and collagen and hyaluronidate synthesis (Sterling et al., 1983; Mapleson et
al., 1981). This is manifest clinically as impaired wound healing and friable
connective tissues (Leibovich & Ross, 1975).
Glucocorticoid excess is associated with hypertension, often without
mineralocorticoid excess, kaliuresis or suppressed plasma renin activity (Krakoff et
al., 1975; Saruta et al., 1986). Glucocorticoids have affinity for MR but evidence for
this being the mechanism is insubstantial (Grunfeld, 1985). Thus the basis for the
hypertension associated with glucocorticoid excess is poorly understood, but may
reflect actions on resistance vessels, or on sodium pumps through mechanisms
distinct from the Na/K ion exchange.
In glucocorticoid deficiency, there is a defect in free water clearance (Slessor,
1951) associated with increased plasma AVP concentrations (Raff, 1987) and, in
rats, an increase in AVP mRNA levels in the paraventricular nucleus of the brain
(Davis et al., 1986). There are GR in the AVP-producing cells in the paraventricular
nucleus (Uht et al., 1988) and the increase in AVP may contribute to maintaining
blood pressure in adrenal insufficiency (Schwartz et al., 1983). Removal of the
adrenals with the capsule and zona glomerulosa left intact results in an inability to
excrete a salt load (Gaunt et al., 1967 & 1968) and glucocorticoid replacement
results in naturesis due in part to induction of secretion and synthesis of atrial
naturetic factor from cardiac myocytes (Matsuraba et al., 1987).
Glucocorticoids have a direct effect on sodium transport in the colon (Sandle
et al., 1987). There are MR in the colon which regulate ion transport but a
glucocorticoid mediated effect has also been demonstrated (Bastl et al., 1987 &
1988). In addition Na+/K+-ATPase oci and B-subunit gene expression in the rat
descending colon is acutely regulated by the synthetic glucocorticoid dexamethasone
(DEX) but not aldosterone (Fuller & Verity, 1990).
Glucocorticoids have multiple effects on the central nervous system (CNS)
including modulation of sleep patterns, mood, cognition and reception of sensory
input (McEwan, 1979). Over half of patient's with Cushing's syndrome have
psychological disturbances, most commonly depression (Cohen, 1980) but euphoria,
manic behaviour and even overt psychosis may occur (Christy, 1979). Adrenal
insufficiency is linked to depression, apathy and lethargy. The mechanisms of these
effects are unclear. Neurones in the CNS contain GR and MR but neuronal responses
are often more rapid than is likely to be mediated via classical steroid receptor-gene
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interactions. Glucocorticoids are directly neurotoxic (Sapolsky, 1985, 1986, 1992)
causing cell death by increasing neuronal vulnerability to a wide range of other
insults by inhibiting glucose uptake and potentiating intracellular Ca++ release
(Virgin et al., 1991; Elliot & Sapolsky, 1993).
Lastly, glucocorticoids have profound effects on many aspects of
development. They regulate organ development and stimulate the maturation of
many cell types (Ballard, 1979). For example, glucocorticoids stimulate the
production of surfactant from type II pneumocytes, a normal developmental process
occurring in the foetus before birth (Cole et al., 1995; Mendelson & Boggaram,
1991). Clinically, exogenous glucocorticoids can be employed to accelerate this
process when premature birth is imminent (Ballard, 1987). In the developing
nervous system, glucocorticoids regulate the differentiation of neural crest
epithelium cells into chromaffin cells (Federoff et al., 1988). Glucocorticoid
exposure in utero retards foetal growth in rats (Benediktsson et al., 1993), is
associated with retarded foetal growth in humans (Reinisch et al., 1978) and may
increase or decrease placental weight depending on dose and/or timing of the
exposure (Gunberg, 1957). Foetal growth retardation has been linked to the risk of
developing high blood pressure or ischaemic heart disease in later life in humans
(Barker et al., 1989a; 1989b; Barker et al., 1990) and in rats (Benediktsson et al.,
1993). Neonatal manipulations can "programme" HPA axis responses, a permanent
effect probably attributable to altered GR expression in the brain (LaRocque et ah,
1992; Meaney et al., 1993) and brief prenatal glucocorticoid exposure has permanent
effects on central noradrenergic activity (Slotkin et al., 1992).
1.1.6 Mineralocorticoid Secretion and Action
Aldosterone secretion is influenced primarily by the renin-angiotensin system
and by plasma levels of potassium (Fig 1.5). ACTH and other POMC-derived
peptides also have minor regulatory roles (Quinn & Williams, 1988).
Renin is secreted from the juxtaglomerular cells of the renal cortex in
response to lowered renal arterial blood pressure, lowered sodium concentration in
the tubular fluid and sympathetic nerve stimulation (Gibbons et al., 1984).
Angiotensinogen is an a2 globulin synthesised in the liver and is cleaved by the
enzymic action of renin to yield angiotensinogen I (Goodfriend et al., 1984) which
has no known biological activity but is converted rapidly to angiotensin II by
angiotensin converting enzyme (ACE), mainly in the pulmonary capillary
endothelium (Page, 1974; Ryan et al., 1975). Plasma renin levels are the rate limiting
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factor in this process (Williams & Dluhy, 1983). Angiotensin II is a powerful
vasoconstrictor and stimulates aldosterone synthesis and secretion (Goodfriend et al.,
1984) in the adrenal zona glomerulosa. Potassium directly stimulates aldosterone
synthesis in the adrenal (McKenna et al., 1978). Renin release is directly inhibited by
angiotensin II, hyperkalaemia and atrial naturetic factor (Williams & Dluhy, 1983;
Rebuffat et al., 1988), and indirectly by aldosterone mediated tubular sodium
reabsorption and plasma volume expansion, thus completing the negative feedback
loop.
Aldosterone is the principal physiological mineralocorticoid. Its most
important action is in the distal tubules and cortical collecting ducts of the kidney
where it promotes active sodium reabsorption in exchange for potassium and
hydrogen ions, thus regulating extracellular volume and hence blood pressure. In the
sweat glands and salivary glands, aldosterone promotes sodium chloride resorbtion
in the primary secretions in exchange for potassium and bicarbonate. This is
important physiologically to conserve salts in situations where sweating or salivary
loss are excessive (Morris, 1981).
Aldosterone may also have effects on the brain and other non-epithelial
tissues where MR are present (Moguilewsky & Raynaud, 1980; Armanini et al.,
1985). Intracerebroventricular (ICV) infusion of low concentrations of aldosterone
promotes salt appetite and increases blood pressure, an effect not mimicked or




Figure 1.5: The renin-angiotensin-aldosterone system.
A schematic outline. See text for details. ACE, angiotensin-converting enzyme.
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1.2 Steroid Receptors
1.2.1 The Steroid Receptor Superfamilv
In the classical model, steroid hormones exert their effects by binding to
intracellular steroid hormone receptors. These ligand-activated receptors function as
nuclear transcription factors which modulate cell function by activating or repressing
target genes or gene networks (reviewed by Beato et al., 1996; Ribeiro et al., 1995).
Many of the known steroid receptors have been cloned, and as a result we
know a great deal about the structure of steroid receptors. Following cloning of the
major rat and human steroid receptors (reviewed by Green & Chambon, 1988;
Evans, 1988; Berg, 1989; Beato, 1989; O'Malley, 1990; King 1992), sequence
comparisons revealed they belong to a highly homologous family (Fig. 1.6). The
steroid receptor superfamily includes GR, MR, thyroid hormone (TRoci, TRbi, TRb2,
c-erbAa2), vitamin D (VDR), retinoid (RARa, RARg, RARy, RXRa, RXRg, RXRy),
progesterone (PR), oestrogen (ER) and androgen (AR) receptors. Other superfamily
members have been cloned, but do not have ligands, or the ligands are yet to be
identified. These receptors are known as orphan receptors (reviewed by O'Malley,
1990; Mills & Duggan, 1994; Laudet & Adelmant, 1995; Mangelsdorf & Evans,
1995) and it has been suggested their ligands may be indigenous to the cells in which
specific orphan receptors are found (O'Malley, 1990).
Steroid receptor proteins have molecular masses of around 65 to 100 kDa.
Each receptor protein binds a single steroid molecule, but the receptors usually
dimerise when bound to DNA (Perlmann et al., 1990; Kumar & Chambon, 1988;
Baniahmad & Tsai, 1993; Yu et al., 1991). Comparative analyses of the cloned
receptors reveals a conserved domain structure (Fig 1.6). The most highly conserved
domain is the cysteine-rich DNA binding domain (O'Malley & Tsai, 1993; Ribeiro et
al., 1995), located towards the centre of the receptor, and within this domain, the
most distinctive feature is the zinc finger structure (Freedman, 1993). The DNA
binding domain contains a number of highly conserved cysteine residues which co¬
ordinate two zinc ions tetrahedrally to form two zinc fingers (Freedman et al., 1988;
Freedman, 1993; Freedman & Luisi, 1993; Glass, 1994), and the zinc atom is
essential for DNA binding (Freedman et al., 1988). The zinc fingers confer
specificity for the steroid response element, are required for and stabilise the
receptor-DNA interaction (Danielson et al., 1989; Mader et al., 1989; Freedman &
Luisi, 1993; Glass, 1994), and are involved in dimerisation of the zinc binding
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Figure 1.6: The steroid receptor superfamily: Sequence identities.
There are three highly conserved regions, the DNA-binding domain and two regions
within the ligand-binding domain. Numbers indicate the percentage identity to GR,
which has been arbitrarily assigned 100%.
23
finger contains a perpendicularly oriented a-helix which extends from the base of
the finger. The first (N-terminal) zinc finger helix interacts with DNA in the major
groove and confers sequence specificity of binding whilst the second zinc finger, in
addition to participating in binding-specificity, may direct subunit interactions and
specify alignment of half-sites (Freedman & Luisi, 1993; Glass, 1994). Steroid
receptors bind to DNA response elements of only two distinct sequence motifs
related to either of the consensus half site sequences, AGAACA or AGGTCA, and
DNA specificity appears to be determined by the orientation and relative spacing of
these motifs (Freedman & Luisi, 1993).
The ligand-binding domain, located at the C-terminus is also highly
conserved throughout all members of the family (O'Malley & Tsai, 1993; Ribeiro et
al., 1995). The C-terminus is also associated with a number of functions regulated by
ligand-binding, including heat-shock protein dissociation, translocation to the
nucleus, ligand-dependent transcriptional-activation, homodimerisation,
heterodimerisation and potential protein-protein interactions with other steroid
receptors and transcriptional regulatory factors (Baniahmad & Tsai, 1993; Green &
Chambon, 1988; Glass, 1994; Parker et al., 1993; Janknecht & Hunter, 1996;
Chakravarti et al., 1996; Kamei et al., 1996). In contrast, the N-terminal domain is
not conserved and in GR is a major immumoreactive epitope (Carlstedt-Duke et al.,
1982). It contains ligand-independent transcriptional activation functions and may
interact with other transcriptional activation proteins in complex response elements
(Ribeiro et al., 1995).
1.2,2 Glucocorticoid Receptors
Glucocorticoids, like all steroid hormones, are thought to enter cells by
passive diffusion (although there is evidence that thyroid hormone (T3) and retinoic
acid entry may involve specific transport processes (Baxter, 1994)) and bind to the
C-terminal ligand binding domain of their receptors (Ribeiro et al., 1995). The GR is
a single chain polypeptide of about 90 kD, and is associated with several heat shock
proteins including heat shock protein 90 (hsp90) (Rexin et al., 1992; Baniahmad &
Tsai, 1993; Beato et al., 1996; Pratt, 1993). Glucocorticoid binding leads to the
dissociation of hsp90 from the receptor, thus "activating" it (Sanchez et al., 1987;
Baniahmad & Tsai, 1993) and enabling it to bind to DNA (Denis et al., 1988;
Meshinchi et al., 1990). The activated receptor-hormone complex then translocates
to the nucleus - a function dependent on a sequence in the ligand-binding domain
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and a sequence in the hinge region between the DNA and ligand-binding domains
(Picard & Yamamoto, 1987; Picard et al., 1990; Ylikomi et al., 1992).
Activated GR bind as homodimers to specific regulatory DNA sequences
called glucocorticoid response elements (GREs). GREs are frequently located near
the promoter region of the target genes (Beato, 1989; Baniahmad & Tsai, 1993) and
the GRE is a partially pallindromic structure with the consensus sequence
AGAACAnnnTGTTCT (Scheidereit et ah, 1983; Strahle et ah, 1987). The DNA
binding domain of the receptor provides specificity for DNA, but high affinity
binding requires additional regions of the receptor (Danielson et ah, 1987).
Transcriptional activation and repression by GR are not fully understood.
Sequences in the N-terminal domain, the DNA binding domain and the hormone
binding domain are all important for efficient transcriptional activation (Beato et ah,
1996). One model for transcriptional activation by steroid receptors proposes that the
DNA-bound hormone receptor complex interacts with the transcriptional machinery
of the cell to form an activation complex (Ptashne, 1986, 1988). Another suggests
the DNA-bound hormone receptor complexes realign or displace nucleosomes to
allow transcription factor binding to previously inaccessible regions of the target
gene promoter (Archer et ah, 1991). Glucocorticoids also repress transcription of
genes (e.g. POMC, prolactin (Ludbland & Roberts, 1988; Drouin et ah, 1987; Sakai,
1988)). However, no clear consensus negative response element has been identified
(Beato et ah, 1996). Transcriptional repression may be due to competition for
common DNA-binding sites, interference of bound receptors with the activity of
other transcription factors or the transcriptional machinery (Beato et ah, 1996).
1.2.3 Mineralocorticoid Receptors
Mineralocorticoid action is mediated by the classical receptor for
aldosterone, MR, which shows a high degree of conservation with GR (Fig 1.6)
Curiously, MR binds both glucocorticoids and mineralocorticoids in vitro with
approximately equal affinity (Krozowski & Funder, 1983; Arriza et ah, 1988). In
vivo, however, MR binds aldosterone selectively in kidney, parotid and colon, but F
or B is the physiological ligand in the heart and hippocampus. Cloning of human
MR (Arriza et ah, 1987) and GR (Hollenberg et ah, 1985) demonstrated that the
receptors are highly homologous in the DNA binding and ligand binding domains,
but distinct in the N-termini. The DNA binding-domain is particularly highly
conserved between MR and GR, with 94% homology, and both receptors can bind to
the GRE (Freedman, 1993). Isolation of a MR cDNA from a rat brain cDNA library
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showed that MR in kidney and brain are identical (Arriza et al., 1988; Patel et al.,
1989). Therefore receptor differences cannot confer the tissue-specific ligand
selectivity ofMR.
Recombinant human MR and GR expressed in mammalian cells are both
activated by F and B, and MR is activated at 10-fold lower concentrations than GR
(Arriza et al., 1988). Thus MR does not appear to have the intrinsic ability to
discriminate between glucocorticoids and mineralocorticoids, and indeed, is a high
affinity receptor for glucocorticoids in vitro. Arriza et al. (1987, 1988) speculated
that both MR and GR may provide responses to glucocorticoids in vivo, with MR
providing a high-sensitivity, low response function and GR a low-sensitivity, high
response function. This model may be particularly relevant to cells where MR and
GR are co-expressed, such as hippocampal neurones (Evans & Arriza, 1989).
The aldosterone-selectivity of MR in vivo, is provided at least in part, by the
enzyme 116-HSD-2 (Morris & Souness, 1992), which is co-expressed with the MR
intracellularly, and metabolises glucocorticoids to inactivate them. Thus aldosterone,
which is not a substrate for the enzyme has sole access to the receptors.
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1.3 llR-Hvdroxvsteroid Dehydrogenase
116-HSD catalyses the reversible conversion of the physiologically active
glucocorticoids (F in humans and B in rats) and their inactive 11 -dehydro forms
(cortisone (E) and 11-dehydrocorticosterone (A)) (Fig. 1.7). The enzyme is thus well
placed to act as a tissue specific regulator of glucocorticoid access to intracellular
corticosteroid receptors (Monder & White, 1993; Seckl, 1993). 11B-HSD activity
has been described in studies since the 1950s in many body tissues (Amelung et al.,
1953; Hubener et ah, 1956). However it was not until the 1970s that its importance
became apparent, with the recognition of 11B-HSD deficiency as a clinical syndrome
(Werder et ah, 1974; New & Levine, 1977; New et ah, 1977; Ulick et ah, 1977,
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Figure 1.7: The major reactions catalysed by 11B-HSD in man and rat.
1 lB-dehydrogenase activity results in oxidation of the hydroxyl group at Cll to an
inactive 11-keto group, whilst 1 lB-reductase catalyses the reverse reaction.
1.3.1 11 B-Hydroxvsteroid Dehydrogenase Type 2
In 1975, the first case of a rare syndrome of severe hypertension and
hypokalaemia, in the absence of detectable plasma renin and low aldosterone was
described (Werder et ah, 1975). Thus the syndrome became known as "apparent
mineralocorticoid excess" (AME). F and ACTH infusion into a AME patient
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exacerbated the hypertension and hypokalaemia, whilst spironolactone (an MR
antagonist) and DEX (a selective GR agonist) reversed the syndrome (Oberfield et
al., 1993). F to E metabolism had previously been demonstrated to be impaired in
this syndrome by measurement of urinary metabolites (New & Levine, 1977; New et
ah, 1977; Ulick et ah, 1977, 1979), whilst 1 IB-reduction appeared to be unaffected
(Ulick et ah, 1979; Monder et ah, 1986), leading to the proposal that 11B-
dehydrogenase activity was impaired in AME such that intra-renal F levels would be
raised sufficiently to occupy and activate MR (Stewart et ah, 1988) (Fig 1.8). This
hypothesis was supported by studies based on the observation that liquorice
ingestion results in similar metabolic abnormalities to AME, with hypertension and
kaliuresis (Card et ah, 1953; Conn et ah, 1968; Stewart et ah, 1987), which are again
reversible by spironolactone or DEX treatment (Salassa et ah, 1962; Hoefnagels &
Kloppenborg, 1983) and that administration of glycyrrhetinic acid (GE) - the active
component of liquorice - to animals, inhibited renal 11B-HSD both in vivo and in
vitro (Monder et ah, 1989).
I i
Normal AME
Figure 1.8: 1 lB-hydroxysteroid dehydrogenase in AME.
Absence of 11B-HSD activity results in failure of normal MR protection and allows
illicit occupation receptor occupation and activation by F. See text for details.
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Thus it was proposed that the in vivo selectivity of renal MR (which bind
both glucocorticoids and mineralocorticoids with similar affinity in vitro) was due to
the inactivation of glucocorticoids by 11B-HSD activity, and this was demonstrated
in experimental studies (Edwards et al., 1988; Funder et al., 1988).
11B-HSD was cloned from the rat liver in 1989 (Agarwal et al., 1989)
(section 1.3.2). However, rather than concluding the story, this raised as many
questions as it answered. Polyclonal antibody staining demonstrated 11B-HSD
immunoreactivity in the proximal convoluted tubules of the kidney (Edwards et al.,
1988; Lakshmi & Monder, 1988; Rundle et al., 1989), whereas MR are located in the
distal convoluted tubules and cortical collecting duct cells (Rundle et al., 1989;
Farman et al., 1991), and 116-HSD activity is found in both microdissected proximal
and distal rabbit tubules (Bonvalet et al., 1990). Kinetic studies on the liver-derived
11B-HSD indicated a pM Km for F and B (Agarwal et al., 1990) - insufficient to
exclude circulating glucocorticoids (present at approximately 500 nM (Dunn et al.,
1981)) from MR, which has a Kd for B of approximately 0.5 nM (Arriza et al., 1987;
Krozowski & Funder, 1983). The cloned 11B-HSD cDNA encoded both 11B-
dehydrogenase and 1 lB-reductase activities, but AME patients appear to have a
selective 116-dehydrogenase deficiency, with 1 lB-reductase unaffected (Ulick et al.,
1979; Monder et al., 1986). Furthermore, genetic analysis of AME patients revealed
no gross deletions or rearrangements of the corresponding 11B-HSD gene (Nikkila et
al., 1993; White et al., 1995). Finally, biochemical studies demonstrated a distinct
NAD-dependent, high affinity 11B-HSD isoform in kidney (Mercer & Krozowski,
1992; Rusvai & Naray-Fejes-Toth, 1993) where it co-localised with MR (Rundle et
al., 1989, Farnan et al., 1991), and in placenta (Brown et al., 1993). Therefore the
weight of evidence suggested a distinct isoform of 11B-HSD was responsible for MR
aldosterone selectivity (Edwards et al., 1989; Funder, 1990, 1993; Stewart &
Edwards, 1990).
This isozyme (termed 11B-HSD-2) has recently been cloned from cDNA
libraries made from sheep, human, rat, mouse and rabbit kidney (Agarwal et al.,
1994; Albiston et al., 1994; Zhou et al., 1995; Cole TJ, 1995; Naray-Fejes-Toth &
Fejes-Toth, 1995) and human placenta (Brown et al., 1996). As predicted, 11B-HSD-
2 has a high affinity (Km in the nM range) for its glucocorticoid substrates, utilises
NAD as co-factor, and is an exclusive 116-dehydrogenase, thus rapidly inactivating
glucocorticoids. 11B-HSD-2 expression is confined to aldosterone-target tissues
(kidney, parotid, colon), the placenta, and a limited number of other sites (Albiston
et al., 1994; Whorwood et al., 1995; Brown et al., 1996). Mutations in the 11B-HSD-
2 gene have been identified in AME patients (Mune et al., 1995; Wilson et al.,
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1995a, 1995b; Milford et al., 1995; Ferrari et al., 1996) providing conclusive
evidence for its function of conferring aldosterone selectivity on MR.
In the placenta, 1lB-dehydrogenase activity provides a barrier to the transfer
of active glucocorticoids to the foetus (Beitins et al., 1973; Bernal & Craft, 1981;
Giannopoulos et al., 1982; Waddell et al., 1988). 1 IB-reduction in placenta is low or
undetectable (Osinski, 1960; Kittinger, 1974: Murphy, 1979; Bernal et al, 1980). The
proposed role therefore, of 11B-HSD-2, is to protect the developing foetus from
potentially harmful circulating maternal glucocorticoids (Murphy et al., 1974;
Munck & Leung, 1977; Slikker et al., 1982), exposure to which may retard foetal
growth (Reinisch et al., 1978). Low birthweight is linked to the occurrence of
cardiovascular and metabolic disorders in adult life, particularly hypertension
(Barker et al., 1989; Whincup et al., 1989; Barker et al., 1990) and non-insulin-
dependent diabetes mellitus (NIDDM) (Hales et al., 1991). Placental 11B-HSD-2
activity correlates positively with birthweight, and negatively with placental weight
(Benediktsson et al., 1993) so that individuals with low birthweight and large
placentae are those likely to be exposed to the highest levels of maternal
glucocorticoid, supporting a role for the enzyme in the pathogenesis of hypertension
(Edwards et al., 1993; Seckl, 1994). In keeping with this hypothesis, inhibition of
11B-HSD in pregnant rats by carbenoxolone (CBX) leads to reduced birthweight and
elevated blood pressure in the adult offspring (Lindsay et al., 1996).
However, if 11B-HSD-2 is an exclusive dehydrogenase restricted to a few
target tissues, then which enzyme is responsible for the widely distributed 11B-HSD
activity observed in vivo, with high expression in several organs, including the liver,
and which enzyme provides hepatic 1 lB-reductase activity (Bush, 1969 and Stewart
et al., 1990)?
1.3.2 1 lB-Hvdroxvsteroid Dehydrogenase Type 1 - Purification and Cloning
Whether 116-dehydrogenase and 1 lB-reductase activities were due to the
tissue-specific behavior of a single enzyme (Nicholas & Lugg, 1982; Torday et al.,
1976; Bush & Mahesh, 1959) or to the expression of two separate enzymes
(Abramovitz et al., 1982; Monder & Shackleton, 1984; Lakshmi & Monder, 1985)
was a matter of debate for many years. Since 11B-HSD activity in liver is NADP-
dependent, in 1988, Lakshmi and Monder purified 11B-HSD from rat liver
microsomes using NADP-agarose affinity chromatography (Lakshmi & Monder,
1988). The homogeneous enzyme exclusively expressed 1 lB-dehydrogenase activity
in the absence of 118-reductase, supporting the two enzyme hypothesis.
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Nevertheless, this did not mean the single enzyme hypothesis had to be rejected as
the 1 lB-reductase component of 118-HSD-l had been shown to be labile in
homogenates and purified microsomes, so that the 1 lB-dehydrogenase activity could
be studied in the absence of the 1 lB-reductase activity (Monder, 1993). Rat liver
1 lB-dehydrogenase is a glycoprotein with a monomer molecular weight of 34 kD
(Lakshmi & Monder, 1988), is NADP-dependent, and has a Km for F of
approximately 17jiM and B of 2 jiM (Monder & Lakshmi, 1989; Monder et al.,
1991).
Production of rabbit-antisera against the purified 11B-HSD (Monder &
Lakshmi, 1990) allowed identification of tissue-specific species of the enzyme by
Western analysis, with liver, kidney, testis and lung microsomes containing a single
34 kD protein. Kidney contained an additional 40 kD band and brain an additional
26 kD band. A 68 kD band in liver and kidney was detected - likely to be a dimer of
the 34 kD species. The 26 kD and 40 kD species were suggested to represent further
isoforms of 11B-HSD (Monder & Lakshmi, 1990; Monder, 1991b), but could
represent differences in post-translational modification or differing transcriptional
start sites within the same gene.
The rat "liver type" 11B-HSD was cloned in 1989 (Agarwal et al., 1989) by
screening a rat liver cDNA library with a monospecific anti-serum to 116-HSD. The
cDNA was 1265 bp long and contained a 861 bp open reading frame predicting a
287 residue polypeptide with a molecular weight of 31 774 kDa. The discrepancy
between this, and the 34 kD purified protein is likely to be due to glycosylation of
the mature protein at the two putative N-linked glycosylation sites at residues 158-
160 and 203-205 (Agarwal et al., 1989).
Expression of the full-length cDNA in Chinese hamster cells (CHO) cells
(Agarwal et al., 1989) and human osteosarcoma cells (Agarwal et al., 1990) revealed
that in intact cells, the recombinant protein encoded roughly equal 11B-
dehydrogenase and 11 B-reductase activities, in contrast to the exclusive 11B-
dehydrogenation of the purified protein, thus indicating that both activities reside in
a single enzyme. More recent studies have demonstrated that in most intact cell
types, expression of 11B-HSD-1 is associated with 1 lB-reductase activity, although
1 lB-dehydrogenase activity is readily detectable in homogenates from the same cells
(Low et al., 1994a; Rajan et al., 1995b; Leckie & Seckl, 1996; Chapter 3).
Northern analysis revealed that the rat "liver type" 11B-HSD cDNA
hybridised to a single mRNA species of approximately 1600-1700 nucleotide (nt) in
liver, testis, ovary, lung, vascular tissue and various brain regions (Agarwal et al.,
1989; Moisan et al., 1992b), but cross-hybridised with at least four species in rat
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kidney (Krozowski et al., 1990; Moisan et al., 1992b). Some, but not all of these
could be attributed to variations in the amount of polyadenylation (Krozowski et al.,
1990), and so these transcripts were proposed to represent products of a separate
11B-HSD gene (Krozowski et al., 1990). However, cloning of the rat '"liver type"
11G-HSD gene demonstrated that the multiple species of renal transcripts all result
from products of differential promoter usage (Moisan et al., 1992b).
This isozyme of 11B-HSD has been designated the type 1 isozyme (11B-
HSD-1), and to date, human, monkey, sheep and mouse homologues have also been
cloned (Tannin et al., 1991; Moore et al., 1993; Yang et al., 1992; Rajan et al.,
1995a). The nucleotide sequences show a high degree of conservation across species.
The human 11B-HSD-1 gene has been localised to chromosome 1, consists of 6
exons and is at least 9 kb in length (Tannin et al., 1991). 11B-HSD-1 is a member of
the short chain alcohol dehydrogenase (SCAD) superfamily (reviewed by
Krozowski, 1992), which includes prokaryotic and eukaryotic enzymes involved in a
wide variety of metabolic processes (Baker et al., 1990a; 1990b; Krook et al., 1990;
Tannin et al., 1991). 11B-HSD-1 has highest sequence similarity with the bacterial
enzyme 3a, 20B-HSD (Marekov et al., 1990) which catalyses the reversible
oxidation of 3a and 20B hydroxyl groups of androstane and pregnane derivatives.
However, human 11B-HSD-1 only shares 28.3% sequence homology with 11G-HSD-
2, also a member of the SCAD superfamily (Brown et al., 1996). Members of the
SCAD family involved in steroid metabolism include 17B-HSD and 3B-HSD, but
they are not closely related to 11B-HSD-1. 11B-HSD-1 is a microsomal enzyme
(Monder & White, 1993), and the characteristics of its tertiary structure can be
deduced from comparisons with that of 3a, 20B-HSD (Ghosh et al., 1991). It is
concluded that 11B-HSD-1 has a single active site capable of catalysing both 11B-
dehydrogenation and 1 IB-reduction (Monder, 1993). Protein structure analysis has
shown that the bulk of the protein molecule is orientated on the lumenal side of the
endoplasmic reticulum and that the catalytic domain is located here (Ozols, 1995).
1.3.3 1 lB-Hydroxvsteroid Dehydrogenase Type 1 - Tissue-Specific Modulator of
Glucocorticoid Receptor Function?
The physiological role of 11B-HSD-2 has been established in aldosterone-
target tissues and placenta. However, despite over 40 years of investigation, the
physiological role of 116-HSD-1 is still obscure. The highest levels of 11B-HSD-1
are in the liver and the proximal tubules of the kidney (Monder & Shackleton, 1984).
These are tissues where MR are not significantly expressed, but GR are abundant,
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and it has therefore been proposed that the role of 11B-HSD-1 is to modulate
glucocorticoid access to intracellular GR in these sites (Moisan et al., 1990b;
Teelucksingh et al., 1990; Whorwood et al., 1991). 116-HSD-l is also present in the
hippocampus where MR are present, but the physiological ligand is glucocorticoid
(Moisan et al., 1990a; Sakai et al., 1992; Lakshmi et al., 1991). The possible role of
11B-HSD-1 in these tissues is considered below.
Although the highest levels of 11B-HSD-1 are found in the liver (Monder &
Shackleton, 1984), very little is known about the biology of hepatic 11B-HSD-1.
11 B-reductase activity appears to predominate over 1 lB-dehydrogenase activity in
liver. The effluent of perfused cat liver contains high levels of F with respect to E
(Bush et al., 1969) and in man, oral administration of E leads to a rise in peripheral
plasma levels of F, but not E, on first-pass through the liver (Stewart et al., 1990).
Thus hepatic 11B-HSD-1 is likely to potentiate glucocorticoid action in the liver,
which is a major target for glucocorticoid action and contains high levels of GR.
Many of the hepatic genes encoding key metabolic enzymes are under glucocorticoid
regulation (section 1.4), suggesting an important role for 11B-HSD-1 in this organ.
Pharmacological levels of circulating glucocorticoids directly suppress
testosterone secretion from the testis in rats (Saez et al., 1977) through GR mediated
actions (Bambino & Hseuh, 1981; Welsh et al., 1982). 11B-HSD-1 immunoreactivity
appears in the testes at puberty in the rat (Philips et al., 1989) and it was therefore
hypothesised that the inactivation of B by 11B-HSD-1 removes this inhibition so that
testosterone production and puberty can proceed (Philips et al., 1989). The
observations that 11B-HSD-1 is present only in the Leydig cells and that CBX
potentiates B inhibition of testosterone release in Leydig cell cultures (Abayasekara
et al., 1990) adds weight to this hypothesis (Monder, 1991). However, 11B-HSD-1
has recently been shown to be a predominant 11B-reductase in primary cultures of
Leydig cells (Leckie & Seckl, 1996). In addition, 11B-HSD-1 is not expressed in
mouse testis (Rajan et al., 1995a) and both sexes of a transgenic 11B-HSD-1 "knock¬
out" mouse recently produced are fertile (Kotelevtsev et al., 1996). Thus the role of
11B-HSD-1 in the testis is unclear.
11B-HSD-1 is present in the ovary (Murphy, 1981; Tannin et al., 1991),
located in the oocyte and the luteal body (Benediktsson et al., 1992) as are GR
(Schreiber et al., 1982). A recent study provided evidence that low 11B-HSD activity
in the granulosa-lutein cells is necessary for a viable pregnancy to occur (Michael et
al., 1993a), possibly as corticosteroids inhibit ovarian steroidogenesis (Michael et
al., 1993b). Ovarian 11B-HSD-1 levels fall in metoestrus in rats (Albiston et al.,
1995) suggesting 11B-HSD-1 may play a role in ovarian steroidogenesis and
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ovulation. There is however evidence that 11B-HSD-2 is expressed in the ovary
(Roland & Funder, 1996), which confuses the issue as studies based on measurement
of 11B-HSD activity often do not discriminate between the isozymes making
retrospective interpretation difficult.
11B-HSD-1 immunoreactivity has been demonstrated in skin (Teelucksingh
et al., 1990) and it has long been known that GE and CBX have an anti¬
inflammatory effect in cutaneous disorders (Colin-Jones, 1957). It was postulated
that 1 lB-dehydrogenase inactivated glucocorticoid thus diminishing its effectiveness
(Teelucksingh et al., 1990). This was borne out by the observation that the potency
of topical application of hydrocortisone in causing GR-mediated cutaneous
vasoconstriction (Marks et al., 1982) was potentiated by GE (Teelucksingh et al.,
1990). However Hammami and Siiteri paradoxically reported that 1 IB-reduction is
the primary activity in cultured human skin fibroblasts (Hammami & Siiteri, 1991).
The recent cloning of 11B-HSD-2 has demonstrated that this enzyme is present in
skin (Agarwal et al., 1995; Brown et al., 1996). Therefore it is likely 11B-HSD-1 and
11B-HSD-2 are expressed in different cell types within the skin, and the overall 11B-
HSD activity in skin will represent a balance between the two activities.
The arterial tree is a target for mineralocorticoids and glucocorticoids
(Kornel et al., 1982) and MR and GR are present in the vascular smooth muscle
affecting corticosteroid modulation of muscle tone and neural and humoral
responsiveness (Kornel et al., 1975; Onoyama et al., 1979). 11B-HSD activity was
reported in the arterial vessels (Kornel et al., 1982; Funder et al., 1989) and 11B-
HSD-1 mRNA localised to the vascular smooth muscle (Walker et al., 1991; Takeda
et al., 1994) where it is appropriately located to modulate glucocorticoid access to
GR. 1 IB-reduction is the primary reaction direction in aortic minces and cultured
vascular smooth muscle cells (Brem et al., 1995). The enzyme is primarily in the
smaller vessels and therefore well placed to modulate glucocorticoid effects on
vascular tone and hence peripheral resistance (Walker, 1994), and recent data
employing CBX inhibition of 11B-HSD supports this (Walker et al., 1994b). The
heart also contains a significant amount of 11B-HSD activity (Funder et al., 1973;
Arriza et al., 1987; Walker et al., 1991; Slight et al., 1993), located in the
cardiomyocytes where it is co-localised with MR (Lombes et al., 1995), but there is
conflicting evidence regarding whether the 11B-HSD activity is due to the
expression of 11B-HSD-1 (Walker et al., 1991) or 116-HSD-2 (Lombes et al., 1995).
11B-HSD-1 is also expressed in the cortico-medullary region of the rat
adrenal, where it may serve a role in maintaining high adrenal medullary
glucocorticoid levels which are essential for catecholamine synthesis (Shimojo et al.,
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1996). Furthermore, 11B-HSD-2 mRNA is present in the adrenal in some species
(Agarwal et al., 1995; Roland & Funder, 1996; Li et al., 1996; Campbell et al.,
1996). However, 11B-HSD-1 appears to be absent from the human adrenal gland
(Shimojo et al., 1996).
The brain is a key target for glucocorticoid action, which, in contrast to the
tissues described thus far, is mediated via MR as well as GR (McEwen et al., 1986;
de Kloet, 1991; Seckl & Olsson, 1995). The hippocampus expresses a high density
of MR, which are occupied by B in vivo (de Kloet et al., 1975; Reul & de Kloet,
1985; McEwan et al., 1986; de Kloet, 1991) owing to the intrinsic lack of specificity
of MR for substrate (Arriza et al., 1987) (to date, no convincing evidence for the
presence of 11B-HSD-2 in the adult hippocampus has been presented (Albiston et al.,
1994; Roland et al., 1995)). As MR bind glucocorticoid with a 10-fold greater
affinity than GR, at physiological concentrations, most B will be bound to MR. This
provides the basis for the "tonic action of MR" hypothesis of Reul and de Kloet
(1985), whereby high MR occupancy provides a baseline sensitive to small changes
in glucocorticoid levels for the purpose of monitoring the external environment,
whilst GR occupancy is low when circulating glucocorticoid levels are low but
increases at the diurnal peak or during stress, and activates negative-feedback
systems. A binary response system has also been proposed, where MR and GR do
not act independently, but exert synergistic or competitive control (Evans, 1989).
11B-HSD-1 is expressed in various brain regions, with highest levels in
hippocampal, cerebellar and cortical neurones (Moisan et al., 1990a; Lakshmi et al.,
1991; Sakai et al., 1992). The high 11B-HSD-1 activity and mRNA expression in the
cerebellum which contains no measurable MR (Moisan et al., 1990b), but well
defined GR (Sousa et al., 1989), supports a role for 11B-HSD-1 in the regulation of
glucocorticoid access to GR. 11B-HSD-1 is co-localised with MR and GR in the
hippocampus (Sakai et al., 1992), thereby possibly modulating glucocorticoid access
to both types of receptor. Hippocampal 11B-HSD-1 is induced by chronic
glucocorticoid excess or stress (Low et al., 1994c), and as glucocorticoids exert
deleterious effects on hippocampal neuronal survival and function (Landfield et al.,
1978; Sapolsky et al., 1985, 1986; Sapolsky, 1992), it has been proposed that this
induction is a protective mechanism (Monder, 1991; Low et al., 1994c; Seckl &
Olsson, 1995). However, recent data has shown that the predominant reaction
direction of 11B-HSD-1 in intact cultured hippocampal cells is reduction (Rajan et
al., 1996), thus 11B-HSD-1 activity is likely to potentiate rather than attenuate the
neurotoxic effects of glucocorticoids, as would the glucocorticoid induction of 116-
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reductase activity. Why this should be the case is unclear, and so the role of 1113-
HSD-1 in the brain is as yet unknown.
1.3.4 1 lB-Hydroxvsteroid Dehydrogenase Type 1 - Hormonal Regulation
Many of the studies on 118-HSD have been carried out by measurement of
enzyme activity, which, as mentioned earlier, does not necessarily distinguish
between the separate isozymes. Therefore, in tissues where 11B-HSD-2 is present
activity studies must be interpreted cautiously. However, where mRNA expression
has been examined, or where 11B-HSD-1 is the only isozyme present (liver, brain
and testis), the interpretation of such studies is much clearer.
In rats, there is sexually dimorphic expression of 11B-HSD activity in several
tissues including liver (Ghraf et al., 1975a; Lax et al., 1978, 1979) and kidney (Ghraf
et al., 1975a, 1975b; Smith and Funder 1991) with male rats having higher hepatic
and renal 11B-HSD activity than female rats. This is mediated by sex steroids, as
evidenced by the differences between the sexes appearing at puberty and data from
studies on the effects of administration and withdrawal of sex steroids (Ghraf et al.,
1975a; Lax et al., 1978, 1979). In the liver, sexual dimorphism is due to repression
of 11B-HSD-1 in females (Lax et al., 1978; Low et al., 1993, 1994b) which is
mediated by sex steroid determination of patterns of growth hormone GH secretion
(see below). In the kidney, oestradiol (E2) represses 11B-HSD-1 mRNA expression,
but overall 11B-HSD activity is upregulated (Low et al., 1993, 1994b; Smith &
Funder, 1991), suggesting differential regulation of the 11B-HSD isoforms by E2 in
this tissue. In lung, castration of male rats decreases 1 lB-reductase activity (Nicholas
& Lugg, 1982), whilst hippocampal 11B-HSD-1 is not subject to sex hormone
control (Low et al., 1993). Therefore sex steroid regulation of 11B-HSD appears to
be tissue-specific.
Sexually dimorphic expression of many hepatic steroid metabolising genes is
due to an indirect effect of sex steroids on the secretory profiles of GH (Gustafsson
et al., 1983a, 1983b; Wehrenberg & Giustina, 1992), which differ in male and
female rats (Saunders et al., 1976; Tannenbaum & Martin, 1976; Eden, 1979). Adult
female rats exhibit frequent low amplitude peaks of GH release (1-2 peaks every 2
h), whilst males show lower frequency, high amplitude peaks every 3-4 h, such that
levels often fall below the limits of detection. It is these low troughs that
differentiate the effects of GH between the sexes. Female rats have approximately
50% of the 11B-HSD-1 activity levels of male rats (Lax et al., 1978; Low et al.,
1993, 1994b). This sexual dimorphism requires the presence of an intact pituitary
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(Lax et al., 1978) and is attributable to the actions of E2 on GH secretory patterns
(Low et al., 1994b). However, exogenous E2 administration to both male and female
rats represses hepatic 118-HSD-l activity by up to 95%, and 11B-HSD-1 mRNA
expression to the limits of detection (Low et al., 1993; Chapter 4). In addition, in the
hypophysectomised rat, E2 represses hepatic 11B-HSD-1, albeit to a lesser extent
than in the intact rat (Low et al, 1994b). This suggests that E2 has an additional
regulatory effect on 11B-HSD-1 in the liver independent from its effects on GH
secretory patterns. The lack of regulation of 11B-HSD-1 by sex steroids in the
hippocampus may be due to the failure of peripheral GH to cross the blood-brain-
barrier (Low et al., 1994b).
T3 regulation of 11B-HSD-1 appears to be not only tissue-specific, but also
species-specific. Thus T3 has been reported to decrease 11B-HSD-1 activity in male
rat liver (Koerner & Hellman, 1964; Lax et al., 1979; Whorwood et al., 1993a),
whilst in humans, indirect methods of glucocorticoid metabolism by measurement of
urinary steroids, have indicated that llB-dehydrogenase activity is increased by T3
(Hellman et al., 1961; Gordon & Southren, 1977; Zumoff et al., 1983).
Hypothyroidism or adrenalectomy (ADX) reverses these responses in both species.
Tissue-specificity was demonstrated by a lack of T3 regulation in the rat kidney
(Koerner & Hellman, 1964; Lax et al., 1979; Smith & Funder, 1991; Whorwood et
al., 1993a) - a result confounded by the presence of both 11B-HSD isozymes in this
tissue, and the reticuloendothelial system (Dougherty et al., 1960). Lastly, the
observation that thyroidectomy increases activity in female rat liver, but decreases it
in the male rat (Lax et al., 1979) led to proposals that T3 controls the available
testosterone and thus indirectly influences 11B-HSD. Overall, the available data are
confusing, and whether T3 has a direct or indirect mechanism of action is still
unknown.
It seems likely that glucocorticoids modulate their own metabolism by
regulating 11B-HSD-1. Studies to date have pointed towards a positive regulation of
11B-HSD-1 by glucocorticoids. Indirect evidence came from the demonstration that
the stress of cold exposure or starvation increases 1 lB-reductase in lung (Nicholas &
Lugg, 1982) and in the same study, ADX led to attenuation of E to F conversion. F
increases 11B-HSD activity in thymocytes (Dougherty et al., 1960). Human foreskin
fibroblast cell 11B-HSD activity is increased by DEX in cell culture (Hammami &
Siiteri, 1991), an effect blocked by the GR antagonists RU38486 and dexamethasone
mesylate, and insulin antagonises this action. DEX also induces 11B-HSD activity
and 11B-HSD-1 mRNA in cultured vascular smooth muscle cells, whilst insulin has
the opposite effect (Takeda et al., 1995).
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In the short- and medium-term, glucocorticoids induce 118-HSD activity and
11B-HSD-1 mRNA expression in the liver and hippocampus in vivo, whilst ADX
decreases enzyme activity and expression (Moisan et al., 1990c; Low et al., 1994c,
Walker et al., 1994). Similar effects have recently been reported in testis, where 1113-
HSD-1 is down-regulated by ADX, and restored by B replacement (Gao et al.,
1996). Recently work from this laboratory, using transfection of a liver-derived cell
line with plasmids in which 11B-HSD-1 promoter DNA is fused to a reporter gene,
suggests that a positive GRE lies within 1800 base pairs of the transcription start of
11B-HSD-1 (Voice et al., 1996).
In contrast, 11B-HSD activity in kidney is unchanged by ADX or DEX
treatment (Moisan et al., 1990c; Smith & Funder, 1991). This could represent tissue-
specific glucocorticoid regulation of 11B-HSD-1, or, more likely, represents the
distinct regulation of the 11B-HSD-2 isozyme.
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1.4 Hepatic Glucose Metabolism
1.4.1 Effects of Glucocorticoids on Metabolism
The role of glucocorticoids in fuel homeostasis was recognised in 1927 when
it was noted that ADX animals cannot maintain hepatic glycogen stores (Cori &
Cori, 1927), but that they are restored by corticosteroid administration (Long et al.,
1940). Glucocorticoids regulate the metabolism of carbohydrates, fats and proteins
in the periphery and in the liver (Fig. 1.9). In the periphery, glucocorticoids mobilise
substrate for hepatic gluconeogenesis. They stimulate the release of gluconeogenic
amino acids from skeletal muscle (Exton., 1979; Long et al., 1940) and lipolysis in
adipose tissue is activated (Fain, 1979), thus releasing fatty acids and glycerol for
transport to the liver. Glucocorticoids also have a permissive role in mediating the
effects of other gluconeogenic hormones, such as glucagon and catecholamines
(Exton, 1979; Friedmann et al., 1967), therefore enhancing their peripheral catabolic
effects. Peripheral glucose uptake and utilisation are inhibited by glucocorticoids
(Munck, 1962; LeBoeuf, 1962; Fain et al., 1963), partly by the direct inhibition of
glucose transport into cells (Olefsky, 1975; Livingston & Lockwood, 1975) due to
decreased expression of glucose transporters (Garvey et al., 1989).
The liver contains all the enzymes necessary for the synthesis and
degradation of glucose, glycogen and fat (Fig 1.10), and can switch the direction of
carbon flow over the metabolic pathways in response to hormonal stimuli and
changes in nutritional status (Granner & Pilkis, 1990). These properties are
responsible for the central role of the liver in the regulation of fuel metabolism.
1.4.2 The Role of the Liver in Glucose Metabolism
The liver's role in glucose homeostasis is dependent on its ability to switch
from net glucose output to net glucose uptake in response to a threshold
concentration of blood glucose (Soskin et al., 1938). When a fast is terminated, the
circulating concentration of glucose rises, stimulating insulin secretion which
promotes uptake and conversion of glucose by the liver into the storage products
glycogen and fat (McGarry et al., 1987). However, only a fraction of the glucose
taken up by the liver is converted into glycogen (Madison, 1969; Madison et al.,
1973), and liver glycogen can be synthesised from carbohydrate-derived sources
other than glucose (Cori, 1981). In quantitative terms, glucose-derived lactate rather
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Figure 1.9: Glucocorticoid effects on fuel metabolism in the liver and the periphery.
See text for details.
+ve=stimulation, -ve=inhibition.
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than glucose itself serves as the precursor for hepatic glycogen synthesis (McGarry
etal., 1987).
The liver is, for practical purposes, the sole source of endogenous glucose
production. Under fasting conditions, in the short term approximately 75% of
hepatic glucose production results from glycogenolysis by glycogen phosphorylase,
and the remainder comes from gluconeogenesis (Fig 1.10). In prolonged fasting (24-
48 h), hepatic glycogen stores become depleted and gluconeogenesis is the sole
source of glucose production (Cryer, 1992). Precursors for hepatic gluconeogenesis
are obtained from the breakdown of muscle protein, lipolysis and ketogenesis and
transported to the liver in the circulation.
Glycolysis is the metabolic pathway through which glucose is utilised in
order to generate ATP and NAD(P)H to fuel cell metabolism (Fig 1.10). The energy
needs of the liver are largely provided by the B-oxidation of fatty acids (Cryer, 1992)
under normal conditions, and the glycolytic flux is low except when glucose
concentrations are high, so that the main function of hepatic glycolysis is to generate
substrate for anabolic pathways.
1.4.3 Hormonal Regulation of Liver Glucose Metabolism
The main glucoregulatory hormones are insulin, glucagon, catecholamines,
glucocorticoids and GH. The dominant glucose-lowering hormone is insulin
(Service, 1983; Cryer, 1988; Cryer et al., 1989) which is secreted from the B cells of
the pancreas into the portal circulation. It promotes glycogen synthesis and inhibits
hepatic glycogenolysis and gluconeogenesis, thus limiting hepatic glucose
production in the post-absorptive state, in order to regulate plasma glucose levels
(Rizza et al., 1981). It also promotes glucose uptake and utilisation in the periphery.
The glucose-raising hormones act synergistically to effect glucose
counterregulation (Shamoon et al., 1981). Glucagon is secreted from pancreatic islet
cells and acts solely on the liver under physiological conditions to activate
glycogenolysis and gluconeogenesis, increasing hepatic glucose production within
minutes (Cryer et al., 1989). Adrenalin also stimulates hepatic glucose production
and limits glucose utilisation via both direct (Rizza et al., 1980; Clutter et al., 1988;
Diebert & DeFronzo, 1980; Rosen et al., 1983) and indirect mechanisms (limiting
insulin secretion (Berk et al., 1985; Clutter et al., 1988) and stimulating glucagon
secretion (Gerich et al., 1978; Gray et al., 1980)). Physiological concentrations of
GH initially lower plasma glucose, but after a few hours, stimulate glucose














Figure 1.10: Schematic representation of glucose metabolism.
Taken from Cryer, 1992.
hyperglycaemic effect of F is only seen after 2-3 hours (Shamoon et al., 1981).
Glycaemic status controls these glucoregulatory hormones such that hypoglycaemia
suppresses insulin secretion and stimulates glucagon, adrenalin, GH and F release
(Cryer et al., 1989).
Glucocorticoids activate glycogen synthase (Hornbrook et al., 1966;
Stalmans & Laloux, 1979) by promoting its dephosphorylation, and inhibit glycogen
phosphorylase (Stalmans & Laloux, 1979), thus promoting glycogen synthesis and
storage (Fig. 1.10). How glucocorticoids bring about glycogen synthase
dephosphorylation is unclear. They may activate a specific hepatic phosphatase or
exert an indirect effect through glycogen phosphorylase which is a phosphorylase
inhibitor. Glucocorticoids also directly activate and repress the expression of the key
hepatic enzymes of glycolysis and gluconeogenesis (reviewed by Exton, 1979).
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1.4.4 Regulation of Expression of the Genes of Hepatic Glucose Metabolism
The balance between hepatic glucose production and utilisation is controlled
by the movement of substrates through three major cycles operated by the major
enzymes of glycolysis and gluconeogenesis (Fig. 1.11). The relative and absolute
activities of these key enzymes dictate the net flux and pace of glucose movement
through the pathways, and they are therefore the main targets of regulatory
mechanisms. The enzymes are subject to both acute and chronic regulation. The
acute regulatory effects are mediated by the supply of substrates and hormonally-
induced allosteric changes and phosphorylation (reviewed by Hers & Hue, 1983;
Pilkis et al., 1988). The principle targets for acute regulation are 6-phosphofructo-l -
kinase (PFK-1), fructose 1,6-bisphosphatase (FBPase-1) (regulated by availability of
fructose 2,6-bisphosphate (FBP-2)), pyruvate kinase (PK) (hormonally regulated by
phosphorylation and dephosphorylation) and 6-phosphofructo-2-kinase/fructose-2,6-
bisphosphatase (PFK-2/FBPase-2). Chronic effects involve changes in the rates of
gene expression and hence protein synthesis, and in some instances by changes in
the rate of degradation of specific mRNAs (reviewed by Granner & Pilkis, 1990;
Pilkis & Granner, 1992; Lemaigre & Rousseau, 1994). The hormonal and nutritional
regulation of the key regulatory enzymes of glycolysis and gluconeogenesis are
summarised briefly here.
Conditions favouring gluconeogenesis, e.g. starvation, result in an increase of
phosphoenolpyruvate carboxykinase (PEPCK), FBPase-1 and glucose 6-phosphatase
(G-6-Pase) activities and a co-ordinate decrease in PK, PFK-1 and glucose kinase
(GK) activities (Granner & Pilkis, 1990; Pilkis & Granner, 1992; Lemaigre &
Rousseau, 1994). Directly opposing effects are seen upon refeeding, and glycolysis
predominates. Glycolysis begins with the efficient conversion of glucose to glucose-
6-phosphate (G-6-P) by GK, which is not subject to feedback inhibition and is not
altered by post-translational modifications (Granner & Pilkis, 1990). Thus activity is
directly related to protein levels. Regulation of the expression of hepatic genes is
predominately controlled at the level of mRNA transcription (Derman et ah, 1991)
and GK gene transcription is potently (20-30 fold) induced by insulin (Sibrowski &
Seitz, 1984; Andreone et ah, 1989) within minutes (Nouspikel & Iynedjian, 1992).
Glucagon (or its intracellular messenger cAMP) inhibits GK transcription, and is the
dominant control (Magnusson et al., 1989; Iynedjian et al., 1989). In cultured
hepatocytes, glucocorticoids enhance the stimulation of GK gene transcription by









Figure 1.11: Hepatic glycolytic and gluconeogenic pathways.
Key regulatory enzymes and their substrates are shown. GK, glucose kinase; G-6-
Pase, glucose 6-phosphatase; PFK-2/FBPase-2, 6-phosphofructo-2-kinase/fructose-
2,6-bisphosphatase; PFK-1, 6-phosphofructo-l-kinase; FBPase-1, fructose-1,6-
bisphosphatase; PEPCK, phosphoenolpyruvate carboxykinase; PK, pyruvate kinase;
G-6-P, glucose 6-phosphate; Fru-6-P, fructose 6-phosphate; FBP-2, fructose 2,6-
bisphosphate; FBP-1, fructose 1,6-bisphosphate; PEP, phosphoenolpyruvate; OAA,
oxaloacetate.
44
PFK-2/FBPase-2 is a dual action enzyme which catalyses the synthesis and
degradation of FBP-2, which exerts a strongly positive regulation on PFK-1. It
therefore can provide a "switch" between glycolysis and gluconeogenesis (Pilkis et
al., 1988). PFK-2/FBPase-2 protein levels fall in starvation and diabetes, although
mRNA levels do not, suggesting a translational mechanism or enhanced protein
degradation may be responsible for the decrease in protein (Colosia et al., 1988;
Crepin et al., 1988). Refeeding and insulin restore PFK-2/FBPase-2 protein levels by
increasing gene transcription (Colosia et al., 1988). Glucocorticoids directly increase
PFK-2/FBPase-2 gene transcription (Marker et al., 1989; Lange et al., 1989;
Kummel & Pilkis, 1990), as does insulin at the cessation of fasting (Colosia et al.,
1988; Crepin et al., 1988; Miralpeix et al., 1992). Glucocorticoids and insulin act
synergistically (Granner & Pilkis, 1990). Their effects require the presence of
glucose and are inhibited by glucagon acting through cAMP (Granner & Pilkis,
1990; Espinet et al., 1993). Glucagon also destabilises PFK-2/FBPase-2 mRNA
(Rosa et al., 1993). Insulin effects depend on the hormonal context and can
antagonise glucocorticoid induction of mRNA synthesis in some situations
(Lemaigre et al., 1994).
PFK-1 catalyses the conversion of fructose-6-phosphate to fructose-1,6-
bisphosphate which is the first rate-limiting step in glycolysis. Activity is reduced in
diabetes and in the fasting state, and mRNA levels are increased upon insulin
administration and refeeding respectively (Dunaway et al., 1978; Gehnrich et al.,
1988), an effect partially blocked by cAMP. This suggests that PFK-1 gene
expression is also under reciprocal control by insulin and cAMP, but this has not
been confirmed.
PK is the last key regulatory enzyme in glycolysis and catalyses the
conversion of phosphoenolpyruvate into pyruvate. Regulation of gene transcription
is very complex. Like PFK-1, PK activity and mRNA are reduced in diabetes and in
the fasting state, and levels are restored by insulin administration and refeeding
(Vaulont et al., 1986; Noguchi et al., 1985). The stimulatory effect of insulin is slow
in onset suggesting induction of another gene product may be required (Vaulont et
al., 1986). Glucose also stimulates transcription (Munnich et al., 1987), but neither
insulin nor glucose can act alone, they are required together (Decaux et al., 1991)
possibly as insulin is required for the production of GK (Vaulont & Kahn, 1994).
Glucagon, acting via cAMP, inhibits PK gene transcription and also accelerates
mRNA degradation (Vaulont et al., 1986; Decaux et al., 1989). Insulin and glucose
on the other hand, stabilise the mRNA (Decaux et al., 1989). Glucocorticoids do not
affect the transcription rate, but exert a permissive effect on glucose and insulin
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induction by acting at the post-transcriptional level (Vaulont et al., 1986; Decaux et
al., 1989).
PEPCK is the most intensely studied gene among those involved in the
regulation of glycolysis and gluconeogenesis and its regulation is well characterised.
It catalyses the synthesis of phosphoenolpyruvate from oxaloacetate and is generally
assumed to be the rate-limiting enzyme of gluconeogenesis in liver (reviewed by
Hanson & Garber, 1972). In contrast to the glycolytic enzymes, hepatic PEPCK
expression is increased by fasting and is markedly reduced by refeeding (Tilghman
et al., 1976). Regulatory effects are largely mediated hormonally, but there is
evidence that the dietary response may be partially due to glucose acting
independently from insulin, as glucose administration results in a decrease in
PEPCK mRNA levels in hepatocyte cultures and in diabetic rats due to both
decreased transcription and accelerated degradation (Kahn et al., 1989; Mayer et al.,
1991). Insulin rapidly inhibits PEPCK mRNA synthesis and hence protein
(Andreone et al., 1982; Granner et al., 1983; Sasaki et al., 1984). Glucagon, acting
through cAMP raises PEPCK levels (Wicks et al., 1972; Iynedjian & Hanson, 1977)
by stimulation of PEPCK gene expression (Lamers et al., 1982; Granner et al., 1983;
Sasaki et al., 1984) and stabilisation of the mRNA (Hod & Hanson, 1988).
Glucocorticoids also raise PEPCK levels through increased gene transcription
(Sasaki et al., 1984) and mRNA stabilisation (Petersen et al., 1989), and the positive
regulation by cAMP and glucocorticoids is additive (Sasaki et al., 1984). Insulin
however, inhibits this induction and this is the dominant effect on transcription
(Magnuson et al., 1987; Sasaki et al., 1984) under normal circumstances. However,
there is evidence that glucocorticoids become the major regulator in diabetes
(Friedman et al., 1993). The dominant regulation by insulin may be due to the
presence of a complex multi-hormone response unit in the PEPCK gene promoter
(Mitchell et al., 1994). This response unit contains an insulin response sequence and
GR binding sites, the functions of which can both be modulated by the same
regulatory proteins (O'Brien et al., 1994). Such an arrangement affords the potential
for complex regulatory patterns.
FBPase-1 has been less intensively studied but its regulation is similar to that
of PEPCK. The effects of insulin and cAMP on gene expression are similar to those
on PEPCK (Granner & Pilkis, 1990) such that FBPase-1 mRNA is induced by
starvation and diabetes and suppressed by insulin (El-Maghrabi et al., 1988).
Likewise, G-6-Pase is also induced by starvation and diabetes (Nordlie et al., 1968).
Therefore the effects of hormones on the expression of the regulatory
enzymes of hepatic glucose metabolism are consistent with their physiological
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actions. Insulin induces the enzymes of glycolysis and represses those of
gluconeogenesis. Glucagon has opposite effects. In all cases, negative control is
dominant so that cAMP has dominant control of glycolysis and insulin has dominant
control of gluconeogenesis. There is a paradox in the role of glucocorticoids, in that
they stimulate levels of PEPCK, and are well known for increasing glucose
production, but also stimulate GK, a glycolytic enzyme. This reflects their
physiological role in fuel metabolism, which is to exert a permissive function on
gluconeogenesis when fasting, but also on glucose disposal by glycogen synthesis
and glycolysis in the post-prandial state and thus maintain glucose homeostasis.
1.4.5 Insulin Resistance and Non-Insulin-Dependent Diabetes Mellitus
Diabetes mellitus is the term used to describe the wide range of
hyperglycaemic disorders which occur. It is characterised by the presence of a
relative or absolute lack of insulin and is associated with a high incidence of
complications, including myocardial infarction, stroke, blindness due to cataract
formation and retinopathy, renal failure and gangrene. NIDDM is the most common
hyperglycaemic state and the high prevalence of NIDDM means it is a major health
concern in all populations.
Under normal conditions, insulin and glucagon, secreted from the 6 cells and
the a cells of the pancreatic Islets of Langerhans respectively, rigorously maintain
plasma glucose levels within normal limits (reviewed by Unger, 1981). A fall in
glucose concentration elicits a prompt response of glucagon secretion, which
together with a simultaneous fall in plasma insulin levels serves to redress the
situation and prevent hypoglycaemia, primarily by the stimulation of hepatic
glycogenolysis and gluconeogenesis and reduced peripheral glucose utilisation (Fig.
1.12). If starvation is prolonged, a shift towards ketone production occurs. In the
case of glucose abundance, glucagon levels fall and there is a prompt release of
insulin to facilitate glucose uptake and disposal in the liver and in the periphery (Fig.
1.12).
NIDDM is characterised by persistent fasting hyperglycaemia in the absence
of diabetic keto-acidosis due to B-cell dysfunction (reviewed by Porte, 1990). This
results initially in defective first-phase or acute glucose-induced insulin secretion
(Porte & Woods, 1990; Seltzer et al., 1967) and a deficiency in glucose-mediated
potentiation of other islet non-glucose secretogogues (Halter & Porte, 1978)
resulting in a reduced maximal capacity to secrete insulin (Fig 1.13). Paradoxically,
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Figure 1.12: Regulation of glucose by insulin and glucagon in the resting state,
starvation and in post-prandial conditions.
+ve = stimulation, -ve = inhibition. Adapted from Unger & Foster, 1992.
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thus stimulates increased insulin secretion, so that insulin levels may exceed the
norm (Perley & Kipnis, 1967). There is still however, an insulin deficiency relative
to the requirements for efficient handling of glucose to maintain normoglycaemia
(Fig 1.13). In the early stages of pathology, fasting plasma glucose levels are
maintained within the normal limits, as basal and second-phase insulin secretion are
not severely affected. However, progressive islet cell failure results in rising glucose
levels in order to maintain adequate insulin levels by compensating for the defective
glucose-stimulation for insulin release (Brunzell et al., 1976). By the time there is
overt hyperglycaemia, 75% of the 6 cell function has been lost (Halter et al., 1979),
and in severe NIDDM the insulin response to glucose may be virtually absent
(Brunzell et al., 1976; Pfeifer et al., 1981). Insulin resistance exacerbates the
situation by further increasing the requirement of insulin and thus the levels of
glucose needed to compensate for defective glucose-stimulation of insulin release
(Fig. 1.13). The result is a steady state of glucose overproduction and
hyperglycaemia. When the renal threshold for glucose is exceeded, this state of
relative insulin deficiency becomes an absolute deficiency, as plasma glucose levels
cannot be further elevated to further stimulate insulin release, and there is a
requirement for exogenous insulin administration.
Insulin resistance is well documented in NIDDM (reviewed by Olefsky &
Kolterman, 1981; Kolterman et al., 1981). It is associated with reduced numbers of
insulin receptors on monocytes, erythrocytes and adipocytes (Bar et al., 1976;
Gambhir et al., 1978; Olefsky, 1976) which shifts the insulin dose-response curve to
the right, therefore increasing insulin requirements and exacerbating the relative
insulin deficiency of NIDDM. Insulin resistance is also a feature of obesity (Baron et
al., 1991). Whether obesity is a cause or effect of insulin resistance is unclear, as
insulin resistance is present in hyperglycaemic states without obesity and vice versa
(Baron et al., 1991; DeFronzo et al., 1982). It has been suggested they are both
caused by hyperinsulinaemia (Modin et al., 1985), but the specific defect in insulin
resistance has not been identified.
The nature of the B cell lesion in NIDDM has not been precisely determined.
It is believed to be, at least in part, due to the decreased activity of the normal
glucose transporter in 8 cells (Johnson et al., 1990). Pancreatic islet deposits of
amyloid are frequently present in NIDDM patients (Clark et al., 1987) which consist
primarily of the protein amylin (Cooper et al., 1987). Pro-amylin and pro-insulin
processing and mature peptide secretion normally occur together (Johnson et al.,
1988) and it has been suggested that abnormal processing of pro-amylin and pro-
insulin may contribute to amylin deposition leading to a loss in B cell mass (Porte &
49
Figure 1.13: Basal glucose regulation in A: normal conditions, B: islet dysfunction
C: insulin resistance and D: islet dysfunction with insulin resistance.
B: Glucose stimulation of islet is impaired, leading to increased glucose production
and impaired utilisation which elevate plasma glucose to compensate until a new
steady-state is reached.
C: Increased glucose production and impaired utilisation leads to increased insulin
secretion. Steady state has mild hyperglycaemia and significant hyperinsulinaemia.
D: Insulin resistance requires greatly increased plasma glucose levels to compensate
for islet dysfunction.


















Kahn, 1989). This process will be accelerated by the increased requirement for
insulin secretion from B cells in insulin resistance. The relationship between B cell
function and insulin resistance is obscure. Insulin resistance may contribute to B cell
dysfunction by causing beta cell "exhaustion" or direct hyperglycaemic damage
(Bonner-Weir et al., 1983). Theoretically, hyperinsulinaemia could induce insulin
resistance by the down-regulation of insulin receptors. Amelioration of
hyperglycaemia improves B cell function and reduces insulin resistance (Andrews et
al., 1984; Scarlett et al., 1982).
As discussed earlier, glucocorticoids antagonise insulin action by inhibiting
peripheral glucose utilisation and promoting hepatic glucose secretion (Dinneen et
al., 1993; Rooney et al., 1994; Gerich, 1993). In Cushing's syndrome, the
glucocorticoid excess often results in overt NIDDM. These effects may be more
pronounced in insulin deficiency, since glucocorticoids replace insulin as the major
regulator of PEPCK in diabetes (Friedman et al., 1993). Glucocorticoids may play a
role in the development of obesity as they increase appetite, decrease brown adipose
tissue thermogenesis and increase lipoprotein lipase in adipocytes (Langley & York,
1990; Strack et al., 1995; Ong et al., 1992), and the HPA axis is activated in obesity
(Migeon et al, 1963; Marin et al., 1992; Weaver et al., 1993). Therefore
glucocorticoids may be involved in the aetiology of obesity, insulin resistance and
NIDDM, and they can certainly influence their expression.
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AIMS OF THE THESIS
It was the purpose of this thesis to examine the regulation and function of 11B-HSD-
1, primarily in the liver and also in the hippocampus. The main aims were:
1. To establish a culture system for rat primary hepatocytes which maintained high
levels of 11B-HSD-1 activity and mRNA expression, for the examination of hepatic
11B-HSD-1 function. In particular, 11B-HSD-1 reaction direction in hepatocytes and
the factors which influence it were to be examined, as well as hormonal regulation
of 11B-HSD-1 mRNA expression and activity levels. Glucocorticoid, insulin, GH,
E2 and T3 regulation of 11B-HSD-1 were to be examined in this system, to gain
information regarding the magnitude (and thus importance), and the mode of action
of these hormonal regulatory effects.
2. To establish a liver perfusion system for examination of 11B-HSD-1 activity by
the measurement of glucocorticoid metabolism across the intact liver. 11B-HSD-1
reaction direction, and a quantitative measurement of hepatic 11B-HSD-1 activity in
vivo were to be obtained, as well as a measurement of the efficacy of 11B-HSD-1
inhibition by CBX in the intact liver.
3. To employ in vivo studies in order to gain an insight into the possible implications
of glucocorticoid metabolism by hepatic 11B-HSD-1 for liver function. The effects
of manipulating levels of hepatic 11B-HSD-1 upon glucocorticoid-inducible gene
expression were to be used as a marker for effects upon liver function. The
consequences of 11B-HSD-1 manipulation for glucose tolerance and insulin
sensitivity were to be examined. In addition, the in vivo hormonal regulation of
hepatic 11B-HSD-1 was to be examined in further detail.
4. To examine the effects of chronic psychosocial stress, as opposed to
glucocorticoid excess, upon hippocampal 11B-HSD-1 activity in a well-documented
model of chronic psychosocial stress in the tree-shrew. The glucocorticoid and GH
(when administered by intracerebroventricular infusion) regulation of 11B-HSD-1
were to be examined in the rat, in order to gain further insight into the tissue-specific







General chemicals, unless otherwise specified, were generally purchased from
Sigma Chemicals Co., Poole, UK..
Steroid Analysis Materials
The Bio-Rad Protein Assay Kit was purchased from Bio-Rad Laboratories Ltd.,
Hemel Hampstead, UK.
Bovine Serum Albumin Fraction V was from ICN, High Wycombe, UK.
1,2,6,7 [3H]-corticosterone (specific activity 84 Ci/mmol) was from Amersham
International, Aylesbury, UK.
Corticosterone, 11-dehydrocorticosterone, 5 a- and 56-dihydrocorticosterone, 3a5a-,
385a-, 3a5B- and 3856-tetrahydrocorticosterone, glycyrrhetinic acid, NADP,
NADPH, NAD, trimethylsilylimidazole and hexamethyldisilazane were from Sigma.
HPLC grade methanol, water, ethyl acetate, acetonitrile, methoxyamine, pyridine,
cyclohexane and hexane were from Rathburn Chemical Co., Walkerburn, UK.
TLC plates were from Merck Ltd., Lutterworth, UK.
Cocktail T, chloroform and ethyl acetate were from BDH Ltd. (Merck Ltd.),
Lutterworth, UK.
LIPIDEX 500 was from Canberra Packard, U.K.
Tissue Culture Materials
All cell culture plasticware was purchased from Costar Ltd., High Wycome, UK.
Matrigel, CR-Dispase, Rat Tail Collagen Type 1 Gel and Nu-serum were from
Collaborative Biomedical Products, Bedford, Massachussets, USA.
DMEM/F12 medium, William's E medium, Nutrient Mixture Ham's F10 medium,
Dulbecco's Modification of Eagle's Medium (DMEM), Hanks Balanced Salts
(HBSS), Foetal Bovine Serum, Donor Horse Serum, lx trypsin/EDTA, penicillin,
streptomycin, L-glutamine, gentamycin sulphate, amphotericin B, Na pyruvate and
sodium bicarbonate were all from GIBCO Laboratories, Paisley, UK.
Collagenase type IV, phosphate buffered saline, epidermal growth factor, linoleic
acid, insulin, dexamethasone, thyroid hormone, 178-oestradiol, tamoxifen, NaN3,
ascorbic acid and carbenoxolone were from Sigma.
Human growth hormone (Humatrope) was from Eli Lilly & Co. Ltd., Basingstoke,
England.
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KCN was from Aldrich, Gillingham, UK.
Materials for In Vivo Studies
Surflo cannulae were purchased from Terumo, Belgium.
Venflow cannulae were from Ohneda, Sweden.
Medical grade silastic tubing and silastic sealant were both from Dow Corning
Corporation, Midland, Michigan, USA.
Alzet osmotic mini-pumps and introcerebroventricular (ICV) cannulae were from
Charles River UK Ltd., Margate, UK.
176-oestradiol, dexamethasone and carbenoxolone were from Sigma.
RU38486 was a gift from Rousel-Uclaf, Romaineville, France.
Human growth hormone (Humatrope) was from Eli Lilly & Co. Ltd.
Materials for DNA and RNA Techniques.
Restriction enzymes and buffers were from Promega Ltd, Southhampton, UK.
The 1 kb DNA ladder and agarose were from GIBCO.
Ampicillin, ethidium bromide, citrate-saturated phenol, chloroforrmisoamylalcohol,
guanidium thiocyanate, B-mercaptoethanol and herring testicular DNA were from
Sigma.
Bactotryptone and bacto yeast extract were from Difco Laboratories Ltd., East
Molesey, UK.
[a32P] dCTP (3000 Ci/mmol), Hybond C Extra and Hybond N were from
Amersham International.
Random Primed DNA Labelling Kits were from Boehringer Mannheim, Lewes, UK.
NICK columns were from Pharmacia Biotech., St. Albans, UK.
Isopropanol, formaldehyde and butanol were from BDH.
2.2.2 Preparation of routinely used buffers and materials
Kreb's Ringer Bicarbonate Buffer: 118 mM NaCl, 3.8 mM KC1, 1.19 mM KH2PO4,
2.54 mM CaCl2, 1.19 mM MgS04.7H20, and 25 mM NaHCC>3 (pH 7.4), gassed
with 95% 02/5% CO2 for 1 h and supplemented with 0.2% glucose.
Metabolism buffer: 10% glycerol, 300 mM NaCl, 1 mM EDTA, 20 mM Tris-HCl
(pH 7.7).
Low pH (pH 5) buffer: 10% glycerol, 300 mM NaCl, 1 mM EDTA, 0.1 M potassium
acetate (pH 5.0).
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Phosphate buffered saline (PBS): 0.01 M phosphate buffer, 0.0027 M KC1, 0.137 M
NaCl (pH 7.4). Obtained by dissolving 1 tablet in 200 ml dH20. Sterilised by
autoclaving.
TM Triton: 0.1% Triton X-100 in 20 mM Tris-HCl (pH 7.5), 2 mM MgCl2.
HEPES buffered saline (HBS): 2 x HBS = 50 mM HEPES (pH 7.1), 280 mM NaCl,
1.5 mM Na2HP04.
Perfusion Buffer /.• 10 mM Hepes, 5 mM glucose, 0.05% KC1, 0.001% phenol red,
0.2 mM EDTA, 0.9% NaCl (pH 7.4). All solutions were filter sterilised through a
0.2 |im Millipore filter before addition to the sterile saline. Sterilised by autoclaving.
Perfusion Buffer II: 5 mM CaCl2, 30 mM Hepes, 10 mM glucose, 0.05% KC1,
0.001% phenol red, 0.9% NaCl (pH 7.4). All solutions were filter sterilised through
a 0.2 |im Millipore filter before addition to the sterile saline. Sterilised by
autoclaving.
Cycling reagent for NADP/NADPH assay: 10 mM isocitric acid, 10 mM MgCl2,
500 (iM MTT, 2 mM phenazine ethosulphate, 1 mg/ml BSA in 100 mM Bicine (pH
8.0).
LB (Luria-Bertoni) broth: Per litre: lOg bactotryptone; 5g bacto yeast extract, lOg
NaCl. Sterilised by autoclaving.
LB agar: LB broth with 15g agar per litre added prior to sterilisation.
GTE: 50 mM glucose, 25 mM Tris-HCl (pH8), 10 mM EDTA.
K acetate: 3 M potassium, 5 M acetate = 294.42g K acetate and 115g acetic acid
made up to 1 litre with dH20.
Alkaline-SDS solution: 0.2 M NaOH, 1% SDS.
lOx TBE: 108g Tris, 55g boric acid, 4.7g EDTA made up to 1 litre with dH20.
Sterilised by autoclaving.
20 x SSC: 175.32g NaCl and 88.23g Na citrate made up to 1 litre with dH20.
Sterilised by autoclaving.
Agarose loading buffer: 0.25% (w/v) bromophenol blue, 0.25% zylene cyanol (w/v),
15% Ficoll (type 100) in dH20.
Tris-EDTA (TE): 10 mM Tris-HCl (pH 8), 0.1 M EDTA. Sterilised by autoclaving.
Denaturing solution: 4 M guanidium thiocyanate, 0.025 M Na citrate, 0.5%
sarcosyl. 0.1 M 6-mercaptoethanol added immediately prior to use.
Tris-saturated phenol: redistilled phenol mixed with an excess volume of 0.5 M Tris
pH 8.0, and the aqueous discarded. Mixed with an excess volume of 0.1 M Tris pH
8.0, and the aqueous discarded three times. Finally, an excess volume of 0.1 M Tris
pH 8.0 added.
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DEPC-treated H2O: dH20 mixed with 0.1% diethylpyrocarbonate and left for 1-24
h before sterilisation by autoclaving.
lOx MOPS: 0.2 M MOPS (pH 7.0), 50 mM NaAc, 5 mM EDTA. Sterilised by
autoclaving.
Prehybridisation buffer: 0.2 M NaH2P04, 0.6 M Na2HP04, 5 mM EDTA, 6% SDS,
10|lg/ml denatured herring testicular DNA.
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2.2 Steroid Analysis Techniques
2.2.1 In Vitro Assay of 1 lB-Dehvdrogenase Activity of 11B-HSD
This assay was used routinely to measure the potential 11B-HSD enzyme
activity in fresh and frozen tissue samples. This assay measures the conversion of B
to A in tissue homogenates and does not discriminate between 11B-HSD-1 and 11B-
HSD-2 activity where there is an abundance of co-factor for both enzymes.
Routinely, this assay was performed on fresh tissue samples, but where this was not
possible tissue was immediately frozen on dry ice and stored at -70°C until required.
All tissues within a single experiment were treated in the same manner.
Tissues were homogenised in Kreb's-Ringer bicarbonate buffer in Dounce
tissue homogenisers. Routinely, half a hippocampus was homogenised in 500 |il
Kreb's-Ringer buffer, whilst the cerebellum was homogenised in 1 ml. 0.1-0.2g of
cerebral cortex, liver, kidney, lung and skeletal muscle were homogenised in 1ml
Kreb's-Ringer buffer. Tissues with high 11B-HSD activity were then diluted 1 in 50
with Kreb's-Ringer buffer. The total protein concentration of each sample was
estimated (section 2.2.5), and aliquots of homogenate containing equal amounts of
protein were incubated in duplicate with 200 pM NADP and 12 nM [3H]-B in a total
volume of 250 pi with Kreb's-Ringer buffer supplemented with 0.2% BSA at 37°C.
Preliminary studies carried out to optimise conditions for the assay and the protein
concentration employed for each tissue in routine assays was chosen such that the
percentage conversion was within the range, 10-50% conversion in a 10 min assay.
The exception to this was tree-shrew hippocampus which required incubation for 60
min. This was so that additional protein led to an approximately linear increase in
percentage conversion of [3H]-B to [3H]-A. The chosen protein concentration varied
between tissues and between species (Fig. 2.1 and Table 2.4). To terminate the
assay, 1 ml of ethyl acetate was added to each sample and mixed to separate the
steroids from the homogenate. The upper ethyl acetate layer was removed into
HPLC tubes and dried down under air at 55°C before analysis by high pressure
liquid chromatography (HPLC) (section 2.2.6) to estimate the conversion of [3H]-B
to [3H]-A. Enzyme activity was expressed as the percentage conversion to product.
In assays where the 11B-HSD inhibitor CBX was employed, it was added to
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Figure 2.1: 11B-HSD-1 activity with varying protein concentrations.
1 lft-HSD activity in male a) rat b) mouse and c) tree-shrew hippocampus, liver and
kidney. 11B-HSD activity is expressed as % conversion B to A at 37°C for 10 min
(60 min for tree-shrew hippocampus) in the presence of 200 pM NADP. Similar
data was collected from other tissues and species, and used to select an appropriate
protein concentration for routine 11B-HSD assays.
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Protein concentrations routinely employed in the llfi-HSD dehydrogenase assay.
In assays where 11B-HSD-2 was to be measured, 200 jaM NAD was
substituted for NADP, and in assays where detection of possible 11B-HSD activity
was the priority rather than a qualitative analysis, incubation times of up to 2 hours
were employed.
2.2.2 In Vitro Assay of 1 lB-Reductase Activity of 11B-HSD
1 lB-reductase activity is specific for 11B-HSD-1 and measures the
conversion of A to B in tissue homogenates. This assay was always performed on
fresh tissue samples as 1 lB-reductase activity is labile and easily lost on freezing.
Essentially, the assay was carried out as for the 11 B-dehydrogenase assay.
However, tissues were homogenised in metabolism buffer and duplicate aliquots of
homogenate were incubated with 200 pM NADPH, 12 nM [3H]-A and 10% low pH
(pH 5) buffer in a total volume of 250 pi with metabolism buffer at 37°C. Routinely,
11 B-dehydrogenase activity was measured in parallel by incubation with 200 pM
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NADP and 12 nM [3H]-B in metabolism buffer. Where 11B-HSD-2 activity was
measured within the same experiment, incubation was with 200 |lM NADP and 12
nM [3H]-B in metabolism buffer.
2.2.3 Quantitation of 11B-HSD Activity in Intact Cells
All 11B-HSD-1 assays in intact hepatocytes were carried out in 35mm
dishes. The medium was aspirated and replaced with 2 ml fresh medium containing
2 nM [3H]-B and a quantity of unlabelled B appropriate for the concentration of B
required, or 2 nM [3H]-A made as described in section 2.10 and unlabelled A as
required. In most experiments, 23 nM unlabelled A or B was added to the medium
giving a final concentration of 25 nM A or B. This concentration was chosen so as to
reflect moderate to high physiological "free" B levels. Aliquots of medium were
removed at various time points as required. Routinely, a 1ml aliquot of medium was
removed from the culture medium after 30 min incubation and the remaining 1ml
removed after 60 min. In the experiment to determine product formation with time
(section 3.3.1), 100 |ll aliquots of medium containing 25 nM [3H]-B or 25 nM [3H]-
A were removed after 15, 30, 60, 90 and 120 min incubation. Steroids were
extracted from the medium with 1 ml of ethyl acetate. The upper ethyl acetate layer
was removed into eppendorf tubes, dried down under air at 55°C and subjected to
analysis by thin layer chromatography (TLC) (section 2.2.7). Cells were washed
twice in fresh medium after each assay and the aspirated medium disposed of as
radioactive waste. Assays were repeated at intervals from 4 h to 28 d after plating.
Assays in intact Y1 cells transfected with pSLl were carried out in 60 mm
dishes 24 h after transfection. To measure 116-dehydrogenase and 1 lB-reductase
activities in intact cells, medium was aspirated and replaced with 6 ml fresh growth
medium containing 25 nM B (2nM [3H]-B and 23 nM unlabelled B) or 25 nM A (2
nM [3H]-A and 23 nM unlabelled A). 750 |il aliquots of medium were removed
from the culture dishes 2, 4, 8 and 24 h later, steroids extracted and analysed by
TLC (section 2.2.7).
2.2.4 Quantitation of 11B-HSD Activity in Cell Homogenates
Seven days after being placed into culture, hepatocytes were harvested from
culture dishes by dissolution of the Matrigel basement membrane. The medium was
aspirated and 1 ml of CR-Dispase was added to each 35 mm culture dish. Following
incubation for 2 h at 37°C, the contents of each dish were transferred to an eppendorf
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tube and gently pipetted up and down to ensure complete dissolution of the Matrigel
to yield a cell suspension. Cells were sedimented by centrifugation at 50g for 2 min
and the supernatant discarded. The pellet was resuspended in 100 pi TM Triton and
the total protein concentration of the suspension estimated. 25 pg of cell homogenate
protein was incubated for 10 min or 60 min at 37°C with either 200 pM NADP and
12 nM [3H]-B or 200 pM NADPH and 12 nM [3H]-A, in a total volume of 250 pi
with Kreb's Ringer buffer supplemented with 0.2% BSA. Steroids were extracted
into 1 ml of ethyl acetate, dried down and resuspended in 600 pi of 65:35 methanol:
HPLC H2O and separated by HPLC (section 2.2.6) to estimate the conversion of
[3H]-A to [3H]-B or [3H]-B to [3H]-A. Enzyme activity in each direction was
expressed as the percentage conversion to product.
To measure 116-HSD activity in Y1 cell homogenates, medium was
aspirated 48 h after transfection, the cells washed with 3 ml PBS and harvested by
scraping into 1 ml PBS and spun down at 14 000 rpm in a bench top centrifuge for 2
min. The cell pellet was resuspended in 100 pi TM Triton, 400 pi Kreb's Ringer
buffer was added and the total protein concentration of each cell suspension
estimated. 125 pg homogenate protein was incubated for 10 min at 37°C with 100
nM [3H]-B and 5 mM NADP in a total volume of 250 pi with Kreb's Ringer buffer
supplemented with 0.2% BSA. Steroids were extracted into ethyl acetate and
analysed by HPLC (section 2.2.6).
2.2,5 Protein Estimation
The protein concentrations of tissue and cell homogenates were estimated
using the Bio-Rad Protein Assay Kit. Protein standards of 1.0, 0.8, 0.6, 0.4, 0.2 and
0.1 mg/ml were prepared by serial dilution of the Protein Assay Standard II supplied
in dH20. 20 pi of each protein standard, of each sample and of Kreb's Ringer buffer
(blank) was pipetted into an eppendorf tube and 1 ml of Protein Assay Dye Reagent
(diluted 1 in 5 with dH20 and passed through a Whatmann No. 1 Filter Paper)
added. The tubes were vortexed and left at room temperature for 15 min before
measurement of absorbance at 595 nm by a Shimadzu UV-160A spectrophotometer.
The concentration of protein in each sample was estimated from the standard curve.
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2.2.6 High Pressure Liquid Chromatography
Following extraction into ethyl acetate, steroids were dried down under air at
55°C in 1 ml HPLC tubes and reconstituted in 600 |il mobile phase (65:35 methanol:
water (HPLC grade). A 200 |il aliquot of each sample was injected onto an HPLC
column. The HPLC apparatus consists of an auto-injector (Waters 712 Wisp), an
HPLC pump (Waters 510), an ultraviolet absorbance detector set at 254 nm for
detecting the elution profile of steroid standards, a Waters reverse phase M-
Bondapak-C18 (3.9 x 300 mm) HPLC column linked to a radioactivity (13) detector
(Berthold LB506 CI), a scintillation fluid pump (Berthold LB5035) and a computer
for analysing and storing data (Berthold HPLC program v. 1.51). The flow rate for
mobile phase employed was 1.8 ml/min.
In order to ascertain the elution times of the major hepatic metabolites of A
and B, the HPLC elution profiles of steroid standards for the major hepatic
metabolites of B were examined by absorbance at 254 nm (Table 2.2). 10"9 moles of
A or B gave clearly identifiable peaks. However, the 5a- and 56- metabolites of B
absorb much less efficiently, and so 10"6 moles of each of these metabolites was
required to give an equivalent peak. Radiolabelled peaks as detected by the on-line 6
counter were compared to the elution profiles of the unlabelled steroid standards to
identify the products of A or B metabolism in tissue homogenates, cultured
hepatocytes or perfused liver. The elution profiles of unlabelled steroid standards
were used to identify the peaks of radiolabelled steroid which came off the column
and the proportion of total counts in each radioactive peak were used to estimate the
conversion of steroids in samples.
2.2.7 Thin Layer Chromatography
Following extraction into ethyl acetate, steroids were dried down under air at
55°C in eppendorf tubes, and resuspended in 100 (il ethanol containing 2.5 mg/ml
each of unlabelled A and B. Silica gel coated aluminium TLC plates were divided
into lanes of 2cm width to allow application of eight 40 fil samples onto each plate.
Following application of the samples, the plates were allowed to dry, and then
chromatographed in sealed tanks containing chloroform: 95% ethanol (92:8) for 1
hour, to allow separation of A and B. The steroid bands were identified by
fluorescence under ultra-violet light and scraped into scintillation vials. 3 ml liquid
scintillant (Cocktail T) was added to each sample and the radioactivity was
quantified by a 6-counter. The conversion of [3H]-A to [3H]-B or [3H]-B to [3H]-A
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was calculated from the radioactivity in each fraction according to the formula %
conversion = [3H]-A or [3H]-B/[3H]-A + [3H]-B. Enzyme activity in each direction
was expressed as the percentage conversion to product.










HPLC elution times of the major metabolites of corticosterone, measured by ultra¬
violet absorbance at 254 nm. Note the clear separation of 5 a and 5J3 reduced
metabolites from B and A.
2.2,8 Preparation of Samples for Gas Chromatographv-Mass Spectrometry
Dried steroid extracts from plasma samples were converted to their
methoxime-trimethylsilyl derivatives as described by Shackleton & Honour (1976).
10 ml HPLC grade ethyl acetate was added to tubes for standards and samples,
internal standard (500 ng each of deuteriated A ([2Hio]-A) and B ([2H9]-B), a gift
from Dr. Ruth Best) was added to each tube and a tube was sealed to serve as the
blank. Standards were prepared by adding 100, 200, 300, 400 and 500 ng of A and B
in acetonitrile to each of 5 tubes which were then sealed. 1.5 ml of each plasma
sample was added to a tube, shaken and sonicated in a sonicating waterbath (Decon)
for 10 seconds. The ethyl acetate was evaporated under N2, and then 50 pi 2%
methoxyamine in pyridine was added and the sample heated to 60°C for 30 min. The
methoxyamine was evaporated, 50 pi of trimethylsilylimidazole added and the
sample heated to 100°C for 2 h. Columns were prepared using pasteur pipettes
plugged with glass wool and with 1 ml LIPIDEX 500 added. 3 ml mobile phase
(cyclohexane:pyridine:hexamethyldisilazane; 98:1:1) was added, followed by the
sample in 2 ml mobile phase. The sample was collected, dried down, and dissolved
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in 50 pi hexane for injection into the gas chromatography-mass spectrometry
(GCMS) system.
2.2.9 Gas Chromatographv-Mass Spectrometry
Samples were subjected to GCMS by Dr. Ruth Best in order to determine
their B and A content. The system is described briefly as follows: a Hewlett Packard
5890 gas chromatograph linked to a VG Trio 1000 mass spectrometer (Fisons
Instruments, Manchester, UK) was used. The oven temperature was maintained at
50°C for 1 min and then increased by 30°C a minute for 10 min. The injection port
was maintained at 290°C and ionisation was carried out in electron impact mode
with an electron energy of 70 eV. The source temperature was 200°C and the
interface was 280°C. A CP-Sil 5CB column (length 25 m, internal diameter 0.32
mm, film thickness 0.12pm) (Chrompack, London, UK) with column head pressure
of 5 psi was used for analysis. Monitoring of the following ions was carried out,
using a dwell time of 0.04 seconds: m/z 427, 517 and 548 for derivatised B; m/z
434, 435, 524, 525, 555 and 556 for derivatised deuteriated B; m/z 474 for
derivatised A and m/z 484 for derivatised deuteriated A. The ratios of the sum of the
peak areas of the ions of the derivatised analyte to those of the derivatised
deuteriated standard were used for quantitation.
2.2.10 Synthesis of I^HI-l 1 -Dehydrocorticosterone
PH]-A was made using homogenised human placenta or placental extract (a
gift from Dr. Roger Brown) as described (Brown et al., 1993a). Human placenta is a
source of high 11B-HSD-2 activity (Brown et al., 1993a) with no detectable 116-
HSD-1 activity and is therefore efficient at producing A with minimal B
contamination. Routinely, 100 pi of placental extract or 0.5g of human placenta
homogenised in 2 ml 0.1 M Tris-HCl (pH 7.5), was incubated with 1 mM NAD in
0.1 M Tris-HCl (pH 7.5) and 150 mM [3H]-B in a total volume of 5 ml at 37°C for 4
h in a shaking waterbath. Steroids were then extracted into 20 ml ethyl acetate, dried
down under air and resuspended in 500 pi ethanol. 1 pi of resuspended steroid was
subjected to HPLC (section 2.2.6) to check the purity of the [3H]-A, which was
routinely >97%. The volume of ethanol in which the steroid was dissolved was then
adjusted to give approximately the same specific activity as the stock [3H]-B. [3HJ-
A was stored at -20°C for up to several months, but was always checked by HPLC
before use as it has a tendency to spontaneously reform [3H]-B.
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2.3 Primary Rat Hepatocvte Cultures
2.3.1 Hepatocvte Isolation
Liver perfusions were carried out by Sharon Rossiter of the Biomedical
Research Facility, Western General Hospital. Adult male Han Wistar rats were
anaesthetised with pentabarbitone (60 mg/kg) injected intraperitoneally and their
livers were perfused in situ with collagenase essentially as described by Seglen,
1976. For each liver perfusion, 500 ml of Perfusion Buffer I and 100ml of Perfusion
Buffer II was prepared. For each perfusion 33 mg of collagenase type IV was added
to 20 ml sterile saline and heated to 37°C for 15 min to dissolve it. It was then
filtered into the Perfusion Buffer II. Both Perfusion Buffers were maintained at 40°C
in a water bath and connected to a peristaltic pump set at a perfusion rate of 30
ml/min. When the rat was fully anaesthetised, the abdomen was cut open and the
intestines retracted to give access to the inferior vena cava (IVC) and the hepatic
portal vein. These vessels were blunt dissected from the surrounding abdominal
adipose tissue and the portal vein was cannulated (18 gauge x 45 mm Venflow
cannula) whilst the IVC was transected. The perfusion system was then attached to
the cannula so that the perfusate flowed through the liver and out through the cut end
of the IVC. The IVC was then cannulated (18 gauge x 45 mm Venflow cannula) by
opening the thoracic cavity and inserting a cannula into the right atrium of the heart
and then into the IVC. The lower end of the IVC was then tied off with suture
material so that the perfusate flowed out of the IVC cannula. Perfusion Buffer I was
pumped through the liver which turned a pale brown as the liver was cleared of
blood. This was followed by Perfusion Buffer II, and the liver swelled slightly as
collagenase digestion took place.
The liver was removed and dissociated in 100 ml of ice cold Hanks Balanced
Salt Solution (HBSS) (Gibco) by teasing apart with tweezers. Hepatocytes were
isolated by filtering through a 60 |im filter mesh and then the suspension was
transferred into two sterile 50 ml centrifuge tubes and spun at 50g for 2 min in a
Fisons MSE Chilspin centrifuge. The liver parenchymal cells sediment in the pellet
while the non-parenchymal and dead hepatocytes remain in the supernatant. The
supernatant was discarded and the washing procedure repeated a further three times
by resuspending the pellet in fresh HBSS and centrifuging. The final pellets were
pooled and resuspended in a total of 30 ml HBSS. Cell concentration and viability
were determined using a haemocytometer. Yields of 5-10xl08 cells per liver with
70-75% viability, as determined by trypan blue exclusion, were routinely obtained.
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2.3.2 Primary Hepatocvte Culture Conditions
Hepatocytes were plated on dishes coated with Rat Tail Collagen Type 1 Gel
or on Matrigel. Dishes were prepared at least 1 d prior to use. Collagen dishes were
prepared by placing an even coating of collagen on the dish (0.2 ml for a 35mm
dish) and exposing to ammonia vapour for 3 min. The dishes were rinsed with
distilled water, allowed to stand for 24 h and then used immediately. Matrigel dishes
were prepared according to the thin gel method whereby after overnight thawing in
the fridge, Matrigel was applied to the dishes (600 pi for a 35 mm dish, 1.5 ml for a
60 mm dish) which were then placed at 37°C for 30 min to set the gel. Dishes were
stored for up to 3 d at room temperature before use. Hepatocytes were routinely
maintained in DMEM/F12 medium containing 5% Nu-serum, 100 units/ml
penicillin, 100 pg/ml streptomycin, 200 pM L-glutamine, 25 pg/ml gentamycin
sulphate, 0.7 pg/ml amphotericin B, 5 pg/ml insulin and 0.1 pM DEX. In
preliminary experiments, hepatocytes were also maintained in William's E medium
containing 100 units/ml penicillin, 100 pg/ml streptomycin, 200 pM L-glutamine, 25
pg/ml gentamycin sulphate, 2 pg/ml insulin, 10 nM DEX, 10 ng/ml epidermal
growth factor, 0.2 mg/ml linoleic acid and 20 mM Na pyruvate. Cells were plated at
a density of 1x106/35 mm dish in 2 ml medium or 3xl06 cells/60 mm dish in 4 ml
medium. The medium was aspirated and replaced with fresh medium 4 and 24 h
after cells were placed into culture and every 24 to 48 h thereafter. Cultures were
maintained at 37°C in a humidified atmosphere containing 5% CO2 and 95% air for
up to 35 d.
2.3.3 Hormonal Manipulation of Hepatocvte Cultures
Test hormones or antagonists were prepared for addition to hepatocyte
culture medium as follows;
17(3-oestradiol (E2): A 10"5 M solution in ethanol was prepared for addition to
medium at a 1 in 1000 dilution to give a final concentration of 10"8 M.
triiodothyronine (T3): 100 mg T3 was dissolved in 1 ml NaOH and 14 ml of
phosphate buffered saline (lx PBS) was added to give a 10"2 M solution. This was
further diluted in lx PBS to give a 10"6 M working solution which was added to
medium at a 1 in 100 dilution giving a final concentration of 10"8 M.
growth hormone (GH): 10 i.u. was resuspended in 2 ml diluent (supplied with the
GH) for addition to medium at 10 pl/ml giving a concentration of 0.05 i.u./ml.
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RU38486: A 10"3 M working solution in ethanol was prepared for addition to
medium at a 1 in 1000 dilution giving a final concentration of 10"6M.
tamoxifen: A 10"3 M working solution in ethanol was prepared for addition to
medium at a 1 in 1000 dilution giving a final concentration of 10"6M.
dexamethasone (DEX) : A 10"3 M working solution in ethanol was prepared for
addition to the medium at a 1 in 10 000 dilution giving a final concentration of 10"7
M.
insulin: lOOmg insulin was dissolved in 19.8 ml mH20 and 0.2 ml glacial acetic
acid for addition to the medium at a 1 in 1000 dilution to give a final concentration
of 1.3xl0"7M.
11G-HSD-1 activity in the intact hepatocytes was measured 48 h after plating
(section 2.2.3) and then test hormones or antagonists were added to hepatocytes in
fresh medium. In some experiments, 48 h after being placed into culture hepatocytes
were transferred to medium containing charcoal-stripped Nu-serum. Stripping
reduced Nu-serum levels of F, E2, progesterone, T3 and T4 to below detection limits
(section 2.3.10). Cells were cultured in medium containing 5% stripped Nu-serum
supplemented with 10"7 M DEX and/or 1.3xl0"7 M insulin (reflecting the level of
glucocorticoid and insulin in control medium containing unstripped Nu-serum),
and/or hormones at the concentrations stated above. In all experiments, the medium
was aspirated daily and fresh medium and hormones added. In some experiments,
11G-HSD-1 activity in the hepatocytes was measured at 2 d intervals. All hormones
were added to the medium at a concentration chosen so as to be close to
physiological levels and antagonists were employed at a concentration appropriate to
block the effects of the levels of hormone present (routinely lOOx the concentration
of hormone). Cells were harvested for mRNA extraction 12 d after the addition of
hormones (section 2.8.1).
2,3.4 Measurement of the Effects of Oxidative Stress on Hepatocvte Cultures
48 h after the hepatocytes were placed in culture, medium was aspirated and
replaced with fresh medium. The culture dishes were placed in plastic sandwich
boxes which had airtight seals of plastic tape. The boxes were then gassed with 2.5%
O2, 21% O2 for 15 min or not at all, through pasteur pipettes inserted into small
holes in the box lids. The holes were then sealed with tape and returned to the
incubator for 4 h. The boxes were opened and 1 ml medium from each dish
removed for lactate analysis (performed by Professor S.K. Chapman, Department of
Chemistry, University of Edinburgh). The remaining medium was aspirated and
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replaced with medium containing [3H]-A or [3H]-B for a further assay of 116-HSD-
1 activity as described in section 2.2.3. The dishes were gassed as before and then
incubated for 1 h, before removal of 1 ml medium for lactate analysis and 1 ml
medium for [3H]-A and [3H]-B analysis to estimate 116-HSD-l activity in the usual
manner.
2.3.5 Metabolic Studies in Hepatocvte Cultures
48 h after being placed in culture, hepatocyte medium was aspirated and
replaced with fresh medium containing metabolic inhibitors 5 mM NaN3 (azide), 1
mM or 10 mM KCN, 10 mM ascorbic acid (Sigma) or vehicle (1% PBS). The
concentrations of azide and KCN employed cause inhibition of oxidative
phosphorylation in cell culture systems (Sakaida et al., 1992, Prehn et al., 1993,
Mason & Sweeny, 1994, Shetty et al., 1993), and 10 mM of ascorbic acid causes an
increase in NADP, and therefore an increase in intracellular NADP/NADPH in cell
culture systems (Schmidt et al., 1993). Cultures were incubated for 4 h at 37°C in the
presence of metabolic inhibitors, the medium was aspirated, and then 116-HSD-l
activity assayed in the intact hepatocytes as described in section 2.2.3 in the
presence of metabolic inhibitor in the assay medium. Cultures incubated with azide
or cyanide were then washed three times in fresh medium without metabolic
inhibitor, and returned to the cell culture incubator. 4 d later the intact cells were re-
assayed for 116-HSD-l activity in the usual manner to assess cell recovery. For
quantitation of NADP and NADPH in hepatocytes treated with azide (5 mM), KCN
(1 mM) or 10 mM ascorbic acid, cultures in 60 mm dishes were incubated for 4 h in
medium containing the metabolic inhibitors and were then assayed for NADP and
NADPH as described in section 2.3.9.
2.3.6 pH Manipulations of Hepatocyte Medium
Medium with a pH of 8.0 was prepared by adjusting the quantity of NaHCC>3
added to the medium upon preparation. Medium with a pH of 6.2 was prepared by
addition of 1 M HC1 to the standard maintenance medium. 48 h after the hepatocytes
were placed into culture, medium was aspirated and replaced with fresh medium of
the required pH. Cultures were then incubated for 4 h at 37°C, the medium aspirated,
and 116-HSD-l activity assayed in the intact cells in usual manner (section 2.2.3) in
medium of the appropriate pH.
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2.3.7 Inhibition of 11B-HSD-1 Activity by Carbenoxolone Treatment of Hepatocvte
Cultures
48 h after the hepatocytes were placed in culture, medium was aspirated and
replaced with fresh medium containing CBX at concentrations from 10-9 M to 10"4
M or, for controls, 1% ethanol. Cultures were then incubated for 2 h at 37°C,
medium aspirated, and 11G-HSD-1 activity assayed in the intact hepatocytes as
described in section 2.2.3, with the appropriate concentration of CBX in the assay
medium.
2.3.8 Analysis of the Products of 11-Dehydrocorticosterone Metabolism
To identify the products of A metabolism and to estimate the conversion of
[3H]-A to [3H]-B in hepatocyte cultures, 48 h after hepatocytes were placed in
culture, medium was aspirated and replaced with fresh medium containing 10 nM
[3H]-A and 15 nM unlabelled A. The cultures were then incubated for 1 h at 37°C,
and 1 ml of medium was removed. Steroids were extracted into ethyl acetate, dried
down and separated by HPLC (section 2.2.6) to identify the products of A
metabolism.
2.3.9 NADP and NADPH Extraction and Quantitation from Hepatocytes
Quantitation of NADP and NADPH was carried out according to the
enzymatic cycling method, as described by Blomquist and Hakanson (1991).
For assay of NADP, medium was aspirated from the cells, which were then
harvested in 1.5 ml ice-cold 500 mM perchloric acid. The addition of perchloric acid
resulted in instant dissolution of the Matrigel. The cell suspension was sonicated for
4 min on ice, left on ice for 15 min, transferred to eppendorf tubes and the cell debris
pelleted by centrifugation at 5000 rpm for 10 min in a bench top centrifuge. For
assay of NADPH, following aspiration of the medium, cells were harvested in 1.5
ml 250 mM NaOH, heated to 60°C for 5 min, and centrifuged at 5000 rpm for 10
min. Thereafter all samples were treated in the same manner. The supernatant was
removed from each sample and 0.3 ml 1 M Bicine (pH 8) added and titrated to pH 8
by the addition of 5 M KOH to the NADP samples and of 2 M HC1 to the NADPH
samples. Standard curves for NADP and NADPH were created by serial dilution of
2.5x10"7 M solutions of each cofactor (in 100 mM Bicine, pH 8) to give standards
from 0.5 to 2.5xl0"7 M NADP or NADPH. 0.8 ml of reagent blank (100 mM Bicine,
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pH 8), standard or sample was added to 1.0 ml cycling reagent. Cycling was started
by the addition of 0.2 ml isocitrate dehydrogenase (1.25 mg/ml in 100 mM Bicine,
pH 8) and samples were incubated at room temperature in the dark for 60 min.
Absorbance at 570 nm was measured and the concentration of NADP or NADPH in
each sample was estimated from the standard curves. The lower detection limits of
the assays were lxlO"8 M for both NADP and NADPH.
2.3.10 Charcoal Stripping of Nu-serum
0.25% charcoal and 0.0025% dextran T70 were incubated overnight at 4°C
whilst stirring, in 0.25 M sucrose, 1.5 mM MgCl2 and 10 mM Hepes (pH 7.4) so the
suspension was completely mixed. 50ml aliquots of the charcoal suspension were
centrifuged for 10 min at 3000 rpm to pellet the charcoal. The supernatant was
discarded and replaced with 50 ml of the Nu-serum to be stripped. This mixture was
vortexed, incubated at 4°C whilst stirring overnight, then filtered through a 0.2 pm
Millipore filter into a 50 ml centrifuge tube and stored at -20°C until use. Samples of
Nu-serum and stripped Nu-serum were analysed by The Department of Clinical
Biochemistry, Royal Infirmary of Edinburgh for content of steroid hormones (Table
2.3) to check the efficacy of the stripping procedure. All the steroid hormones
assayed were below the limits of detection of the assays employed. However based
on the values of oestradiol, the stripping procedure removed >99.8% of steroid.
Hormone Nu-serum Stripped Nu-serum
f 45nM b.d. (< 30nM)
e2 20 900pM b.d. (< 37pM)
t3 1.2nM b.d. (< 30nM)
t4 34nM b.d. (< 30nM)
progesterone 24.8nM b.d. (< 3nM)
Table 2.3:
Steroid hormone content of Nu-serum before and after charcoal stripping. b.d.=
below detection.
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2.4 llfi-HSD Activity Studies in Y1 Adrenocortical Cells
2.4.1 Maintenance of Y1 cells in culture
Y1 adrenocortical cells were maintained in vented 75 cm2 flasks in Nutrient
Mixture Ham's F10 supplemented with 100 units/ml penicillin, 100 |ig/ml
streptomycin, 15% donor horse serum and 10% foetal bovine serum at 37°C in 5%
CO2. Cells were passaged twice per week. Medium was aspirated and the cells
washed in 2ml lx trypsin/EDTA (to remove residual serum-containing medium
which inactivates the trypsin/EDTA). 2 ml of trypsin/EDTA was added and the cells
incubated at 37°C for 5 min until the cells detached from the flask surface with
gentle agitation. 1/4 of the cells were placed in each of 4 fresh 75 cm2 flasks, 12 ml
of culture medium added, and the cells incubated at 37°C in 5% CO2 until confluent.
Three 75 cm2 flasks of cells were maintained and required for each experiment.
2.4.2 Calcium Phosphate Transfection of Cells
Cells were harvested, resuspended in 10 ml fresh medium and counted using
a haemocytometer. Cells were plated at a density of 5 x 105 cells per 60 mm cell
culture dish (in 6 ml medium) for 116-HSD assay in intact cells or 1.5 x 106 cells
per 100 mm dishes (in 10 ml medium) for assay in cell homogenates. The following
day, 1.5 h prior to transfections, the medium was aspirated and replaced with
"transfection medium" (Dulbecco's Modification of Eagle's Medium (DMEM)
supplemented with 100 units/ml penicillin, 100 pg/ml streptomycin, 200 mM
glutamine and 10% foetal calf serum). For each transfection in a 60 mm dish, 300 pi
and for each 100 mm dish, 450 pi of 2x HEPES buffered saline was pipetted into a
sterile eppendorf tube. In separate tubes, 5 pg of either pSLl (Low et al., 1994a) or
pJ3 (Morgenstern & Land, 1990) was made up to 300 pi (for each 60 mm dish) with
37pl 2 M CaCl2 and filter sterilised mH20 or 450 pi (for each 100 mm dish) with
55pl 2 M CaCl2 and mH20. The prepared DNA solution was added dropwise to the
2x HBS whilst aerating, so that the resulting solution was slightly opaque due to the
co-precipitation of DNA with calcium phosphate. The solution was incubated at
room temperature for 30 min, vortexed and added dropwise to the plates while
swirling to evenly distribute the precipitate, and avoid local acidification of the cells.
The cells were then returned to the incubator. "Transfection medium" was replaced
after 24 h with Nutrient Mixture Ham's F10 medium as above.
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2.5 Liver Perfusion Studies
2.5.1 The Liver Perfusion System
For each perfusion, two 500 ml bottles of Kreb's Ringer buffer supplemented
with 0.2% glucose and B (10~8M) or A (from 10~9M to 10~6M as required) were
prepared and maintained at 40°C in a water bath whilst constantly bubbled with 95%
02/5% CO2. Each bottle was connected to a peristaltic pump set at a perfusion rate
of 2 ml/min. Surgery and cannulations were carried out by Sharon Rossiter of the
Biomedical Research Facility, Western General Hospital. Adult Han Wistar rats
were anaesthetised with pentabarbitone (60 mg/kg) injected intraperitoneally. When
the rat was fully anaesthetised, the abdomen was cut open and the vascular bundle
supplying the stomach, pancreas and small intestine was tied off with suture material
(if this was not done, these organs were perfused and became oedematous). The
intestines were retracted to give access to the hepatic artery, the IVC and the hepatic
portal vein. These vessels were blunt dissected from the surrounding abdominal
adipose tissue and sutures passed underneath them. The hepatic artery was
cannulated with a 24 gauge x 0.75 inch Surflo cannula (Terumo, Belgium) and 250
i.u. heparin in 2 ml of Kreb's Ringer buffer was injected to prevent clotting in the
artery and to check the catheter was patent. Once blanching of the liver was
observed, the catheter was tied in firmly with the suture and connected to one of the
perfusion systems with perfusate pumping through at 2 ml/min. Then the IVC was
cannulated posterior to the inflow of the hepatic vein with a 18 gauge x 45 mm
Venflow cannula (Ohneda, Sweden) which was attached to a length of tubing, and
the rat's head was elevated to aid the flow of the perfusate out of the IVC. Finally,
the hepatic portal vein was cannulated with a 18 gauge x 45 mm Venflow cannula,
flushed with 250 i.u. heparin in 2 ml of Kreb's Ringer buffer and connected to the
other perfusion system, with perfusate pumped at 2 ml/min. Thus the perfusate was
pumped into the liver through the hepatic artery and the hepatic portal vein, and
collected from the hepatic vein via the IVC. Routinely, the perfusion rate was then
increased to 7.5 ml/min through each vessel in male rats and 5 ml/min in female rats
(as this was the maximum flow rate the hepatic artery could accommodate in
females), the preparation was examined for visible leakage and the outflow
measured to ensure there were no leaks in the system. At this point, 10~9 M [3H]-A
or 10"9 M [3H]-B was added to the perfusate, and the system was allowed to
equilibrate for 10-15 min before collection of samples began. Flow rates were
altered from between 0-20 ml/min through each of the vessels. When the flow rates
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were altered within a single preparation, the system was allowed to equilibrate for 5-
10 min before further collection of samples. 10 ml aliquots of perfusate were
collected in duplicate, the steroids extracted into ethyl acetate, dried down and
analysed by HPLC (section 2.2.6). Controls consisted of perfusate which had not
been passed through the liver. For all samples, the products of A metabolism in the
liver were examined and the proportion of steroid recovered was calculated (section
2.2.6).
2.5.2 Inhibition of 11B-HSD-1 Activity by Carbenoxolone in Perfused Liver
Liver perfusions were carried out in male rats with 10"8 M unlabelled A and
10~9 M [3H]-A in the perfusate and a flow rate of 7.5 ml/min through both the
hepatic artery and the hepatic portal vein. Following equilibration of the preparation,
CBX was added at increasing concentrations from 10~9 M to 10~4 M. When the
concentration of CBX was altered, the system was allowed to equilibrate for 5-10
min before further collection of samples. Samples were taken at each concentration,
and analysed by HPLC in order to establish the concentration at which 11B-HSD-1
activity was effectively inhibited.
2.5.3 Analysis of the Products of 11-Dehydrocorticosterone Metabolism
A liver perfusion was carried out in a male rat with 10"8 M unlabelled A and
5 x 10"9 M [3H]-A in the perfusate. This was to ensure there was enough
radiolabeled steroid in the samples to give clear separation of peaks representing the
products of metabolism of A in the perfused liver. The flow rate employed was 7.5
ml/min through the hepatic artery and the hepatic portal vein and 10 ml samples
were collected in triplicate. Steroids were extracted into ethyl acetate, dried down
and separated by HPLC as described in section 2.2.6. The proportion of steroid
recovered was calculated as (cpm recovered in sample/cpm recovered in blank (no
homogenate) incubates) x 100%.
74
2.6 In Vivo Studies
2.6.1 Animal Maintenance
Han Wistar male and female rats and male tree shrews were used for the in
vivo studies. Rats were maintained under conditions of controlled lighting (lights on
from 07.00 to 19.00 h) and temperature (22°C), and had access to water and food ad
libitum, except where stated. Following surgery, and during experimental
procedures, animals were observed closely, and any animals which appeared to be
suffering or in ill health were killed immediately. Keith Chalmers and Andy Wilson
of the Biomedical Research Facility, Western General Hospital carried out the day to
day care of the rats used in in vivo studies, and administered any daily injections
throughout the course of the experiments. In vivo studies in tree-shrews were carried
out at the German Primate Centre (Gottingen, Germany) and details of animal
maintenance are described by Fuchs & Schumacher, 1990.
2.6.2 Adrenalectomy ± Oestradiol Treatment
The surgical procedures in this study were carried out with the assistance of
Sharon Rossiter and June Noble. Male Han Wistar Rats (200-250g; n=5-10/group)
were anaesthetised with 4% halothane, gonadectomised and either bilaterally
adrenalectomised or sham-operated through dorsal incisions. Animals were
implanted subcutaneously with silicone elastomer capsules (1.95 mm internal
diameter, 3.125 mm external diameter) containing 176-oestradiol which produce
levels of E2 not significantly different from those found in the plasma of adult
female rats (Painson et al., 1992). The capsules were made by sealing one end of a
12 mm length of medical grade silastic tubing with silastic sealant. The sealant was
allowed to set overnight, the capsules completely filled with 17B-oestradiol or left
empty and the other end of the capsules sealed. Before implantation, the capsules
were incubated overnight in 0.9% NaCl. Some ADX animals were injected
subcutaneously with "high dose" DEX (250 p.g/kg/day), whilst other ADX and sham
ADX animals received vehicle (0.1 ml of 4% ethanol in saline). For animals treated
for 42 d with E2, the capsules were removed and replaced after 21 d. Control
animals were implanted with blank capsules. ADX rats were maintained on 0.9%
saline to maintain their electrolyte balance. Rats were killed 10, 21 or 42 d after
surgery. Tissues were collected for assay of 11B-HSD activity and extraction of
RNA.
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2.6.3 Carbenoxolone Administration and Glucose Tolerance Tests
Male Han Wistar Rats (200-250g; n=8-10/group) were injected
subcutaneously with either 1 mg, 3 mg or 10 mg of CBX or vehicle (0.2 ml 0.9%
saline) daily for 14 d. After 13 d of CBX administration, animals were fasted from
16.00 h until 09.00 h the next day when glucose tolerance tests were performed with
the assistance of Keith Chalmers. Rats were weighed and a 2g/kg dose of glucose
administered by gavage as a 0.5g/ml solution in water. 100 p.1 blood samples were
taken by tail nick at 0, 30, 60, 90 and 120 min after glucose administration. Blood
samples were collected into heparinised eppendorfs (prepared by filling with 1000
i.u./ml heparin and emptying) and immediately placed on ice. As soon as possible (5
min) they were spun at 5000 rpm for 2 min in a bench top centrifuge and the plasma
was removed into fresh eppendorfs and placed on dry ice. Plasma samples were
stored at -70°C until analysis for glucose and insulin content. The following day, rats
were killed. Trunk blood was collected into heparinised tubes, the plasma separated
by centrifugation at 5000 rpm for 10 min and stored at -20°C until analysis for K+,
Na+ and CI" content (performed by Dr. Mark Lindsay of the Metabolic Unit,
Western General Hospital), and for B and A. Liver was collected for assay of 118-
HSD activity and extraction of RNA.
2.6.4 Adrenalectomy ± Adrenal Steroid Replacement
Male Han Wistar Rats (200-250g; n=5/group) were bilaterally
adrenalectomised or sham-operated through dorsal incisions whilst under halothane
anaesthesia. Some ADX animals were injected subcutaneously with high dose DEX
(250 (ig/kg/day), whilst the other ADX animals and the sham ADX animals received
vehicle (0.1 ml of 4% ethanol in saline). ADX rats were maintained on 0.9% saline
to maintain their electrolyte balance. Rats were killed 2, 5, 9, 15 or 21 d after
surgery. Untouched animals served as controls. Tissues were collected for assay of
118-HSD activity and extraction of RNA.
2.6.5 Intracerebroventricular Administration of Growth Hormone
Osmotic mini-pumps were filled with 100 pi of 2.1 pg/pl human GH or
vehicle (artificial CSF). These were incubated overnight in 0.9% saline at 37°C in
order to allow the rate of pumping to equilibrate at 12 pl/d. Thus 25 pg/d GH was
delivered at a constant rate. The following day, male Han Wistar Rats (200-250g;
76
n=4-5/group) were anaesthetised with 4% halothane. June Noble and Joyce Yau of
the Department of Medicine, Western General Hospital assisted with the
implantation of introcerebroventricular (ICV) cannulae, which were implanted 1.4
mm to the right of bregma and at a depth of 4.5 mm. Fixing screws were inserted
into the skull at 3 mm posterior and at 4 mm lateral to the cannulae and the entire
apparatus fixed to the skull with dental cement. The osmotic mini-pumps were
implanted subcutaneously in the intrascapular fascia and connected to the cannulae.
Rats were killed 5 d later and tissues were collected for extraction of RNA. The





pllDH 1.2 kb EcoRl fragment of rat 11B-HSD-1
cDNA subcloned into pBluescript. Has the
capability to maintain a high copy number
and contains the ampicillin resistance gene 8
lactamase2.
Agarwal et al., 1989
pJ3 3.5 kb vector containing the ampicillin
resistance gene and Simian Virus 40 origin
and early promoter. Used as expression
vector in mammalian cells.
Morgenstern &
Land, 1990
pSLl 1.2 kb EcoRl/Stl fragment of the rat 118-
HSD-1 cDNA subcloned into pJ3. Used to
express 11B-HSD-1 cDNA in mammalian
cells.
Low et ah, 1994a
p7S Coding region of 7S cDNA subcloned into
pAT 153.
Balmain et ah, 1982
pX3 2.5 kb full-length mouse PEPCK cDNA
subcloned into pBluescript KS at EcoRl site.
Ruppert et ah, 1990
pRagU0.3A 305bp Stul/Rsal fragment of rat
angiotensinogen cDNA subcloned into the
HincII site of pUC19.
Ohkubo et ah, 1983
pX2 1.5 kb EcoRl fragment of mouse SAMS
cDNA subcloned into pBluescript KS.
Ruppert et ah, 1990
pmcTAT4 1.0 kb EcoRl-BamHI fragment of mouse
SAMS cDNA subcloned into pBluescript.
Ruppert et ah, 1990
pmTF-1 1.5 kb EcoRl fragment of mouse transferrin
cDNA subcloned into pBluescript.
Ruppert et ah, 1990
Table 2.4:
Plasmid vectors. aAll these plasmids contain the ampicillin resistance gene.
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2.7.2 Bacterial Transformation
Escherichia coli HB101 cells were made competent for DNA uptake as
described by Sambrook et al., 1989. Cells were grown in 100 ml LB (Luria-Bertoni)
broth at 37°C in a shaking incubator to mid-log phase (A600 = 0.3-0.6). The cells and
broth were centrifuged at 3000 rpm in a Beckman J20 rotor for 10 min at 4°C, the
pellet resuspended in 10ml ice-cold 0.1 M CaCl2 and left on ice for 10 min. Cells
were then pelleted again by centrifugation, and resuspended in 2 ml 0.1 M CaCl2.
These competent cells could be stored for up to 4 d at 4°C before transformation.
150 (ll of competent cells were mixed with 50ng plasmid DNA in a volume
of 10|il TE and left on ice for 10 min. The cells were heat shocked at 42°C for 90 s
and then transferred back onto ice for 5 min before spreading onto LB agar plates
containing 100 fig/ml ampicillin, using a flame sterilised glass spreader. Plates were
incubated at 37°C overnight. Control plates for transformations included a negative
control of HB101 cells without added DNA. HB101 cells do not have the ampicillin
resistance gene and so do not grow. The positive control consisted of HB101 cells
transformed with pGEM3, which contains the ampicillin resistance gene, indicating
transformation has taken place. Colonies which grew on the selection media
contained cells which had transformed successfully and contained the ampicillin
resistance marker. Plates with transformed colonies were stored at 4°C for up to 3
months.
2.7.3 Plasmid DNA Preparation
A single transformed bacterial colony was transferred from an LB agar plate
into 3 ml LB with 100 flg/ml ampicillin and incubated overnight in a rotating tube at
37°C. The overnight culture was added to 500 ml LB with 100 |ag/ml ampicillin, and
incubated overnight, whilst shaking, in a 2 1 flask at 37°C. The resulting culture was
centrifuged at 6000 rpm for 5 min at 4°C in a Beckman J14 centrifuge to pellet the
cells, and the supernatant discarded. The pellet was resuspended in 12 ml of ice-cold
GTE solution, mixed with 24 ml of alkaline-SDS solution and left on ice for 5 min
before the addition of 16 ml of ice-cold potassium acetate. The mixture was left on
ice for 10 min and centrifuged at 6000 rpm for 10 min at 4°C. It was then strained
through sterile gauze to remove the precipitate, and 32 ml isopropanol added to
precipitate DNA from the supernatant which was left at room temperature for 30
min. The DNA was recovered by centrifugation at 10 000 rpm in a Beckman J20
centrifuge for 5 min at 4°C. The pellet was dried in an oven at 37°C for 30 min and
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resuspended in 1.5 ml TE (pH 8.0) buffer, lg of CsCl was added for each 1 ml of
DNA solution, and dissolved in the DNA solution by warming, 50 p.1 of ethidium
bromide (10 mg/ml) was added, and the resulting solution transferred to 3 ml
Beckman Quickseal ultracentrifuge tubes. The tubes were topped up with CsCl
solution (lOOg CsCl plus 100 ml TE) and volume adjusted to balance the tubes for
weight, and centrifuged at 70 000 rpm for 20 h at 20°C in a Beckman Optima TLX
Ultracentrifuge. The DNA bands (identified by visualisation of the ethidium
bromide) were collected with a syringe and 21 gauge needle, transferred to fresh
ultracentrifuge tubes, filled as before and centrifuged for 4 h at 100 000 rpm at 20°C.
The DNA bands were collected and pooled, and the ethidium bromide was removed
by extracting repeatedly with equal volumes of water saturated butanol until both
aqueous and organic layers were no longer pink, and then once more. 2 vol of
ethanol was added to precipitate the DNA, the mixture vortexed and left at room
temperature for 10 min before centrifugation for 5 min at 14 OOOg. The supernatant
was removed and the DNA pellet washed with 70% ethanol. The DNA pellet was
dried briefly at room temperature and resuspended in an appropriate volume of TE
(usually 1 ml). The concentration and purity of recovered plasmid DNA was
estimated spectrophotometrically by measuring the absorbance at 260 nm and 280
nm.
2.7.4 Plasmid DNA Minipreparation
A single transformed bacterial colony was transferred from an LB agar plate
into 3 ml LB with 100 (tg/ml ampicillin and incubated overnight in a rotating tube at
37°C. 1.5 ml of the overnight culture was centrifuged at 14 OOOg in a bench top
centrifuge for 1 min and the pellet was resuspended in 100 [il ice cold GTE and
mixed with 200 fll of alkaline-SDS solution and left on ice for 5-10 min. 150 |al of
ice-cold potassium acetate was added and gently mixed before leaving on ice for 5-
10 min. The mixture was centrifuged for 5 min to remove denatured chromosomal
DNA and cellular proteins. The supernatant was removed and retained, and the DNA
extracted from it with an equal volume of Tris-saturated phenol and
chloroforrmisoamylalcohol (24:1 v/v). The mixture was vortexed, centrifuged for 2
min, and the supernatant transferred to a fresh eppendorf tube. 1 ml of ethanol was
added to precipitate the DNA, the mixture vortexed and left at room temperature for
5 min before centrifugation for 5 min. The supernatant was removed and the DNA
pellet washed with 70% ethanol. The pellet was dried at room temperature for 15
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min and resuspended in 50pl TE (pH 8.0) with DNase-free RNase (20 pg/ml). DNA
was stored at -20°C.
2.7.5 Restriction Endonuclease Digestion and Electrophoresis of DNA
Plasmid DNA was digested with 1 unit of restriction enzyme per pg of DNA
in lx restriction buffer and distilled water to the required volume (Table 2.5).
Routinely 10 pg of DNA was digested in a total volume of 100 (0,1 for 2 h at 37°C.
Complete digestion of DNA was verified by electrophoresis of a 5 |ol aliquot of the
digest through a 1% agarose gel. Gels were routinely run at 100V with a 1 kb DNA
ladder containing DNA fragments from 75 bp to 12 kb as size markers, for as long
as was needed to separate DNA fragments enough to allow them to be cut out of the
gel. 1% agarose gels (w/v) were prepared by dissolving 0.25g agarose in 25 ml lx
TBE in a microwave oven. The agarose solution was cooled slightly and 1 pi of
ethidium bromide (10 mg/ml) was added and mixed by swirling. The solution was
poured into a horizontal gel apparatus with a comb in place and left to set. Once set,
enough lx TBE was added to cover the surface of the gel and the electrodes
connected to the gel apparatus. 1 pi of agarose loading buffer was added to the DNA
sample before loading onto the gel. To isolate DNA fragments from cut plasmid
DNA, 3 pi of agarose loading buffer was added to the remaining digest, which was
run as above on a low melting point agarose gel in a single large well, and the insert
fragment was cut out of the gel using a sterile scalpel blade. The gel was heated at
65°C in an eppendorf tube until it melted, which took 10-30 min. To clean up the
DNA, 100 pi Tris-saturated phenol was added, the mixture vortexed, left on dry ice
for 5-15 min and centrifuged for 5 min at 14 OOOg. The upper aqueous phase which
contained the DNA was removed and extracted once with 100 pi Tris-saturated
phenol, once with 100 pi Tris-saturated phenol and 100 pi chloroform:
isoamylalcohol (24:1 v/v) and once with 100 pi chloroform: isoamylalcohol. The
DNA was ethanol precipitated by the addition of 0.15 volumes of 5M NaCl and 2.5
volumes of ethanol, left on dry ice for 5-10 min and centrifuged at 14 OOOg for 5
min. The supernatant was discarded and the DNA pellet left to dry for 10 min at
room temperature before resuspention in 20 pi TE. Recovery of DNA was checked
by electrophoresis of a 1pi aliquot of the total recovered DNA through a 1% agarose
gel as described above.
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2.7.6 32P-Labelling of DNA Fragments
This was accomplished using the method of random priming of DNA which
is based on the hybridisation of a mixture of hexanucleotides to the DNA to be
labelled (Feinberg & Vogelstein, 1983). Hexanucleotide primers are extended from
the 3' OH termini using the Klenow fragment of DNA polymerase 1 in the presence
of radiolabeled nucleotide. A random prime DNA labelling kit was used to label
DNA fragments prepared as described in section 2.7.5.






pmcTAT4 EcoRl /BamHl TAT
pmTF-2 EcoRl Transferrin
Table 2.5:
Restriction enzymes used to isolate (or linearise in the case of p7S) fragments of
cDNA from plasmids.
Approximately 25 ng of DNA fragment or linearised p7S (1-2 |il) was made
up to 9 |il with dH20 in an eppendorf tube and denatured by boiling for 10 min
immediately followed by incubation on ice for 1-2 min. The tube was spun for 10 s
in a bench top centrifuge (to bring the contents to the bottom of the tube) and 2 jil
hexanucleotide primer mixture, lpl each of dATP, dTTP and dGTP, 5|il [a32P]
dCTP and 1 |al of Klenow added to complete the reaction mixture. The reaction was
incubated at 37°C for 2 h and unincorporated [32P]-dCTP removed by passage over
a NICK column. The NICK column was washed with 3ml TE and then the reaction
mixture was added to the top of the column, 400|il TE run through and the eluate
discarded. A further 800|il TE was applied to the column and the eluate collected in
an eppendorf tube. This fraction contained the labelled DNA. Unincorporated
radioactivity was retained by the column. The probe was heated to 100°C to
denature the DNA and routinely, 1 p,l of the probe was added to 3 ml Cocktail T to
check incorporation of radioactivity in a scintillation counter.
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2.8 Northern Analysis of RNA
2.8.1 Extraction of RNA from tissues and cells
Animals were killed by decapitation, tissues immediately dissected on ice,
frozen on dry ice and stored at -70°C until required. Hepatocytes in culture were
harvested from culture dishes by dissolution of the Matrigel basement membrane,
lml of CR-Dispase was added to each 35 mm culture dish following aspiration of
the medium, and incubated for 2 h at 37°C. The contents of each dish were
transferred to an eppendorf tube and gently pipetted up and down to ensure complete
dissolution of the Matrigel and yield a cell suspension. Cells were sedimented by
centrifugation at 50g for 2 min, the supernatant discarded and extraction of RNA
performed immediately.
Total RNA was extracted from brain regions, liver, kidney and cultured
hepatocytes by the guanidium thiocyanate method as described by Chomczynski and
Sacchi (1987). Routinely, approximately O.lg of tissue, or the pellet of hepatocytes
harvested from one dish, was homogenised in 500 |il of denaturing solution using
sterilised Dounce homogenisers. The homogenate was transferred to a 1.5 ml
eppendorf tube and 50 pi 0.2M sodium acetate (pH 4) was added to precipitate
DNA. The mixture was vortexed and protein was removed by extraction with 500 pi
citrate-saturated phenol and 100 pi chloroforrmisoamyl alcohol (49:1). The
homogenates were vortexed thoroughly and left on ice for 15 min before
centrifugation at 14 OOOg for 20 min. The upper aqueous phase containing the RNA
was transferred to fresh tubes, mixed with 200 pi isopropanol to precipitate the
RNA, and left at -20°C for at least 1 h. The tube was centrifuged again for 20 min to
pellet the RNA, the supernatant removed, and the pellet resuspended in 60 pi
denaturing solution and 60 pi isopropanol. The RNA was reprecipitated at -20°C for
at least 1 h and the RNA recovered by centrifugation for 10 min. The pellet was
washed in 200 pi 70% ethanol, dried briefly at room temperature and resuspended in
an appropriate volume of DEPC-treated H2O. This was generally 30 pi for brain
RNA, 50 pi for kidney RNA, 100 pi for liver RNA and 20 pi for cultured
hepatocytes, depending on the size of the RNA pellet. RNA concentration and purity
were estimated spectrophotometrically by measuring the absorbance at 260 nm and
280 nm. RNA was stored at -20°C for short periods of time prior to use.
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2.8.2 RNA Electrophoresis and Capillary Transfer
Total RNA was electrophoresed on 1.2% agarose-2% formaldehyde
denaturing gels to fractionate it. For a 100 ml gel, 1.2g of agarose was melted in
88ml DEPC-treated H2O, allowed to cool slightly before the addition of 2 ml 40%
formaldehyde and 10 ml lOx MOPS buffer, then poured into a gel mould with a
comb whose tooth size allowed 25-40 jxl to be loaded into each well. After setting,
the gel was soaked in lx MOPS buffer in the gel tank for approximately 30 min.
Aliquots of total RNA from tissues (20 |Xg) or cultured hepatocytes (half the total
RNA isolated from one dish) were adjusted to a volume of 10 ]il by the addition of
DEPC-H2O or by volume reduction in a sample concentrator as required. 10 jil
deionised formamide, 2.5 pi formaldehyde and 2.5 |il lOx MOPS were added to
each sample to give a total volume of 25 |il and the RNA was denatured by heating
at 65°C for 15 min. 1 |al of 10 mg/ml ethidium bromide was added to each 20 p.1 of
loading buffer, and 2 pi of this was added to each RNA sample before loading onto
the gel. Gels were routinely run at 100V for 2-8 h depending upon gel size. The gel
was soaked in 20x SSC for 15 min, and photographed under UV light before blotting
onto a nitrocellulose (Hybond C Extra) or nylon (Hybond N) membrane. The gel
was laid onto a wick of Whatman 3MM filter paper draped over an upturned gel
mould running into a plastic tray containing 20x SSC. The membrane (cut to exactly
the same size as the gel) was placed on top of the gel, 3 sheets of Whatman 3MM
filter paper were placed over the membrane and a wad of paper towels on top of this
to draw the 20x SSC. A weight balanced on a glass plate was placed on top of the
apparatus to secure it, and capillary transfer allowed to take place at room
temperature overnight. The efficiency of transfer was checked under UV light, the
membrane photographed and then baked between two sheets of Whatman 3MM
paper at 80°C for 2 h.
2.8.3 Hybridisation to 32P-Labelled cDNAs
Nitrocellulose and nylon membranes were rehydrated in 20x SSC after
baking, rolled up and put into a Hybaid mini hybridisation bottle containing 9 ml
pre-hybridisation buffer, taking care to ensure there were no air bubbles between the
filter and the bottle. Filters were prehybridised for at least 2 h at 55°C whilst rotating
in a Hybaid mini hybridisation oven before addition of the random-primed 32P-
labelled cDNA probe, prepared as described in section 2.7.6. The filters were
hybridised overnight at 55°C. The following day the probe was disposed of, and the
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filters washed in the hybridisation bottle with approximately 50 ml of lx SSC and
0.1% SDS for a total of 3 washes, each for 20 min at room temperature. This was
followed by a stringent wash in 0.3x SSC and 0.1% SDS at 55°C for 15-30 min
depending on the level of radioactive signal remaining on the membrane. Filters
were then wrapped in clingfilm and exposed to Reflection NEF-495 (Dupont) or
Kodak X-OMAT AR (Sigma) autoradiography film at -70°C overnight against an
intensifying screen. Films were developed in Kodak D19 developing solution
(Ilford) for 2 min, and fixed in a 1 in 5 dilution of Amfix fixative (Champion) for 2
min. Signals were quantified by computer densitometry (Seescan, Cambridge, UK)
and filters were re-exposed for time intervals as necessary to ensure that the signal
density was within the linear range. They were then rehybridised with 7S or
transferrin in exactly the same way as above, to control for RNA loading. If filters
were to be rehybridised with another probe, they were stripped by pouring boiling
water over them, and the stripping was checked by exposing the filters overnight.
Signals were expressed as a ratio of the optical density of the signal of interest to 7S
which is a ribosomal RNA found in relative abundance in numerous cells (Balmain
et al., 1982) and can therefore be used to control for RNA loading on northern
analysis, or as a ratio of the optical density of the signal of interest to transferrin in
the experiments described in sections 4.2.1.2 and 4.2.1.3, as expression of transferrin
is not altered by E2 or glucocorticoid.
2.9 Statistics
All data, where statistically analysed as indicated in the text, were compared
by Analysis of Variance followed by post hoc tests or by the Student's t-Test, as
appropriate. Significance was set at p<0.05. Values are expressed as means ± SEM.
Where data is expressed as a percentage of control values for clarity, statistical
analysis was performed on raw data.
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CHAPTER 3
THE FUNCTION AND REGULATION OF
116-HSD-l IN CELL CULTURE
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3.1 Introduction
The highest levels of 11B-HSD-1 are found in the liver (Monder &
Shackleton, 1984) which also expresses high levels of glucocorticoid receptors and it
has therefore been proposed that the role of hepatic 11B-HSD-1 is to modulate
glucocorticoid access to hepatic GR (Whorwood et al., 1991). 11B-HSD-1 is bi¬
directional in tissue homogenates and purified microsomal fractions (Lakshmi &
Monder, 1988). However, transfection studies have indicated that the reaction
direction of 11B-HSD-1 varies between clonal cell types, with bi-directional activity
in some cells such as CHO cells (Agarwal et al., 1989), but predominant 1 IB-
reduction (reactivation of inert 11-keto metabolites) in others such as TBM and
COS-7 cells (Duperrex et al., 1993; Low et al., 1994a). The reaction direction has
been proposed to reflect intracellular co-substrate (NADP/NADPH) ratios, with
NADP favouring 1 lB-dehydrogenase activity and NADPH favouring 1 IB-reduction
(Agarwal et al., 1989). pH and glycosylation status have also been implicated in
control of direction (Deckx & De Moore, 1966; Agarwal et al., 1989). In vitro, acid
pH favours reduction and alkaline pH favours dehydrogenase activity, whilst
inhibition of glycosylation selectively inhibits dehydrogenase activity leaving
reductase activity unaffected (Agarwal et al., 1989). Clearly the cellular context is
crucial to the direction of 11B-HSD-1 enzyme activity.
The reaction direction of 11B-HSD-1 in liver, which highly expresses this
isoform without detectable 11B-HSD-2 activity or mRNA expression (Brown et al.,
1993; Albiston et al., 1994; Brown et al., 1996), is unknown, although indirect
evidence suggests that in liver 1 lB-reductase predominates. The effluent of perfused
cat liver has a high F to E ratio (Bush, 1969), and following the oral administration
of E in humans, peripheral plasma levels of F but not E rise (Walker et al., 1992),
suggesting that E is activated to F by 1 lB-reductase on first pass through the liver.
However, the reaction direction of 11B-HSD-1 in hepatocytes has not been directly
addressed.
Hepatic 11B-HSD-1 is regulated in vivo by various hormones, including
glucocorticoids, insulin, T3, GH and sex steroids, in a tissue- and developmentally-
specific manner (section 1.3.4). Whether any of these hormonal effects are mediated
directly upon hepatocytes remains unknown, and such studies have been hampered
by the absence of liver-derived clonal cell systems which express 11B-HSD-1.
The aim of the work described in this chapter was to establish primary
hepatocyte cell cultures optimal for the maintenance of 11B-HSD-1 activity and
mRNA expression, in which to (a) investigate the reaction direction of hepatic 116-
87
HSD-1, (b) investigate the hormonal regulation of hepatic 11B-HSD-1 and (c) to
determine the factors which influence 11B-HSD-1 reaction direction in vivo.
3.2 Results
3.2.1 Optimisation of Culture Conditions for Maintenance of 11B-HSD Activity and
Measurement of Enzyme Direction
In preliminary experiments, carried out by Dr. Karen Chapman and Mrs.
Ruth Wallace, primary hepatocytes plated onto either plastic culture dishes or
collagen-coated dishes either did not attach well to the dishes or showed loss of 11B-
HSD-1 mRNA expression in otherwise viable primary hepatocyte cultures. This was
borne out by two experiments in which I cultured hepatocytes on dishes coated with
Rat Tail Collagen Type 1 gel and on dishes coated with Matrigel (section 2.3.2) for
comparison of 118-HSD-l mRNA expression. In one experiment, expression was
completely lost by 48 h on dishes coated with collagen gel, and in the other,
expression persisted at 96 h, but at a lower level than on Matrigel (data not shown).
In contrast, maintenance of 11B-HSD-1 mRNA expression over an extended period
of time of at least 14 d was achieved by culturing hepatocytes on Matrigel (a gel
matrix extracted from the EHS mouse tumour) (Fig. 3.1). Therefore all further
experiments utilised hepatocytes cultured on Matrigel.
A comparison between the maintenance of 118-HSD-l activity in William's
E medium which is serum-free and DMEM/F12 medium containing 5% Nu-serum,
showed that activity was well maintained in both media and that the predominant
reaction direction of 11B-HSD-1 enzyme activity in intact cells was 1 IB-reduction
(Fig. 3.2). However, after 15 d in culture, 11B-HSD-1 activity was higher in cultures
maintained in DMEM/F12, and this discrepancy increased over time, so that at 27 d
cultures maintained in DMEM/F12 clearly had greater 11B-HSD-1 activity (Fig.
3.2). In addition, changes in cell morphology were noted. After 4 d, cells cultured in
William's E were starting to form aggregates, flattening and enlarging. By 7 d, all
these cells were clumped. Cells in DMEM/F12 retained normal morphology with
little clumping for up to 28 days and so DMEM/F12 was routinely used in
experiments thereafter.
Measurement of enzyme activity in intact cells over 35 days confirmed that
the predominant reaction direction was 1 IB-reduction and that activity was
maintained for up to 28 days (Fig. 3.3). 1 lB-dehydrogenase activity was below the
limit of detection, except for low levels over the first 2-3 days after plating and after
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Odays 1 day 3 days 7 days 10 days 14 days
Figure 3.1: 11B-HSD-1 mRNA expression in primary hepatocyte cultures.
Autoradiograph of a representative northern blot of RNA from freshly isolated
hepatocytes (0 days) and from hepatocytes maintained for up to 14 d in culture,
probed with 11G-HSD-1 and 7S RNA cDNAs. Replicates represent RNA extracted
from hepatocytes from separate culture dishes from the same culture preparation and
are typical of results obtained from several different culture preparations. All
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Figure 3.2; 11B-HSD-1 activity of cultures maintained in DMEM/F12 or Williams E
medium.
Hepatocytes were plated on Matrigel basement membrane matrix and maintained for
up to 27 d. 11B-HSD-1 activity was measured at intervals. Activity is expressed as
% conversion of A to B (1113-reductase) or B to A (11B-dehydrogenase) in the
medium overlying the cells after 2 hours. Results are from duplicate samples.
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cells had been cultured for more than 28 days (Fig. 3.3). At both these time-points,
but not during the intervening period, dead and dying cells were present and by 35
days, some cell loss became apparent.
That 1 IB-reduction was the predominant reaction direction held true over a
wide range of physiologically relevant substrate concentrations from 10"9M to
10"7M (Fig. 3.4). Product formation was linear with incubation time over at least 1 h
(Fig. 3.5) and so measurements of levels of 11B-HSD-1 activity for comparison were
routinely estimated by steroid conversion in the medium at 30 min. Measurement of
11B-HSD activity in cell homogenates demonstrated that 1 lB-dehydrogenase activity
(conversion of B to A) is readily detectable under these conditions with 53.9 ±0.1%
and 93.2 ± 2.4% conversion after 10 min and 60 min incubation, respectively. In
contrast, 1 lB-reductase activity (conversion of B to A) appeared to be unstable in
homogenates as previously documented (Low et al., 1993; Lakshmi & Monder,
1988) and was undetectable after 60 min incubation.
3.2.2 Products of 11-Dehvdrocorticosterone Metabolism in Hepatocvte Cultures
In order to detect products of metabolism other than B and verify that the
major product of A metabolism in hepatocyte cultures was indeed B and not a
compound which co-chromatographed in TLC analysis in these experiments,
steroids present in the medium of cells incubated with [3H]-A were extracted and
separated by HPLC. Radiolabeled peaks were compared to the elution profiles of
steroid standards of the major hepatic metabolites of A and B (Table 2.3) to identify
the products. A representative HPLC trace of the UV absorbance of the steroid
standards and of the radiolabeled peaks is shown in Fig 3.6. B was the major
product of A metabolism (86.3±0.6%) over a 1 h assay, and another smaller peak
corresponding to 3B5 a-tetrahydrocorticosterone (13.7±0.6%) was identified.
3.2.3 1 lB-Reductase Activity Predominates Under Conditions of Oxidative stress.
Metabolic Inhibition and Altered pH in Hepatocyte Cultures
11B-HSD-1 reaction direction has been proposed to reflect intracellular co-
substrate (NADP/NADPH) ratios, with NADP favouring 1 lB-dehydrogenase activity
and NADPH favouring 1 IB-reduction (Agarwal et al., 1989). pH has also been
implicated in control of direction, in vitro, acid pH favours reduction and alkaline
pH favours dehydrogenase activity (Deckx & De Moore, 1966; Agarwal et al.,
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Figure 3.3: 11B-HSD-1 activity in primary hepatocyte cultures.
Hepatocytes were plated on Matrigel basement membrane matrix and maintained in
hepatocyte culture medium as defined in section 2.3.2 for up to 35 days. 11G-HSD-1
activity was measured at intervals. Activity is expressed as % conversion ± SEM of
A to B (11G-reductase) or B to A (1 lG-dehydrogenase) in the medium overlying the
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Figure 3.4: 116-HSD-l activity in intact hepatocytes over a range of substrate
concentrations.
Activity is expressed as % conversion of A to B (1 lB-reductase) or B to A (1113-
dehydrogenase) in the medium overlying the cells after 30 min, n=3.
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Figure 3.5: Time course of 11B-HSD-1 activity in intact hepatocytes.
Conversion of substrate to product by 118-HSD-l activity was measured over a time
course of 120 min. Activity is expressed as % conversion of A to B (118-reductase)





Figure 3.6: Products of 11-dehydrocorticosterone metabolism in hepatocyte
cultures.
(a) Elution profiles of steroid standards of the major hepatic metabolites of A and B




(b) Representative HPLC trace of the radiolabeled peaks in an extract of medium
from hepatocyte cultures incubated with [3H-A],
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alteration of intracellular co-substrate or pH could influence the direction of 116-
HSD-1 in hepatocyte cultures.
3.2.3.1 Oxidative stress of Hepatocvte Cultures
Oxidative stress in cells results in anaerobic respiration, thus increasing
intracellular NADP levels at the expense of NADPH, and lowering the intracellular
pH through the production of lactic acid. Thus, whilst on the one hand, the altered
co-substrate ratio would be predicted to favour 116-dehydrogenation, the change in
pH should favour 116-reduction.
Hepatocyte cultures were exposed to O2 concentrations by gassing, as
described in section 2.3.4 (that is, 2.5% O2 or 21% O2), and incubated in sealed
containers to maintain the required O2 tension, or they were maintained in their
normal environment (also 21% O2) in the cell culture incubator. 4 h later, medium
was collected for lactate analysis. The gassed hepatocytes were then re-exposed to
the O2 concentrations as previously for 15 min, sealed, and incubated for a further 1
h during which 11B-HSD-1 activity was measured in the usual manner. Finally, the
lactate concentration in the medium overlying the cells at the end of the experiment
was measured (Table 3.1).
Compared to the ungassed controls, hepatocyte cultures exposed to low O2 or
gassed with an equivalent O2 concentration to their normal environment, showed a
trend for the lactate concentration in the medium overlying the cells to be lower than
those not gassed at all. Similarly, there was a trend for 116-HSD-l activity to be
higher in both the 116-reductase and 116-dehydrogenase directions in the gassed
cells when compared to the control dishes. This experiment was performed only
once as an inconclusive result was obtained, possibly due in part to leakage of
gasses, or confounding effects due to lactate being a substrate for gluconeogenesis in
hepatocytes.
3.2.3.2 Effects of Metabolic Inhibitors on Hepatocyte Cultures
Treatment of 3 day old hepatocyte cultures with 5mM NaN3, ImM KCN
(both compounds are inhibitors of oxidative phosphorylation in cell culture systems
at these concentrations (Sakaida et al., 1992, Prehn et al., 1993, Mason & Sweeny,
1994, Shetty et al., 1993) and hence increase intracellular NADPH levels at the
expense of NADP) or lOmM ascorbic acid (which causes an increase in NADP, and
therefore an increase in intracellular NADP/NADPH in cell culture systems
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Control (21% 02) 2.5% 02 21% 02
[lactate] 4 h 0.98 M 0.58 M 0.38 M
[lactate] 1 h 0.57 M 0.30 M 0.35 M
1 lB-reductase 70.0 % 64.5% 63.9 %
1 lB-dehydrogenase 7.4% 3.4% 2.6%
Table 3.1:
Lactate concentration in the medium overlying the cells and 11J3-HSD-1 activity
following exposure to varying concentrations ofO 2-
[lactate] 4 h is the concentration of lactate in the culture medium following 4 h
incubation, [lactate] 1 h is the concentration of lactate in the culture medium
following the 1 h incubation at the end of the experiment (refer to text for details).
llfi-HSD-1 activity is expressed as % conversion ofA to B (1 lfi-reductase) or B to A
(1 lfi-dehydrogenase) in the medium overlying the cells after 60 min. All figures are
the average ofduplicates from a single experiment.
(Schmidt et al., 1993)) as described in section 2.3.5, did not alter 116-HSD activity
or direction (Fig. 3.7). Indeed, 116-dehydrogenase activity had a tendency to fall
below detectable limits with both azide and cyanide treatment. However, KCN at
lOmM did increase 1 lB-reductase activity, whilst 116-dehydrogenation was
undetectable (Fig. 3.7).
To order to ascertain that intracellular co-substrate ratios had been altered in
hepatocytes, NADP and NADPH concentrations were measured following
incubation with sodium azide or KCN (Fig. 3.8). ImM KCN decreased NADP levels
in comparison with extracts from untreated cells, and 5mM azide decreased NADP
to levels below detection (<1x10~8M), demonstrating that the metabolic inhibitors (at
the concentrations used) significantly depleted NADP, whilst having no effect on
NADPH levels within the hepatocytes. This represents a large alteration in the
intracellular co-substrate ratio (Fig. 3.8).
3.2.3.3 Effects of pH Manipulations on 11B-HSD-1 in Hepatocvte Cultures
11B-HSD activity was measured in primary hepatocytes cultured in medium










































□ 10mM ascorbic acid
11 B-reductase 11 B-dehydrogenase
Figure 3.7: Effect of metabolic manipulations on 11B-HSD-1 activity in hepatocyte
cultures.
a) Hepatocytes were incubated for 4 h with 5 mM sodium azide, 1 mM KCN or 10
mM KCN before 11B-HSD-1 activity was measured. n=7 for 5 mM azide and 1 mM
KCN, n=3 for 10 mM KCN. ND=not detectable. Results are from 3 separate culture
preparations.
b) Hepatocytes were incubated for 4 h with lOmM ascorbic acid before 11B-HSD-1
activity was measured. n=6.
Values are expressed as % conversion of A to B (11 B-reductase) or B to A (11B-














































Figure 3.8: Effect of metabolic inhibitors on (a) NADP/NADPH levels and (b)
NADP/NADPH ratios in hepatocyte cultures.
Hepatocytes were incubated for 4 hours with 5 mM sodium azide or 1 mM KCN
before extraction and quantitation of NADP and NADPH by enzymatic cycling.
Values are expressed as (a) the concentration of co-substrate (b) NADP/NADPH
ratio in sample extract. ND=not detectable. *P<0.05 vs. control.
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A to B in 30 min) nor 1 lB-dehydrogenase activity (conversion of B to A in 30 min)
were altered (Fig. 3.9).
3.2.4 11B-HSD-1 Expression in Y1 Adrenocortical Cells
To date CHO cells are the only cell type, either of transfected cell lines or
primary cells, which display 1 lB-dehydrogenase activity in intact cells that is clearly
attributable to 11B-HSD-1 (as opposed to 11B-HSD-2). CHO cells are steroidogenic,
in contrast to other cell lines in which 11B-HSD-1 has been expressed, which raised
the question of whether an intrinsic difference in the cellular localisation of the 11B-
HSD-1 protein in steroidogenic cells might account for the observed difference in
reaction direction. To examine the reaction direction of 11B-HSD-1 in another
steroidogenic cell line, Y1 adrenocortical cells (Yasamura et al., 1966) were
transfected with the rat 11B-HSD-1 expression plasmid SL1 (Low et al., 1994a).
Y1 cells transiently transfected with the vector pJ3 expressed no detectable
1 lB-reductase activity over a 24 hour assay (Fig. 3.10). However, cells transfected
with pJ3 contained clearly detectable endogenous 1 lB-dehydrogenase activity (likely
to be due to 11B-HSD-2). In contrast, 11 B-reductase activity was readily apparent in
Y1 cells transfected with pSLl; furthermore, 1 lB-dehydrogenase activity was
reduced by approximately 50% (Fig. 3.10).
When measured in cell homogenates, 116-dehydrogenase activity was clearly
measurable in homogenates of cells transfected with pSLl (9.7±1.9% conversion of
B to A), whilst in mock transfected cells or cells transfected with pJ3, 11B-
dehydrogenase activity was detectable at much lower levels (2.3±0.2% conversion of
B to A).
3.2.5 Hormonal regulation of 11B-HSD-1 in hepatocvtes in culture
Glucocorticoids, T3, GH and sex steroids all regulate hepatic 11B-HSD-1 in
vivo (section 1.3.4). Whether any of these hormonal effects are mediated directly
upon hepatocytes remains unknown, and so I have examined the effects of these
hormones and of insulin (which regulates 118-HSD activity in cultured fibroblasts)

































Figure 3.9: Effect of pH on 11B-HSD-1 activity in hepatocyte cultures.
Hepatocytes were incubated with culture media of pH 6.2, pH 7.4 or pH 8.0 for 4
hours before 11B-HSD-1 activity was measured. Values are expressed as %





pJ3 - 11 R-reductase
pSL1 -11 B-reductase
pJ3 - 11(B-dehydrogenase
pSL1 - 11 ^-dehydrogenase
Figure 3.10: 1 1B-HSD activity in Y1 adrenocortical cells transiently transfected
with 11B-HSD-1 cDNA.
Activity is expressed as % conversion of A to B (1 lB-reductase) or B to A (11B-
dehydrogenase) in the medium overlying the cells. ND=not detectable. Results are
the means of triplicate samples.
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3.2.5.1 The Effects of Glucocorticoids and Insulin Upon llfi-HSD-1 Activity and
mRNA Expression in Hepatocvte Cultures
In order to examine the effects of glucocorticoid and insulin on 118-HSD-l
activity in hepatocytes, Nu-serum was charcoal-stripped to remove endogenous
steroids and small peptides before addition to the medium (insulin levels were
decreased >5000-fold and F became undetectable - section 2.3.10). 11B-HSD
activity was decreased from 31.2 ± 3.0% to 23.4 ± 0.7% conversion of A to B in
hepatocytes cultured for 12 d in medium containing charcoal-stripped Nu-serum.
DEX (10"7M) and insulin (1.3xl0~7M) were added to medium containing the
stripped serum, both singly and in combination, to give concentrations reflecting
those in the standard maintenance media. DEX increased both 11B-HSD activity and
11B-HSD-1 mRNA expression (Fig. 3.11). In contrast, insulin decreased 11B-HSD-1
mRNA expression, although enzyme activity was not significantly altered by 12 d
treatment with insulin (Fig. 3.11). Insulin also antagonised the increase in 11B-HSD-
1 mRNA by DEX when the hormones were added in combination (Fig. 3.11).
3.2.5.2 The Effects of Oestradiol. Growth Hormone and Thyroid Hormone Upon
11B-HSD-1 Activity and mRNA Expression in Hepatocvte Cultures
Primary hepatocytes were cultured in the presence of E2, GH, T3 or a
combination of these hormones, and 11B-HSD-1 activity was measured every 3 d
over a 12 d period. The 1 lB-reductase activity of hepatocytes cultured for 12 d in the
presence of hormones is shown in Fig. 3.12. No change in 11B-HSD-1 activity was
observed at any time in cells exposed to 10-8 M E2, 0.05 i.u./ml GH, 10~8 M T3 or a
combination of E2 and GH. In addition, 118-HSD-l mRNA expression was
unaltered by 12 d treatment with T3. In case the effects of E2 were obscured by high
endogenous levels in the culture medium of oestrogenic compounds (phenol red is
known to have oestrogenic activity at the levels used in normal cell culture medium
(Berthois et al., 1986)), the effect of the oestrogen receptor antagonist tamoxifen was
examined. Tamoxifen did not have an effect on 11B-HSD-1 activity in cultured
hepatocytes (either 1 lB-reductase or dehydrogenase activities) over 12 d (data not
shown), indicating that repression of 11B-HSD-1 activity by high levels of























Figure 3.11: Regulation of 11G-HSD-1 (a) activity and (b) mRNA expression in
hepatocyte cultures by dexamethasone and insulin.
Hepatocytes were maintained in standard medium (5% Nu-serum) or medium
containing 5% charcoal-stripped Nu-serum to which DEX (10_7M) and/or insulin
(1.3xl0"7 M) were added. 11G-HSD-1 activity and mRNA were quantified after 12
d. Activity is expressed as % conversion A to B (1113-reductase) after 30 min.
mRNA levels are expressed as a percentage of control levels normalised for loading.







Figure 3.12: Effects of oestradiol, growth hormone and thyroid hormone on 116-
HSD-1 activity in hepatocyte cultures.
Hepatocytes were maintained in media with E2 (10"8M), GH (0.05 i.u./ml) or T3
(10_8M) added. Activity was measured after 12 days. Values are expressed as %
conversion A to B (116-reductase) after 30 min. Results are from 2 (T3) or 3 (GH
and E2) separate culture preparations.
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3.3 Discussion
I have established conditions for culture of primary rat hepatocyte cultures
which maintain 11B-HSD-1 activity for 4 weeks. Most cell culture conditions are
associated with rapid loss of differentiated functions in primary hepatocyte cultures
(Clayton et al., 1983, 1985), including loss of 11B-HSD-1 mRNA expression and
enzyme activity. When hepatocytes are dissociated they "turn off' unnecessary
differentiated functions and begin to divide, a process perhaps akin to hepatic
"regeneration" (Mischoulon et al., 1992; Mooney et al., 1992). Maintenance on a gel
matrix (Matrigel) in media containing high levels of glucocorticoids, insulin and
other peptides, presumably more closely resembles the milieu of the intact liver and
thus allows isolated cells to maintain differentiated functions, including the
expression of 11B-HSD-1. The maintenance of 11B-HSD-1 expression over an
extensive time period makes this system useful for the investigation of the role and
regulation of 11B-HSD-1 in hepatocytes.
Using this cell culture system I demonstrated that 1 IB-reduction is the
primary activity of 11B-HSD-1 in intact hepatocytes over a wide range of
physiologically relevant substrate concentrations. The major product of A
metabolism was B with the only other product identified as 3B5a-
tetrahydrocorticosterone, a further metabolite of B resulting from the activities of
5a-reductase and 3B-HSD. 1 lB-dehydrogenase activity was undetectable or barely
detectable. Likewise, intact COS7 cells transiently transfected with 11B-HSD-1
cDNA show only 1 IB-reduction (Low et al., 1994a). However, in homogenates
made from liver, primary cultures of hepatocytes or 11B-HSD-1-transfected COS7
cells, 1 lB-dehydrogenase activity is readily detectable (this chapter, Low et al.,
1994; Lax et al., 1978; Low et al., 1993b) demonstrating that 116-HSD-l in these
cells is clearly capable of 1 lB-dehydrogenation under certain conditions. The 11B-
dehydrogenation detectable in hepatocytes in culture over the first 2-3 days after
plating and after 28 days, is present at a time where dead and dying cells are visibly
present and may be due to enzyme released from dead or dying cells. In contrast,
intact CHO cells transiently transfected with 11B-HSD-1 cDNA show both
dehydrogenation and reduction in approximately equal proportions (Agarwal et al.,
1989).
The determination of 11B-HSD-1 enzyme direction in vivo has been
postulated to be determined by post translational modifications including
glycosylation of the 11B-HSD-1 protein. 11B-HSD-1 has two putative N-linked
glycosylation sites, and inhibition of glycosylation selectively inhibits
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dehydrogenase activity leaving reductase unaffected (Agarwal et al., 1989).
However, changes in glycosylation cannot explain the exclusive 1 IB-reduction
observed in intact COS-7 cells transfected with 11B-HSD-1 cDNA, which
nonetheless show 116-dehydrogenation when the enzyme is assayed in homogenates
of the same transfected cells (Low et al., 1994a). In all cases, 116-dehydrogenase
activity is readily detectable in homogenates, whereas the equilibrium shifts to
favour reduction in most intact cells (this work and Agarwal et al., 1989; Low et al.,
1994a, Raj an et al., 1995). Therefore the direction in vivo is likely to reflect some
aspect of the cellular environment of the protein.
To date CHO cells are the only cell type in which 11G-HSD-1 exhibits 116-
dehydrogenase activity in intact cells. CHO cells are steroidogenic, which raised the
question of whether a difference in the cellular localisation of the 116-HSD-l protein
in steroidogenic cells could account for the difference in reaction direction.
Y1 cells are derived from a mouse adrenocortical tumour (Cohen et al., 1957)
and retain many tissue-specific characteristics including steroid synthesis and
responsiveness to ACTH ( Pierson, 1967; Yasumura et al., 1966). Steroidogenic Y1
adrenocortical cells were found to have intrinsic 116-dehydrogenase activity with no
116-reductase. However, transient expression of rat 116-HSD-l cDNA in Y1 cells
resulted in 116-reductase activity which antagonised the intrinsic 116-dehydrogenase
activity. As expected, 116-dehydrogenase activity was readily detectable in cell
homogenates. 11G-HSD-2 is present in the mouse and rat adrenal (Y1 cells are
derived from a mouse adrenocortical tumour (Cohen et al., 1957), but is absent from
the human adrenal (Shimojo et al., 1996). These results are consistent with the
presence of 116-HSD-2 in Y1 cells, which is counteracted by expression of 11-HSD-
1 encoding 116-reductase activity. Thus it seems that in this cell line the 116-HSD-l
protein is again predominately a reductase. Why 116-HSD-l in CHO cells
demonstrates bi-directional activity remains unclear, but it is most likely a
consequence of overexpression of the 116-HSD-l protein in the transient expression
system. CHO cells stably transfected with 116-HSD-l show 116-reductase activity
only (C Leckie & JR Seckl, personal communication). It is likely that transient
transfection of 116-HSD-l results in 116-HSD-l protein levels which exceed the
cells' ability to localise it correctly, allowing excess mislocalised protein to function
as a dehydrogenase.
In principle, co-substrate availability might determine reaction direction, as it
indeed does in homogenates, with NADP favouring dehydrogenation and NADPH
favouring reduction (Agarwal et al., 1989). Oxidative stress results in anaerobic
respiration, thus increasing intracellular NADP levels at the expense of NADPH, and
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lowering the intracellular pH through the production of lactic acid. However,
oxidative stress did not result in changes in 11B-HSD-1 reaction direction or activity
in primary hepatocytes, and the lactate concentration was decreased in cells exposed
to low or normal levels of O2 when compared to controls. It is possible that
problems with gas leakage, compounded with the use of lactate as a substrate for
gluconeogenesis in hepatocytes led to the lack of an interpretable result. Thus, the
metabolic poisons azide and cyanide were used to put the cells under a greater
oxidative stress, in a more easily controllable system. Although treatment with very
high concentrations of cyanide (10 mM) did increase 1 lB-reductase activity in
keeping with the theory that a relative increase in NADPH will favour 1 IB-
reduction, the large changes in NADP/NADPH ratios achieved with metabolic
poisons used here had remarkably little effect on reaction direction. These data
suggest that the availability of NADP does not determine reaction direction in vivo.
However, it remains to be determined whether limiting the availability of NADPH,
particularly in the specific subcompartment containing 11B-HSD-1, could shift the
reaction direction in intact cells towards 1 lB-dehydrogenation. Similarly, although in
cell homogenates pH influences the equilibrium of 11B-HSD-1 (reduction is
favoured at acid pH and dehydrogenation at alkaline pH in vitro (Monder &
Shackleton, 1984)) there was no alteration in enzyme direction or activity in intact
hepatocytes over a range of extracellular pH. However, whether the intracellular pH
was altered in this experiment is undetermined, and if it was altered, it still remains
possible that within a subcellular compartment pH may be very different to that
within the cell as a whole.
11B-HSD-1 is a membrane-associated protein which shows a microsomal
location (Monder & White, 1993), whilst 11B-HSD-2, an exclusive dehydrogenase
which is also a membrane-associated protein shows a different intracellular
distribution to 11B-HSD-1 (Brown et al., 1993). The key determinants of reaction
direction probably reflect more than the mere presence of membrane (as this is also
present in homogenates) and may be controlled by the sub-organelle
microenvironment generated, for example, by neighbouring enzymes. The precise
intracellular localisation of both isoforms of 11B-HSD awaits the development of
highly specific antisera suitable for electron microscopical studies.
Previous studies have shown that 11B-HSD-1 is sexually dimorphic in the
liver, with lower levels in females than males (Lax et al., 1978; Low et al., 1993). E2
markedly attenuates hepatic 11B-HSD-1 activity and mRNA expression in vivo, an
effect that is, in part, mediated by GH (Low et al., 1994b). In primary hepatocyte
cultures, neither E2 nor GH affected 11B-HSD-1 enzyme activity. The failure of GH
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to regulate 11B-HSD-1 in primary hepatocytes in culture might reflect an indirect
mechanism of action. However, hepatic enzymes exhibiting sexual dimorphism have
been demonstrated to be directly regulated by GH in hepatocyte cultures (Guzelian
et al., 1988; Schuetz et al., 1990; Toilet et al., 1990), and so it is more likely to be
due to a reduction in the number of GH receptors on the cells, the expression of
which are variable in primary culture (Crabb & Roepke, 1987; Niimi et al., 1991).
Other sexually dimorphic enzymes which contain a GH-response element in their
promoter region lose their GH regulation in hepatocyte culture (Legraverend et al.,
1992; Matsunaga et al., 1990; Yoshioka et al., 1990). Therefore, an alternative
explanation has been proposed, such that the differences between in vivo and in vitro
GH transcriptional responses may be due to the loss, in vitro, of a repressive function
(Legraverend et al., 1992). The absence of effects of E2 and T3 presumably reflect
the indirect nature of their effects upon hepatic 11B-HSD-1, since loss of their
receptors is unlikely and these receptors act directly upon target DNA (Ribeiro et al.,
1995). Although sequences resembling E2 or T3 response elements are found within
the 11B-HSD-1 gene promoter (Moisan et al., 1992), the data presented here support
in vivo evidence that the regulation of 11B-HSD-1 expression by sex steroids, and
possibly T3, is mediated indirectly, in part via their effects on GH secretion. GH
secretion is almost totally dependent on T3 which also markedly increases GH
mRNA and protein synthesis (Evans et al., 1992; Spindler et al., 1992; Peake at al.,
1973; Hervas et al., 1975; Coiro et al., 1979). Indeed, the latter contention is
supported by the sexually dimorphic effects of T3 on 11B-HSD-1 in rat liver, with
thyroidectomy increasing 116-HSD activity in females, but decreasing activity in
males (Lax et al., 1979).
In contrast, DEX and insulin clearly regulate 11B-HSD-1 in hepatocyte
cultures. Previous studies have shown that ADX of rats attenuates hepatic 11B-HSD
enzyme activity and also attenuates reactivation of E to F (presumably mediated by
hepatic 11B-HSD-1) (Nicholas & Lugg, 1982); administration of glucocorticoids to
ADX rats increases hepatic 11B-HSD-1 activity and mRNA (Low et al., 1994c). This
appears to be a direct effect upon hepatocytes as DEX increased 11B-HSD-1 activity
and mRNA expression in hepatocyte cultures. The regulation of hepatic 116-HSD-l
by glucocorticoids is further explored in Chapter 6. The molecular mechanism is
unknown, but sequences resembling the GRE have been reported in both human
(Tannin et al., 1991) and rat (Moisan et al., 1992b) 11B-HSD-1 genes, and data from
transfection experiments of HepG2 cells with plasmids in which 11B-HSD-1
promoter DNA is fused to a reporter gene suggest that a GRE lies within 1800 base
pairs of the transcription start of 11B-HSD-1 (Voice et al., 1996). The antagonism by
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insulin of DEX-induced 11G-HSD-1 activity and mRNA expression in cultured
hepatocytes reflects similar regulation in cultures of human fibroblasts (Hammami &
Siiteri, 1991). This is a common pattern of regulation, and many key metabolic
enzymes in the liver are antagonistically regulated by insulin and glucocorticoids
(section 1.4.4). The data presented here suggest similar controls apply to hepatic
11B-HSD-1.
These data are evidence for the predominance of the 11G-reductase activity of
11G-HSD-1 in the intact liver. 11B-HSD-1 is therefore likely to exert effects on
glucocorticoid action within the liver via its effects on glucocorticoid metabolism
and the possible significance of this is addressed in Chapter 4.
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CHAPTER 4




GR are highly expressed in the liver (Wrange et al., 1979; Govindan et al.,
1985), which is therefore a major target for glucocorticoid action. The tissue
distribution of 11B-HSD-1 is similar to that of GR, which has led to the proposal that
11B-HSD-1 regulates ligand access to GR (Moisan et al., 1990b; Teellucksingh et al,
1990; Whorwood et al., 1991).
In the last chapter, I demonstrated that the predominant reaction direction of
11B-HSD-1 in hepatocytes is 1 IB-reduction, thus potentially increasing local
concentrations of active glucocorticoids and potentiating intrahepatic glucocorticoid
action. This has important implications for liver physiology. Glucocorticoids
regulate the transcription of many of the key hepatic enzymes involved in
carbohydrate and fat metabolism (section 1.4.4). It may be that 1 lB-reductase
activity is necessary to maintain adequate occupation of GR by ligand within the
liver during fluctuations in circulating levels of glucocorticoids e.g. during the daily
Cortisol nadir (section 1.1.2).
Glucocorticoids antagonise the action of insulin (de Feo et al., 1989; Dinneen
et al., 1993) within the liver by promoting hepatic glucose secretion (Rooney et al.,
1994), an effect mediated in part by promoting the transcription of PEPCK
(Friedman et al., 1993; Lamers et al., 1982; Sasaki et al., 1984), the rate-limiting
enzyme in gluconeogenesis (reviewed by Hanson & Garber, 1972 and see section
1.4.4). Insulin resistance is associated with a number of diseases including obesity
(Baron et al., 1991), NIDDM (Kolterman et al., 1981) and essential hypertension
(Welborn et al., 1966; Ferrannini et al., 1987), and there is evidence that
glucocorticoid metabolism is abnormal in these conditions (section 1.4.5).
Recent data have suggested that inhibition of 11B-HSD (both isozymes) by
CBX increases fasting hepatic insulin sensitivity in humans in vivo, consistent with
decreased GR activation. This effect is most likely to be due to the attenuation of
hepatic glucocorticoid regeneration by 1 lB-reductase activity in the liver
counteracting the F antagonism of insulin action (Walker et al., 1995). Thus it can be
predicted that decreased 118-HSD-l activity in the liver, by decreasing
glucocorticoid action in the liver, will decrease the expression of hepatic
glucocorticoid-inducible genes, and increase insulin sensitivity and glucose
tolerance in the rat in vivo. I have tested this hypothesis in two model systems of
decreased hepatic 11B-HSD-1 activity; attenuation of hepatic 11B-HSD-1 expression
by E2 administration and inhibition of 11B-HSD activity by CBX administration. A
third potential model for examination of these ideas, achieved by the creation of the
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11B-HSD-1 "knockout" mouse (Kotelevtsev et al., 1996) has been verified as
providing the extreme case of a complete deficiency of 118-HSD-l.
In the rat liver, 11B-HSD-1 shows pronounced sexual dimorphism, with two¬
fold lower activity in females (discussed in section 1.3.4). This effect is attributable
to the sex steroid determination of patterns of GH secretion (section 1.3.4). E2 has
an additional tissue-specific repressive effect on 116-HSD-l such that chronic E2
administration almost completely suppresses hepatic and renal 11B-HSD-1
expression in both male and female rats (Lax et al., 1978; Low et al., 1993; Low et
al., 1994b). This regulation appears to be tissue- and isozyme-specific, as E2 does
not attenuate 11B-HSD-1 expression in the hippocampus or 11B-HSD-2 activity in
the kidney (Low et al., 1993). In the experiments described in this chapter, I have
exploited the selective suppression of hepatic 11B-HSD-1 by E2 in vivo in order to
examine the effect of attenuated hepatic 11B-HSD-1 on the expression of hepatic
glucocorticoid-inducible genes.
CBX is the hemi-succinate derivative of GE (the active constituent of
liquorice which inhibits renal 11B-HSD activity). It has been demonstrated that CBX
(Stewart et al., 1990), but not glyccyrhetinic acid (Walker & Edwards, 1994),
inhibits hepatic 1 lB-reductase in vivo. Walker et al. (1995) have shown that CBX
administration to humans increases whole body insulin sensitivity, and so I have
used CBX to inhibit 116-HSD in rats in vivo to investigate the effects of inhibition
of hepatic 116-HSD-l on insulin sensitivity and glucose tolerance and the
expression of PEPCK. The disadvantage of CBX administration, is that it
competitively inhibits the activity of both isozymes of 11B-HSD.
As the proposed model for 11B-HSD-1 function in liver also predicts that
increased hepatic 11B-HSD-1 activity should lead to increased glucocorticoid levels
in the liver, and thus decreased insulin sensitivity, I have examined 11B-HSD-1
activity in the obese fa/fa Zucker rat (Zucker & Zucker, 1967), which is a well
established model of obesity and insulin resistance (Bray, 1977). Obese Zucker rats
are hyperinsulinaemic, show reduced glucose tolerance (Rohner-Jeanrenaud et al.,
1986) and are hypercorticosteronaemic (Krief & Basin, 1991), all of which are risk
factors for the onset of NIDDM in humans (section 1.4.5).
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4.2 Results
4,2.1 Effect of Attenuation of Hepatic 11B-HSD-1 by Chronic Oestradiol Treatment
on Hepatic Glucocorticoid Modulated Gene Expression
4.2.1.1 Effect of Chronic Oestradiol Treatment on 11B-HSD-1 Activity and mRNA
Expression
E2 administration for 10, 21 and 42 d to gonadectomised male rats (section
2.6.2) resulted in marked decreases in hepatic 11B-HSD activity (Fig. 4.1). However,
11B-HSD activity was not completely abolished since prolonged (60 min) incubation
of liver homogenates from rats given E2 for 42 d showed detectable (12.2±4.7%)
conversion of B to A. 11B-HSD-1 mRNA expression fell to undetectable levels after
42 d of E2 treatment (Fig. 4.2) and indeed was undetectable after 21 d treatment
(Fig. 4.5) in accordance with previous studies (Low et al., 1993). 11B-HSD activity
in the hippocampus was unaltered by E2 treatment for 21 or 42 d (Fig. 4.1). The
control mRNA, transferrin, which is unaffected by glucocorticoids (Ruppert et al.,
1990) was unaffected by E2 treatment (Fig. 4.2).
4.2.1.2 Effect of Oestradiol on Hepatic Glucocorticoid-Inducible Gene Expression
To examine the effect of attenuated hepatic 11B-HSD-1 activity on local
glucocorticoid action, the expression of hepatic glucocorticoid-inducible genes was
measured after 42 d of E2. Northern analysis was used to measure expression of
PEPCK, angiotensinogen, SAMS and TAT mRNA in the livers of control and E2
treated animals. A representative northern blot of PEPCK is shown in Fig. 4.3. E2
treatment dramatically decreased PEPCK mRNA whilst leaving transferrin mRNA
unaffected (Fig. 4.3). Quantitation of mRNA expression demonstrated that PEPCK
and angiotensinogen mRNA expression were significantly reduced by E2 treatment,
whilst SAMS and TAT mRNA expression were not significantly altered, although a
downwards trend was noted (Fig. 4.4).
4.2.1.3 Effect of Oestradiol ± Adrenalectomy on Hepatic Glucocorticoid-Inducible
Gene Expression
To examine whether these effects of E2 on hepatic gene expression were
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Figure 4.1: Effect of oestradiol administration on 11B-HSD-1 activity.
E2 repression of (a) hepatic and (b) hippocampal 11B-HSD-1 activity. 11B-HSD-1
activity was assayed in homogenates of liver from gonadectomised male rats
receiving E2 for 10, 21 and 42 d and homogenates of hippocampus from
gonadectomised male rats receiving E2 for 21 and 42 d. Data are expressed as a
percentage of activity (±SEM) in control animals receiving vehicle. n=5-10. *P<0.05
compared with controls.
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Figure 4.2: Oestradiol repression of hepatic 11G-HSD-1 mRNA expression in liver.
Autoradiograph of northern blots of RNA from the livers of gonadectomised male
rats receiving E2 for 42 days and from controls receiving vehicle. Each lane contains
20 p,g total RNA from an individual animal. Hybridised to llft-HSD-1 and






Figure 4.3: Effect of oestradiol on hepatic PEPCK mRNA expression in liver.
Autoradiograph of a representative northern blot of RNA from the livers of
gonadectomised male rats receiving E2 for 42 d and from controls receiving vehicle.
Each lane contains 20 pig total RNA from an individual animal. Hybridised to
PEPCK and transferrin cDNAs.
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Figure 4.4: Effect of oestradiol on glucocorticoid-modulated hepatic gene
expression.
mRNA levels from the livers of male gonadectomised rats receiving E2 for 42 d and
from controls receiving vehicle was quantified by northern analyses. Data are
normalised to expression of transferrin, and expressed as a percentage of mRNA
levels (±SEM) in control animals. n=5. *P<0.05 compared with controls.
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altered glucocorticoid action in the liver, the effects of E2 in ADX animals or sham
ADX controls were examined (section 2.6.2). Animals were killed after 21 d. ADX
increased hepatic 11B-HSD-1 gene expression and activity compared with sham
ADX controls (Fig. 4.5 and Fig. 4.6). E2 reduced hepatic gene expression and
activity in ADX rats, and although mRNA was higher than E2-treated adrenally-
intact rats, it was reduced compared with untreated controls (Fig 4.6).
Hepatic PEPCK gene expression was decreased after 21 d of E2 treatment,
albeit to a lesser extent than after 42 d (Fig. 4.7 and Fig 4.8). Unsurprisingly, ADX
also attenuated hepatic PEPCK gene expression, but in ADX rats E2 no longer
reduced, but indeed increased PEPCK mRNA levels when compared with ADX
alone. At this time point, E2 had no significant effect upon angiotensinogen mRNA
expression in adrenally-intact rats, although E2 did increase angiotensinogen gene
expression in ADX rats (Fig. 4.8). Neither SAMS nor TAT mRNA levels were
affected by E2 for 21 d (Fig. 4.8), consistent with the 42 d data. Interestingly, TAT
mRNA levels were significantly decreased by ADX and E2 markedly increased TAT
mRNA expression in ADX animals (Fig. 4.8).
4.2.1.4 Effect of Oestradiol on Endogenous Hepatic Metabolism of Corticosterone
In order to determine whether the effects of E2 upon glucocorticoid-sensitive
mRNAs was due to actions upon other pathways of B metabolism in the liver, the
metabolism of B in liver homogenates from E2-treated (42 days) and control animals
was measured (Table 4.1). All values are corrected for the values in blank (no
homogenate) incubates. There were no differences between the HPLC steroid
profiles (section 2.2.6) of the control and E2-treated sample incubates except in the
relative quantities of A and B, and no additional products of B metabolism were
detected (Table 4.1). The recovery of [3H]-B as ([3H]-B + [3H]-A) was 109±13%
and 107±14% for the control and E2-treated sample incubates, respectively.
4.2.2 The Effect of Carbenoxolone Administration on 11B-HSD-1 and Glucose
Tolerance
CBX administration for 14 d to intact male rats (section 2.6.3) had no
significant effect on hepatic 11B-HSD enzyme activity ex vivo at any of the dosages
employed (Fig. 4.9). However 10 mg per day CBX did reduce hepatic mRNA









Figure 4.5: Effect of adrenalectomy and oestradiol on hepatic 1 18-HSD-l mRNA
expression.
Autoradiograph of northern blots of RNA from the livers of gonadectomised male
rats receiving E2 or vehicle for 21 d following ADX or sham ADX. Hybridised to
118-HSD-l and transferrin cDNAs. Each lane contains 20 |ig total RNA from an
individual animal. All samples were electrophoresed on a single northern gel,
hybridised on a single blot, exposed to the same film for the same length of time and
expressed relative to each other. Differences in background density are due to













































Figure 4.6: Effect of adrenalectomy and oestradiol on hepatic 11B-HSD-1 activity
and mRNA expression.
(a) 11B-HSD-1 activity was assayed in homogenates and (b) 11B-HSD-1 mRNA was
quantified from the livers of gonadectomised male rats receiving E2 or vehicle for 21
d following ADX or sham ADX. Data are expressed as a percentage of (a) activity
or (b) mRNA levels (normalised to expression of transferrin) ±SEM in control sham
ADX animals receiving vehicle.
E2=oestradiol, ADX=adrenalectomy, ADX+E2=adrenalectomy+oestradiol. n=9-10.




Figure 4.7: Effect of adrenalectomy and oestradiol on hepatic PEPCK mRNA
expression.
Autoradiograph of northern blots of RNA from the livers of gonadectomised male
rats receiving E2 or vehicle for 21 d following ADX or sham ADX. Hybridised to
PEPCK and transferrin cDNAs. Each lane contains 20 pg total RNA from an
individual animal. All samples were electrophoresed on a single northern gel,
hybridised on a single blot, exposed to the same film for the same length of time and













Figure 4.8: The effect of oestradiol on hepatic gene expression is dependent upon
adrenal steroids.
Levels of mRNA from the livers of male gonadectomised rats receiving E2 or
vehicle for 21d following ADX or sham ADX was quantified by northern analyses.
Data are normalised to expression of transferrin, and expressed as a percentage of
mRNA levels (±SEM) in control sham ADX animals receiving vehicle.
E2=oestradiol, ADX=adrenalectomy, ADX+E2=adrenalectomy+oestradiol. n=9-10.
















Figure 4.9: Effect of carbenoxolone administration on hepatic 11G-HSD-1 activity.
11B-HSD-1 activity was assayed in homogenates of liver from male rats receiving
daily injections of 1, 3 or lOmg CBX for 14 days. Data are expressed as a percentage
of activity (±SEM) in control animals receiving vehicle. n=8.
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Products of corticosterone metabolism in liver homogenates from gonadectomised
male rats receiving oestradiol (E2) for 42 d and control animals receiving vehicle.
The relative quantities ofmetabolites detected are expressed as a percentage of total
[^HJ-steroid recovered. A=11 -dehydrocorticosterone, B=corticosterone, C=other
radiolabeled steroid metabolites (refer to Table 2.3). Note that E2 attenuates
production ofA, but that production ofother B metabolites remains negligible.
effect on the weight of the rats, when compared to controls receiving vehicle (data
not shown).
Administration of 3 mg or 10 mg CBX daily for 14 d to intact male rats
resulted in a fall in fasting plasma glucose levels (Fig 4.10). There was no difference
in response to an oral glucose load given in a glucose tolerance test (section 2.6.3) in
terms of glucose disposal (Fig 4.11). There was no significant difference in fasting
plasma insulin concentration (Fig. 4.12) resulting from CBX treatment or in the total
amount of insulin secreted in response to the glucose load (Fig. 4.13). However
there was a trend for both the level of fasting plasma insulin and the total amount of
insulin secreted in response to the glucose load to decrease as the dosage of CBX
increased.
Measurement of plasma sodium, chloride and potassium showed that whilst
sodium and chloride levels rose as the dosage of CBX increased, potassium levels
remained unaltered and were elevated above the expected normal levels (Fig 4.14).
This was most likely due to haemolysis of red blood cells during blood collection,
which releases potassium into the plasma leading to artificially high levels when
measured.
Measurement of plasma A by GCMS (section 2.2.8 and 2.2.9) showed no


























Figure 4.10: Effect of carbenoxolone administration on fasting plasma glucose.
Fasting plasma glucose concentration was measured in male rats receiving daily
injections of 1, 3 or lOg CBX for 14 d. Data are expressed as mean±SEM. n=6-8.














































Figure 4.11: Effect of carbenoxolone administration on glucose tolerance.
Glucose tolerance tests were carried out in male rats after receiving daily injections
of 1, 3 or 10 mg CBX for 14 d. (a) Time course of plasma glucose concentration
following an oral glucose load (section 2.6.3). (b) Areas under the curves of plasma












Figure 4.12: Effect of carbenoxolone administration on fasting plasma insulin.
Fasting plasma insulin concentration was measured in male rats receiving daily












Figure 4.13: Effect of carbenoxolone administration on insulin secretion.
Glucose tolerance tests were carried out in male rats after receiving daily injections
of 1, 3 or 10 mg CBX for 14 d. (a) Time course of plasma insulin concentration
following an oral glucose load (section 2.6.3). (b) Areas under the curves of plasma




Figure 4.14: Effect of carbenoxolone administration on plasma electrolytes.
Plasma electrolytes were measured in male rats after receiving daily injections of 1,
3 or 10 mg CBX for 14 d. Data are expressed as mean+SEM. n=8.
*P<0.05 compared with controls.
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CBX (mg per day) Plasma A (|ig/ 100ml)
Control 2.9 ± 0.4
1 mg 3.7 ±0.4
3 mg 2.6±0.5
10 mg 3.4 ± 0.4
Table 4.2:
Plasma levels of 11 -dehydrocorticosterone following 14 days of carbenoxolone
administration as measured by GCMS.
Data are mean+SEM. n=8.
Furthermore, PEPCK mRNA expression was unaltered by a daily dose of 10
mg carbenoxolone for 14 days (93.819.1% of levels in controls receiving vehicle).
4.2.3 11B-HSD-1 Activity in the Obese Zucker Rat
Measurement of 11G-HSD activity in the liver and skeletal muscle
(quadriceps) of obese fa/fa Zucker rats showed a significant reduction in 11B-HSD
activity when compared to their lean Fa/fa or Fa/Fa littermates in both tissues (Fig
4.15). Neither plasma insulin levels nor B levels showed a correlation with 11G-HSD
activity in the obese Zucker rats (Table 4.3). Therefore in this animal model, hepatic
1113-HSD-l activity did not show an association with the NIDDM risk factors of
hyperinsulinaemia or hypercorticosteronaemia. Plasma B measurements were
carried out by Dr. Chris Kenyon and are reproduced here with kind permission.
4.2.4 11B-HSD-1 Activity in the 11B-HSD-1 "Knock-Out" Mouse
Gene targeting of 11B-HSD-1 was used to obtain homozygous mice with a
targeted disruption of the 11B-HSD-1 gene (Kotelevtsev et al., 1996). Tissues from a
female mouse homozygous for the gene disruption were assayed for 11B-HSD
activity and a heterozygote littermate was used as a control (Table 4.4). Negligible
11B-HSD activity was detectable in liver, brain or lung, all tissues in which 11B-
HSD-1 is highly or moderately expressed, confirming that the homozygous mutant
mouse possessed no 11B-HSD-1 activity. The low level of 11B-HSD activity
remaining in the kidney when assayed for 11B-HSD-1 dehydrogenase activity with
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Figure 4.15: 1 16-HSD-l activity in obese Zucker rats.
116-HSD-l activity was assayed in homogenates of liver and skeletal muscle from
obese fa/fa Zucker rats and their lean littermates which served as controls. Data are
expressed as a percentage of activity (±SEM) in control animals. n=5-6.
*P<0.001 compared with controls. |P<0.01 compared with controls.
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116-HSD 116-HSD Plasma Insulin Plasma B Body Weight
Activity-Liver Activity- (mU/1) (nmol/1) (grams)
Skeletal Muscle
Lean
51.5 85.2 15 87 228
44.9 71.2 27 217 222
43.5 28.8 26 220 200
38.9 37.6 16 46 222
30.8 54.7 5 190 244
Obese
34.9 25.2 758 741 290
26.7 17.0 742 808 318
19.2 18 345 727 354
18.2 15.8 343 666 372
14.7 19 631 530 340
Table 4.3:
1 lfi-HSD-1 activity in obese Zucker rats and lean controls.
llfi-HSD-1 activity (expressed as % conversion B->A) in liver and skeletal muscle,
plasma insulin and B, and body weight of each individual animal are presented in
each row. Animals are ranked in order of their 1 lfi-HSD-1 activity with the highest
activity levels in liver at the top.
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Tissue Activity "Knock-Out" Control
Liver 116-HSD-l Dehydrogenase 0 16.4
11B-HSD-1 Reductase 0.5 1.4
Brain 11B-HSD-1 Dehydrogenase 0 17.8
11B-HSD-1 Reductase 0.1 12.3
Lung 11B-HSD-1 Dehydrogenase 1.0 14.5
11B-HSD-1 Reductase 0.1 1.1
Kidney 11B-HSD-1 Dehydrogenase 2.9 2.8
11B-HSD-1 Reductase 0.7 0.6
11B-HSD-2 Dehydrogenase 47.2 40.8
Table 4.4:
llfi-HSD activity in the llfi-HSD-1 "knock-out" mouse.
Tissues from a female mouse homozygous for the mutation were assayed for both
1 lfi-dehydrogenase and 1 lfi-reductase activity of llfi-HSD-1 (sections 2.2.1 and
2.2.2). Kidney was also assayedfor 1 lfi-dehydrogenase activity of 1 lfi-HSD-2 (NAD
supplied as cofactor). Tissues from a female mouse homozygous for the mutation
were assayedfor llfi-HSD activity. A heterozygote littermate provided the control.
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NADP as cofactor, is likely to be due to 11B-HSD-2, active in the presence of low
levels of endogenous co-factor (NAD).
To examine the dose effect of the gene on 11I3-HSD-1 activity in vivo, 1113-
dehydrogenase of 1113-HSD-l was measured in tissues of female mice homozygous
for the mutation, heterozygotes and wild-type mice of the parent strain. No
consistent dose effect of the gene was observed throughout the tissues. However, in
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Figure 4.16: 118-HSD activity in the 116-HSD-l "knock-out" mouse.
116-HSD activity was assayed in homogenates of tissues from female wild-type
mice and female mice heterozygous and homozygous for the inactive mutated 1113-
HSD-1 gene. Data are expressed as a percentage of activity (±SEM) in control (wild-
type) mice. n=5-8.
*P<0.001 compared with wild-type. tP<0.001 compared with heterozygotes.
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4.3 Discussion
E2 administration for both 21 and 42 d resulted in undetectable hepatic 118-
HSD-1 mRNA expression and markedly reduced 118-HSD activity (although this
remained clearly measurable), confirming previous studies (Lax et al., 1978; Low et
al., 1993). The discrepancy between mRNA expression and activity might be due to
much slower turnover of the 116-HSD-l protein or, more likely, due to the
transcription and translation of residual low levels of 116-HSD-l mRNA,
undetectable by northern analysis. This effect of sex steroids may be idiosyncratic to
the rat (Rajan et al., 1995a and Chapter 6). However it is relatively specific to the
liver, since hippocampal 116-HSD-l was unaffected, and previous studies have
shown that 118-HSD-2 is not attenuated by E2, in either the kidney or placenta (Low
et al., 1993; Low et al., 1994b; Baggia et al., 1990). Thus the advantage of
exploiting E2 down-regulation of hepatic 116-HSD-l, as opposed to conventional
liquorice-related inhibitors of the enzyme, is that 118-HSD-2 is unaffected. The
mechanism of E2 down-regulation of hepatic 118-HSD-l, which presumably occurs
at the level of transcription, is unclear and appears partly to depend upon sex steroid -
determined patterns of GH secretion (Lax et al., 1978; Low et al., 1993; Low et al.,
1994b), but E2 repression of hepatic 118-HSD-l in the hypophysectomised rat,
albeit to a lesser extent than in the intact rat, suggests that it has an additional direct
regulatory effect (Low et al, 1994b).
Following 42 d of E2 treatment, hepatic expression of mRNAs encoding
PEPCK and angiotensinogen was clearly reduced. Although the alterations in TAT
and SAMS expression did not reach significance, they too showed a downwards
trend with E2 treatment. In principle, these effects of chronic E2 treatment may be
explained in several ways: (i) E2 may act directly to repress hepatic gene expression;
(ii) E2 may alter corticosteroid metabolism in the liver. Reduced hepatic 116-HSD-
1-mediated reactivation of otherwise inert A is anticipated to reduce expression of
these glucocorticoid-sensitive transcripts. Alternatively, 'feminisation' of the male
liver may induce 5a-reductase activity (Leblanc & Waxman, 1988) which might be
expected to increase B metabolism to inactive products; (iii) there may be other
indirect effects of chronic E2 administration mediated through factors other than
116-HSD-l, in a situation analogous with the effects of patterns of GH secretion on
the expression of liver enzymes (Lax et al., 1978; Mode, 1993; Low et al., 1994b).
At least for PEPCK, TAT and angiotensinogen, direct inhibition by E2 appears
unlikely, since these transcripts are stimulated by E2 in ADX rats and in other
circumstances in vivo (this chapter; Eggena & Barrett, 1992; Kunapuli et al., 1987).
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Angiotensinogen and SAMS mRNA expression were not significantly affected by
E2 for 21 days (although for SAMS, a downward trend was noted at 42 d when
angiotensinogen mRNA had fallen significantly). However, under these
experimental conditions, glucocorticoids do not appear to be a potent regulator in
vivo for angiotensinogen and SAMS, as illustrated by the lack of effect of ADX
alone. Thus it is not surprising that attenuation of 11B-HSD-1 expression by E2 had
little effect on their mRNA expression. This, together with the loss of the attenuating
effect of E2 on PEPCK expression in ADX rats suggests a requirement for
glucocorticoids in the process, rather than any other indirect effect. Glucocorticoid
induction of TAT gene expression has been well characterised (Ruppert et al., 1990)
and ADX reduced TAT mRNA expression. However, up-regulation of TAT by E2 in
ADX animals was greater than for any other transcript, and this action may have
opposed the influence of down-regulation of 11B-HSD-1 in intact animals.
Alterations in the activity of other enzymes in the liver responsible for the
metabolism of B is also unlikely to be responsible for the effects on hepatic gene
transcription observed in this study since no products of B metabolism other than A
were observed in incubates. In particular, there was no observed increase in 5 a-
reduction of B, despite using the appropriate cofactor (Bhattacharyya et al., 1994) in
physiological buffer at physiological temperature and pH. These data suggest that
the attenuated expression of hepatic glucocorticoid-sensitive mRNAs observed
following E2 is not due to enhanced metabolism of B in this model.
Glucocorticoids increase expression of PEPCK in the liver (Friedman et al.,
1993; Lamers et al., 1982; Sasaki et al., 1984), and so this pattern of changes is
compatible with the glucocorticoid control of expression of this gene. The effect of
E2 in intact rats was as potent as ADX alone in attenuating PEPCK mRNA
expression. These data are therefore consistent with the effects of E2 being indirectly
mediated via the marked loss of 116-HSD-l (reductase), which thus attenuates
intrahepatic glucocorticoid regeneration. Given that E2 in adrenalectomised rats did
not decrease, but indeed increased PEPCK mRNA levels, these data indicate that the
1 lB-reductase activity of 11B-HSD-1 is likely to be of key importance in producing
sufficiently high intrahepatic B levels to elevate PEPCK above the minimum levels
maintained by basal (non-glucocorticoid) factors. The discrepancy between the E2-
mediated increase in hepatic PEPCK and other transcripts in the complete absence of
glucocorticoids, but fall in PEPCK mRNA levels with E2-mediated repression of
11B-HSD-1 (and the presumed relative reduction in intrahepatic glucocorticoid
levels) may reflect other effects of E2 occurring via mechanisms which have a
qualitative rather than quantitative requirement for glucocorticoids. Similar effects
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are seen with the hepatic xenobiotic metabolising enzymes, which are also regulated
in opposite directions by sex steroids in the presence or absence of glucocorticoids
(Nemoto & Sakurai, 1995), and with the dependence of E2 receptor expression upon
glucocorticoids in some tissues (Ulisse & Tata, 1994).
In vivo F shows a pronounced diurnal variation, whereas E levels vary little
and are of similar magnitude to "free" F concentrations during the diurnal maximum
(Walker et al., 1992b). In humans, plasma levels of inert E (which is largely
unbound to plasma proteins and circulates at levels around 100 nM) are considerably
higher than "free" F concentrations during the nadir (perhaps 5 nM compared with
25-50 nM during the diurnal maximum or stress), since most F is tightly bound to
CBG (Walker et al., 1992b). Similarly, in the rat, A levels of around 50 nM are
found (R Best and JR Seckl, unpublished data and section 4.2.2) again in excess of
low nanomolar "free" B levels for most of the day. Thus the potential reservoir of
substrate available for 116-HSD-l reductase activity is usually in considerable
excess of active free glucocorticoid, and variations in 1 lB-reductase activity may
therefore be critical in determining intracellular levels of active glucocorticoid. This
mechanism would be not dissimilar to that controlling the intracellular levels of
active testosterone or T4 hormone, both of which circulate in a largely inactive form
(Stewart & Sheppard, 1992) and are converted to their active forms of
dihydrotestosterone and T3 respectively by intracellular enzymes at the site of
action. Thus activation of inert steroid may allow hepatocytes to maintain adequate
levels of active 11-hydroxysteroids to ensure glucocorticoid-regulated metabolic
functions are not compromised in the face of fluctuating F or B levels during the
daily Cortisol nadir. This will occur irrespective of circulating F or B levels as the
latter will be determined by the activity of the HPA axis (Akana et al., 1992).
There are important implications of the potential influence of 116-HSD-l on
liver metabolic processes. PEPCK is the rate-limiting enzyme in gluconeogenesis
and its expression is regulated by its rate of gene transcription. Over-expression of
PEPCK in transgenic mice increases gluconeogenesis, producing hyperglycaemia
and impaired glucose tolerance (Valera et al., 1994). Therefore decreased 116-
reductase activity resulting in attenuated PEPCK gene transcription would be
expected to increase insulin sensitivity. Inhibition of 11B-HSD-1 with CBX
increases hepatic insulin sensitivity in man (Walker et al., 1995) and so in order to
further test the hypothesis that hepatic 1 lB-reductase activity enhances
glucocorticoid action in the liver, with consequent effects upon hepatic insulin
sensitivity, the effects of CBX administration upon insulin sensitivity in the rat was
examined.
139
Hepatic 11B-HSD-1 activity was not altered by CBX administration as
measured by the in vitro assay technique. However, the concentration of liver
protein employed in assay incubates requires an effective tissue dilution of
approximately 1 in 5000. Thus the consequent dilution of CBX present in tissue is
likely to reduce the concentration to a level below that required for competitive
enzyme inhibition. The assay therefore indicates that the CBX administration had no
effect on the levels of 11B-HSD-1 protein present in the liver, but gives no
information regarding the extent of 11B-HSD-1 inhibition in vivo. Interestingly,
CBX administration decreased 11B-HSD-1 mRNA expression, in accordance with
previously reported transcriptional inhibition of 11B-HSD-1 mRNA by glycyrrhizic
acid (Whorwood et al., 1993b). This discrepancy between protein levels and mRNA
levels is likely to be due to the slower turnover of protein in vivo. The administration
of CBX to rats resulted in a lowering of fasting plasma glucose with a trend (not
reaching significance) for fasting plasma insulin to fall also, consistent with an
increase in insulin sensitivity. This finding is in accordance with the data of Walker
et al. (1995), which demonstrated a trend for CBX to decrease fasting insulin levels
without affecting plasma glucose. Likewise, there was a trend - not reaching
significance - for insulin secretion to be lower following CBX, with no change in the
rate of glucose disposal, which would indicate increased insulin sensitivity. There
were no changes in the levels of hepatic PEPCK mRNA expression, or of plasma A,
which might be expected to rise in the presence of impaired 1 IB-reduction.
Therefore these data are suggestive of CBX effecting an increase in whole
body insulin sensitivity. However, the dose of CBX which can be employed in in
vivo studies is limited due to its side effect of "apparent renal mineralocorticoid
excess" consequent upon 11B-HSD-2 inhibition (as witnessed by the increase in
plasma sodium and chloride in this study). In addition, although CBX has a Kj of 3.3
nM for 11B-HSD activity in vitro (Stewart, 1994), the studies in Chapter 5 show that
it is a much less efficient inhibitor of hepatic 11B-HSD-1 in vivo. This, together with
the presence of an inflammatory reaction and a granular lesion at the injection site of
the higher doses of CBX administration, and the likelihood that a high constant level
of circulating drug is not achieved by this route of administration, make it probable
that inhibition of hepatic 11B-HSD-1 activity is not optimal for the purposes of this
study.
Nevertheless, the results are supportive of a role for 11B-HSD-1 in the
control of insulin sensitivity. Glucocorticoids antagonise insulin action not only in
the liver, but also in the peripheral tissues. Whitney (1953) reported a decrease in
peripheral glucose utilisation of 40% and an 8% increase in hepatic glucose
140
production consequent upon F infusion in humans. 11B-HSD activity is present in
skeletal muscle (Monder, 1993) and adipocytes (BR Walker, personal
communication; A Napolitano, personal communication) and so a contribution to the
increased insulin sensitivity observed following CBX administration from reduced
levels of active glucocorticoid in these tissues must be considered. However, high
concentrations of CBX in the absence of glucocorticoids antagonised insulin action
in adipocytes (Gomez-Capilla et al., 1988). In addition, the data of Walker et al.,
(1995) demonstrated an increase in whole body insulin sensitivity without increased
peripheral uptake of glucose. This, taken together with the data from the experiments
of E2 administration to rats described in this chapter, suggests the most likely
explanation is that the main site of action of CBX is within the liver, with reduced
intrahepatic glucocorticoid levels resulting in decreased glucocorticoid receptor
activation within the liver. It should be mentioned that CBX inhibits other enzymes
involved in the metabolism of glucocorticoids, most notably 513-reductase (Latif et
al., 1990), but inhibition of this enzyme would reduce B metabolism, thus
potentially raising intrahepatic glucocorticoid levels which would antagonise insulin
action.
The implications of abnormal 1 lB-reductase activity for disease are
unknown, but in principle, an inappropriate increase in hepatic 11B-HSD-1 activity
could be a contributing factor in syndromes of central insulin resistance including
NIDDM (Fery, 1994) as excess activity could increase gluconeogenesis by induction
of the gluconeogenic enzymes, and attenuate insulin sensitivity by antagonism of
insulin action. However, the measurement of 11B-HSD-1 activity in the liver and
skeletal muscle of the Zucker rat (a well recognised model of obesity and insulin
resistance) demonstrated a dramatic reduction in enzyme activity. In polycystic
ovary syndrome (a condition characterised by insulin resistance) abnormal ratios of
urinary metabolites are consistent with impaired 1 lB-reductase activity (Rodin et al.,
1994) and, in hypertensive rats, hepatic 11B-HSD-1 activity and mRNA expression
are decreased (Stewart et al., 1993). Therefore, contrary to the predictions of the
hypothesis, in syndromes of central insulin resistance, 11B-HSD-1 is impaired,
suggesting the raised insulin levels have mediated the decrease in 11B-HSD-1.
Changes in 11B-HSD-1 may therefore be a consequence, rather than a cause of these
syndromes, and may even represent a physiological adaptation to alleviate the
insulin resistance. Therefore it is likely that changes in hepatic 118-HSD-l are
consequential rather than causative in the above mentioned syndromes of insulin
resistance. However, it remains possible that alterations in hepatic 11B-HSD-1
activity may be causative of (or exacerbate) insulin resistance under different
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conditions. The interactions between 11B-HSD-1 and insulin activities may be
mutual since insulin decreases 11B-HSD-1 mRNA in hepatocytes in culture (Chapter
3), thus probably decreasing glucocorticoid regeneration and increasing insulin
action.
Nevertheless, the potential to alter gluconeogenesis/insulin sensitivity by
manipulating 11B-HSD-1 activity in the liver is of clear therapeutic interest. Enzyme
inhibition may provide a useful therapeutic target for manipulating glucose
homeostasis. Agents which improve insulin sensitivity (Petrie & Donnelly, 1994)
often have a proportionally greater effect as insulin resistance becomes more severe
(Nolan et al., 1994; Mimura et al., 1994). This may be the case for the attenuation of
hepatic 11 B-reductase activity, particularly as there is evidence that glucocorticoid
antagonism of insulin action may also be greater. In obesity the HPA axis is
activated in humans (Marin et al., 1992; Weaver et al., 1993) and in the Zucker rat
(Krief & Basin, 1991), and tissue sensitivity to glucocorticoids are increased in
essential hypertension (Walker at al., 1992c). In addition, glucocorticoids become
the major regulator of PEPCK gene transcription during diabetes (Friedman et al.,
1993; Gerich, 1993). A more effective inhibitor of 11B-HSD-1 without the unwanted
side effect of 11B-HSD-2 inhibition may be a useful therapeutic agent, and would
certainly aid further investigations.
One useful tool in such studies is likely to be the 11B-HSD-1 "knock-out"
mouse created by Yuri Kotelevtsev working in association with this laboratory
(Kotelevtsev et al., 1996). Assay of the tissues of mice homozygous for the mutation
in the 11B-HSD-1 gene demonstrated no 11B-HSD activity in the brain or in the
liver, indicating that both tissues contain this isoform only, at least at levels
detectable by the 11B-HSD-1 activity assay employed. As expected, the kidney
contained high levels of 11 B-dehydrogenase activity owing to the high levels of the
11B-HSD-2 expressed in this tissue. The lower levels of activity present in the ovary
and lung are evidence that an isozyme other than 11B-HSD-1 is present in these
tissues. 11B-HSD activity in the lung was previously assumed to be attributable to
11B-HSD-1 and the clear reduction of activity in the homozygote when compared to
the heterozygote and wildtype mouse indicates 11B-HSD-1 is certainly present, but
clearly this isozyme is not wholly responsible for 11B-HSD activity in this organ.
Likewise, activity is reduced in the ovary when compared to the heterozygote and
wildtype mouse. 11B-HSD-2 has been reported to be expressed in the rat ovary
(Roland & Funder, 1996), and in the rat lung (Zhou et al., 1995) and it is therefore
likely that this isozyme is responsible for the activity present in these organs in the
11B-HSD-1 "knock-out" mouse. It has been suggested that 118-HSD-2 activity in
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the ovary is induced in lutinised cells to prevent the inhibition of LH-stimulated
progesterone biosynthesis by glucocorticoids (Michael & Cooke, 1994). The lung is
not an aldosterone target tissue and what the role of 11B-HSD-2 (or of any other
11B-HSD isozyme which the measured activity represents) in this organ might be is
not at all clear.
Obviously, as the "knock-out" mouse has a complete absence of any hepatic
11B-HSD-1 activity, it will provide a useful model to further examine the role of
hepatic 116-HSD-l in liver function and its relationship to glucose homeostasis and
insulin sensitivity. Indeed, studies on these aspects of 11B-HSD-1 in these mice are
now underway in this laboratory.
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CHAPTER 5




In Chapter 3,1 demonstrated that the predominant reaction direction of 116-
HSD-1 in intact isolated hepatocytes in culture is 1 IB-reduction, thus producing
active glucocorticoid from inert substrate. The data presented in Chapter 4 suggest
that 116-reductase activity in the liver in vivo plays an important role in liver
physiology by maintaining the expression of key glucocorticoid-regulated hepatic
transcripts and I have postulated that the intrahepatic activation of glucocorticoids
by 11B-HSD-1 may allow hepatocytes to maintain adequate levels of active 11-
hydroxysteroids to ensure that glucocorticoid-regulated metabolic functions are not
compromised in the face of fluctuating F or B levels.
The conversion of A to corticosterone in hepatocyte cultures is
approximately 40% after 30 min over a wide range of substrate concentrations,
whilst in vivo, the substrate is subject to a rapid passage through the liver of a few
seconds. Therefore the percentage conversion of substrate to product during one
passage through the liver by 116-HSD-l, as inferred from the efficiency of
conversion observed in hepatocyte culture studies, would be very small and not
capable of responding rapidly to decreases in substrate availability in vivo in order to
maintain levels of active glucocorticoid. However the conditions in cell culture are
very different from those that pertain in vivo. In the experiments described in
Chapter 3, although the substrate was exposed to the cells for a prolonged period,
the hepatocyte mass, and hence overall enzyme activity is much less than that in
vivo. Previous studies have suggested that hepatic 1 lB-reductase activity in vivo is
extremely efficient. The effluent of perfused cat liver has a high F to E ratio (Bush,
1969) and the measurement of the F to E ratio in the plasma of humans by selective
venous catheterisation shows that the venous effluent of most organs has a ratio of F
to E of around 10:1, whilst in the hepatic vein the ratio is 55:1, consistent with
effective 1 IB-reduction (Walker et al., 1992b). E administered orally is converted to
F by 1 lB-reductase on first pass through the liver (Stewart et al., 1990).
In the rat liver, 116-HSD-l shows pronounced sexual dimorphism, with
females having approximately 50% of the levels in male rats (Ghraf et al., 1975a;
Lax et al., 1978; Low et al., 1993)(discussed in section 1.3.4) as quantified by in
vitro assay techniques. Whether this is physiologically significant is unknown. In
addition, glucocorticoids are subject to a number of metabolic processes within the
liver (section 1.1.5) including reduction, oxidation, hydroxylation and conjugation
(Orth et al., 1992), and so it is likely that in the intact liver there are multiple
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products of the metabolism of A or E entering the liver from the bloodstream or
produced within the liver.
Therefore, in order to address these issues, and to gain further insight into the
physiological function of 118-HSD-l in the intact liver, I have examined the
metabolism of glucocorticoid across the intact perfused rat liver.
5.2 Results
5.2.1 11B-HSD-1 Activity Across the Intact Perfused Liver
The intact liver, in either male or female rats, was perfused in situ with
Kreb's Ringer buffer containing either [3H]-A or [3H]-B in order to examine the
products of glucocorticoid metabolism in the liver. The flow rate was 7.5ml/min
through both the hepatic artery and the hepatic portal vein in male rats and 5ml/min
through each vessel in female rats (as this was the maximum flow rate which could
be achieved in female rats). The recovery of perfused steroid was 10.6±1.4% from
male rat liver and 5.0±0.6% from female rat liver, which represents significantly
greater recovery in male rats (P<0.05). The recovery of steroid was not flow rate
dependent (data not shown). HPLC analysis (section 2.2.6) of the steroid products
produced by liver metabolism of A in the intact perfused male rat liver showed that
43.5±5.0% of the total steroid recovered had been converted to B by 116-reductase
activity (Fig. 5.1). In the female rat liver, this figure dropped significantly to
20.8±2.3%, indicating that on passage through the liver, the total conversion to
product in the liver by 118-reductase activity in females is approximately half of that
seen in males. Hepatic metabolism of A perfused through the liver also produced
steroid products other than B, accounting for 15.2±2.7% and 19.4±2.9% of steroid
present in the effluent from male or female rat liver, respectively. Measurement of
the products of metabolism of B by the intact perfused male rat liver showed that
9.5±0.5% of the total steroid recovered had been converted to A and 22.6±3.1% to
other steroids (Fig 5.3).
5.2.2 Effect of Route of Delivery Upon 11B-HSD-1 Activity in the Perfused Liver
To examine the possible influence of the route of delivery of glucocorticoids
upon their metabolism, steroid was perfused through either the hepatic artery, or the
hepatic portal vein, or a combination of the two routes, using the livers of male rats.
As the proportion of the perfusate delivered through the hepatic artery was increased
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Figure 5.1; 11B-HSD-1 activity across the intact perfused liver.
The data represents the % of [3H]-labelled steroid recovered from the effluent of
livers perfused with 10"8M A as: 11-dehydrocorticosterone (A), corticosterone (B)
and other steroids (C).
P<0.01 compared with Male B. n=5.
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with respect to the proportion delivered via the hepatic portal vein, the conversion of
A to B showed a decreasing trend such that the percentage of steroid recovered as B
is significantly lower when 100% of the perfusate is delivered via the hepatic artery
than when 100% is delivered by the hepatic portal vein (P<0.05) (Fig. 5.2). The
percentage of steroid recovered as other steroid products did not change with the
route of delivery of the A substrate. In contrast, the proportions of the steroid
products recovered when the livers were perfused with B did not alter with changes
in the route of substrate delivery (Fig 5.3).
5.2.3 Effect of Substrate Concentration on 116-HSD-l Activity in the Perfused Liver
As the concentration of A perfused through the liver was varied across a
wide range of physiologically relevant concentrations, the percentage of steroid
recovered as B tended to decrease as the substrate concentration increased (Fig. 5.4),
but this was not significant over the range of concentrations employed. The
percentage of steroid recovered as steroid products other than A and B did not
change with the concentration of A substrate. The total recovery of [3H]-steroid in
the effluent was not altered (data not shown).
5.2.4 Carbenoxolone Inhibition of 11B-HSD-1 Activity in the Perfused Liver
Conversion of A to corticosterone in the intact perfused liver was not
significantly inhibited by simultaneous perfusion with CBX until the concentration
of CBX reached 10" 3M, when the percentage of steroid recovered as B was reduced
by 44.5±6% when compared to 10"6M CBX (Fig. 5.5). It was not however
significantly different from control values. The percentage of steroid recovered as
steroid products other than A and B did not change with the concentration of CBX
present in the perfusate. The total recovery of steroid did not change with CBX
present in the perfusate (data not shown).
5.2.5 Products of 11-Dehydrocorticosterone Metabolism Across the Perfused Liver
In order to detect steroid products of A metabolism other than B and to
verify that the major product recovered in the effluent was indeed B, liver perfusion
was carried out in a male rat with 5 x 10"9M [3H]-A in the perfusate, which is five
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Figure 5.2: Effect of route of delivery upon 116-reductase activity in the perfused
liver.
The data show the effect of varying the proportion of the perfusate delivered via the
hepatic artery to that delivered via the hepatic portal vein from 0 to 100%.
The % of [3H]-labelled steroid recovered from the effluent of male rat livers
perfused with 10"8M A is shown as: A=11-dehydrocorticosterone, B=corticosterone,
C=other steroids. n=5.
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Figure 5.3; Effect of route of delivery upon 1 lB-dehydrogenase activity in the
perfused liver.
The data show the effect of varying the proportion of the perfusate delivered via the
hepatic artery to that delivered via the hepatic portal vein from 0 to 100%.
The % of [3H]-labelled steroid recovered from the effluent of male rat livers
perfused with 10"8M B is shown as: A=11-dehydrocorticosterone, B=corticosterone,
C=other steroids. n=5.
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Figure 5.4: Effect of substrate concentration upon 1 lB-reductase activity in the
perfused liver.
The data shows the % of [3H]-labelled steroid recovered from the effluent of male
rat livers perfused with varying concentrations of A as: A=ll-
dehydrocorticosterone, B=corticosterone, C=other steroids. The flow rate was















Control 10-6 10-5 10-4 10-3
Concentration of Carbenoxolone
Figure 5.5; Carbenoxolone inhibition of 1 lB-reductase activity in the perfused liver.
The data represents the % of [3H]-labelled steroid recovered from the effluent of
male rat livers perfused with 10" 8M A together with various concentrations of CBX
as: A=11-dehydrocorticosterone, B=corticosterone, C=other steroids. The flow rate
was 7.5ml/min through both the hepatic artery and the hepatic portal vein. P<0.05












Products of 11 -dehydrocorticosterone metabolism in the perfused liver.
The HPLC elution times of the radiolabeled peaks of the steroids in the effluent
from the intact perfused liver. The elution times were compared to the major hepatic
metabolites of B as measured by ultra-violet absorbance at 254nm (Table 2.3) in
order to identify the products. The major product ofA metabolism was identified as
corticosterone. However the other two radiolabeled peaks were not identified.
ensure there was enough radiolabelled steroid in the samples to give clear separation
of peaks representing the products of A metabolism in perfused liver. Steroids were
separated by HPLC and the radiolabelled peaks were compared to the elution
profiles of steroid standards of the major hepatic metabolites of A and B (Table 2.3)
to identify the products (Table 5.2). A representative HPLC trace of the UV
absorbance of the steroid standards and of the radiolabelled peaks in perfusate is
shown in Fig 5.6. The major product of A metabolism was identified as B. However
two small peaks accounting for up to 30% of the total radiolabelled steroid recovered
did not exactly co-elute with any of the steroid standards examined and so could not
be identified.
5.2.5 Carbenoxolone Inhibition of 11B-HSD-1 in Hepatocvte Cultures
The lack of inhibition of 1 lB-reductase activity by CBX in the intact perfused
liver is not in accordance with previous accounts of CBX inhibition of 11B-HSD-1.
CBX has a Ki of 10~9 to 10~8M for 11B-HSD-1 activity in tissues homogenates in
vitro (Monder et al., 1989), and lOOmg of CBX administered every 8 h to humans
inhibits 1 lB-reductase by approximately 50% (Walker et al., 1995; Stewart et al.,
1990). Therefore CBX inhibition of 11B-HSD-1 in primary hepatocyte cultures and
in homogenates of rat liver was measured as described in section 2.3.7 and section
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2.2.1 respectively. The Kj of CBX in hepatocyte cultures was calculated as







Figure 5.6: Products of 11-dehydrocorticosterone metabolism in the perfused liver.
(a) Elution profiles of steroid standards of the major hepatic metabolites of A and B




(b) Representative HPLC trace of the radiolabeled peaks in an extract of effluent
























Control 1 0-9M 10-8M 10-7M 10-6M 10-5M 10-4M
Concentration of Carbenoxolone
Figure 5.7; Carbenoxolone inhibition of 116-HSD-l in (a) hepatocyte cultures and
(b) homogenised liver.
(a) Activity is expressed as % conversion A to B (1 lB-reductase) in the medium
overlying the cells after 30 min. n=3-5. Results are from 3 separate culture
preparations. *P<0.05 vs. control, |P<0.001 vs. control.
(b) 11B-HSD-1 activity was assayed in homogenates of male rat liver. 11B-HSD-1
activity is expressed as % conversion B to A at 37°C for 10 min in the presence of




Examination of the metabolism of A and B across the intact perfused rat liver
demonstrated that 116-HSD-l activity is present and measurable in this system. This
makes the liver perfusion model extremely useful for investigation of hepatic 116-
HSD-1 as it allows examination of the function and the physiological role of the
enzyme in the isolated organ, and provides a system for easy manipulation of
conditions within the liver without the problems which beset in vivo experiments.
The studies described in Chapter 4 of this thesis provide a valuable insight into the
physiological role of hepatic 116-HSD-l, but are complicated by the lack of
specificity of the methods employed to manipulate hepatic 116-HSD-l. These
methods either have additional actions in other tissues or on other physiological
processes, (e.g. CBX inhibition of renal 116-HSD-2 and of 116-HSD-l in tissues
other than liver), or are limited by the restricted access to the organ of interest. This,
for example, enforced the estimation of hepatic insulin sensitivity by measurement
of whole body glucose levels in the experiments in Chapter 4. This liver perfusion
system overcomes some of these obstacles and allows more detailed examination of
liver physiology in relation to 116-HSD-l.
Over 40% of A is converted to active B in the intact liver, reinforcing the
evidence that 116-reduction is the primary activity of hepatic 116-HSD-l. However,
in contrast to the data from Chapter 3 demonstrating its near exclusive 116-reduction
in hepatocyte cultures, and from the other studies on 116-HSD-l function in intact
cells which demonstrate predominant 116-reduction (Low et al., 1994a; Agarwal et
al., 1989; Rajan et al., 1995b), on passage through the intact liver, approximately
10% of B is converted to A. The reasons for this are not clear, but there are three
possible explanations. Firstly, the equilibrium reached by 116-HSD-l may differ in
intact liver, as opposed to hepatocyte culture conditions. The equilibrium position of
116-HSD-l will be determined by substrate availability, product inhibition and co-
factor availability, all of which will differ in vivo from the in vitro situation.
However, 116-reduction is the favoured direction and still predominates in the
experiments described in this chapter (although in vivo 116-dehydrogenase is
significant). Studies in humans in vivo, which have estimated hepatic 116-HSD-l
activity by indirect methods in the presence of endogenous steroids (Walker et al.,
1995), would not have detected a small amount of 116-dehydrogenase activity in the
presence of a predominance of 116-reductase activity. In contrast to the studies in
hepatocyte cultures (Chapter 3), the cellular environment of hepatocytes in vivo is
dynamic, with constant fluxes in substrate and product concentrations dependent
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upon delivery and removal via the circulation, and on the processes of steroid
metabolism within the liver. The experiments described in Chapter 4 indicated that
cofactor availability is unlikely to be important in determining 11G-HSD-1 reaction
direction, but did not succeed in limiting the availability of NADPH, which could, in
theory, shift the reaction direction in intact cells towards 116-dehydrogenation.
Thus, if the 116-dehydrogenase activity is indeed due to the action of 11B-HSD-1,
then the precise factors which may determine reaction direction are still to be
identified.
Secondly, the 1 lB-dehydrogenation observed could be an experimental
artefact. 1 lB-dehydrogenase is readily demonstrable in homogenates of tissues or
cells containing the 11B-HSD-1 protein (Chapter 3; Low et al., 1993; Low et ah,
1994b), and so in a compromised tissue such as a perfused liver, 11B-HSD-1 protein
may be released from its cellular context and carry out the dehydrogenation reaction.
However, if this was the case, it would be expected that 1 lB-dehydrogenation would
increase over the course of the experiment, which it does not, making this an
unlikely explanation.
Lastly, the bi-directionality of 11B-HSD activity in the whole liver may be
due to the presence of another enzyme catalysing the 1 lB-dehydrogenation reaction.
11B-HSD-2 is the only other enzyme known to have 1 lB-dehydrogenase activity and
it is not present in the liver parenchyma (Brown et ah, 1993; Albiston et ah, 1994;
Brown et ah, 1996). However its presence in the bile ducts (ZS Krozowski, personal
communication) may account for the 1 lB-dehydrogenation of glucocorticoid
observed following perfusion through the whole liver.
The conversion of A to B increased as the proportion of substrate delivered
via the hepatic portal vein increased with respect to the hepatic artery. The hepatic
artery normally delivers some 20% of the volume of blood delivered via the hepatic
portal vein to the liver (Blomley et al, 1995), and so this route of flow will have a
smaller total volume capacity and therefore a faster passage time through the liver.
However, this does not appear to be a purely mechanical phenomenon as the
proportion of A converted to other steroid products did not vary to a similar extent
and 1 lB-dehydrogenation did not vary with route of substrate delivery. Although the
total passage time through the hepatic circulation will be less for perfusate delivered
via the hepatic artery, the passage time through the actual hepatic lobule will be the
same regardless of the route, as the both routes merge at the level of the lobular
circulation (Bloom & Fawcett, 1975). The functional significance of this difference
in metabolism with route of delivery, if any, is not clear as both are afferent blood
vessels and so deliver substrate to the hepatic lobule in the periportal zone (Bloom &
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Fawcett, 1975). Closer examination of the distribution of 11G-HSD-1 within the
liver, particularly with respect to its intralobular localisation may yield an
explanation for this discrepancy.
In the rat, A circulates at levels of around 50 nM (R Best and JR Seckl,
unpublished data and section 4.2.2) and a large portion of this is unbound to plasma
proteins. Thus the lack of effect of A concentration on the percentage of substrate to
product conversion by 116-reductase in the perfused liver when concentrations of up
to l|iM A were employed, indicates that the enzyme has a huge reserve capacity.
Supraphysiological A levels do not saturate the enzyme, in agreement with what
would be predicted from the (iM Km of the enzyme (Monder & Lakshmi, 1989;
Monder et al., 1991), and so physiological variations in substrate levels are unlikely
to affect hepatic 1 lB-reductase function.
The rate of blood flow through the male rat liver is normally approximately
1.75 ml/min/g (Angus et al., 1995), and so the rate of flow employed in these
experiments (normally 15 ml/min) is not very different to the physiological flow
rate. There was approximately 40% conversion of A to active B on a single pass
through the male rat liver in these experiments, whilst in female rats, the conversion
was approximately half this amount, consistent with measurements in vitro (Lax et
al., 1978; Low et al., 1993). This is on a single pass through the liver. Therefore,
whether the difference in hepatic levels of 11G-HSD-1 between the sexes is of
physiological significance under normal conditions must remain in question, since
such avid generation of active glucocorticoid within the liver may ensure that
sufficient intrahepatic glucocorticoid levels to ensure that glucocorticoid dependent
hepatic functions are not compromised are always maintained. Nevertheless, changes
in hepatic 11G-HSD-1 activity will alter the equilibrium reached such that
intrahepatic glucocorticoid levels will be higher when 11B-HSD-1 activity is greater.
Given the antagonism of insulin action by glucocorticoids in the liver (de Feo et al.,
1989; Dinneen et al., 1993; Rooney et al., 1994), this would have implications for
insulin sensitivity, particularly in situations of insulin deficiency, either relative
(NIDDM) or absolute (insulin-dependent diabetes mellitus). Glucocorticoid action
may be more pronounced in situations of insulin deficiency, since F replaces insulin
as the major regulator of PEPCK in diabetes (Friedman et al., 1993).
The efficiency of conversion of A to B suggests that a substantial reduction
in 11B-HSD-1 activity within the liver would be needed in order to effect changes in
insulin sensitivity in a normal individual. Nevertheless, the potential for quantitative
alterations in hepatic 11B-HSD-1 is large, and as discussed in Chapter 4, means of
improving insulin sensitivity by attenuation of hepatic 11B-HSD-1 may have a
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proportionally greater effect in situations of insulin resistance. However, in this
perfusion model, CBX, which is the most potent inhibitor of 11G-HSD-1 available at
present, showed itself to be extremely ineffective. At 10~3M, CBX forms a very
viscous solution, which apart from making it a difficult concentration to employ in
vivo, probably poorly accesses its proposed (intracellular) site of action. At this
concentration, CBX also inhibits other steroid metabolising enzymes, most notably
5B-reductase (Latif et al., 1990), and activates both MR and GR (Armanini et al.,
1983), adding to the impracticalities of employing it as a selective 11B-HSD-1
inhibitor. In hepatocyte cultures, 5xl0_5M CBX effectively inhibited 11B-HSD-1,
presumably due to easier access to the hepatocytes. This may account for the effects
of CBX on insulin sensitivity when administered in vivo (Walker et al., 1995,
Chapter 4), where continuous administration of CBX may allow an equilibrium to
become established over some time as the drug gains access to hepatocytes ("drug
loading"). Alternatively, the decrease in 11B-HSD-1 mRNA expression following
CBX administration in vivo (section 4.2.3) may be the mechanism by which CBX
decreases hepatic 11B-HSD-1 activity, or a combination of these mechanisms may
operate. Therefore a greater effect of CBX on 11B-HSD-1 inhibition may be
observed in perfused livers from animals pre-treated with CBX. Information on the
metabolism of CBX is scant but it may be that hepatic metabolism of the drug is an
important causative factor in its lack of efficiency in 11B-HSD-1 inhibition in the
intact liver. That aside, these data show that the concentration of CBX required to
inhibit 1 lB-reductase in intact cells is at least 100 times that required in
homogenates, and is even greater in the whole organ over a short time period. This
highlights again the need for a potent and selective inhibitor for 11B-HSD-1 in order
to carry out further studies, and as a potential therapeutic agent.
More detailed information on the fate of the glucocorticoid entering the
perfused liver in these experiments is required in order to validate the model. Up to
95% of the steroid delivered in the perfusate was sequestered within the liver. In
vivo, at physiological concentrations, 90-97% of circulating F is protein-bound, 93%
of which is bound to CBG (Dunn et al., 1981; Partridge, 1981). The concentration of
steroid employed in the liver perfusions was chosen as an approximation of the
concentration of "free" hormone circulating in the plasma, as the intracellular
concentration of a hormone, and thus the amount available for metabolism by 11B-
HSD-1, is proportional to the concentration of free hormone in the plasma and not to
that of the plasma protein bound hormone (Mendel, 1989). The perfusate was
therefore protein-free. However, this means that a large proportion of the
glucocorticoid in the perfusate will bind when exposed to binding-proteins. CBG is
160
produced primarily in the liver (Brien, 1981) and it is therefore likely that some B
will be sequestered within the liver by CBG. CBG may also bind A, but at a much
lower level. Thus there will probably be a quantitatively lesser sequestration of A. In
addition, B will bind within the liver to intracellular GR. DEX is not bound by CBG
(Pugeat et al., 1981), but has high affinity for GR and so could be used to estimate
glucocorticoid associated with GR over the course of a perfusion. Perfusate
containing plasma protein may lessen the glucocorticoid loss within the liver,
although hormone enters tissues exclusively from the pool of free hormone
following spontaneous dissociation from the binding proteins in the circulation
(Mendel, 1989) and so excess protein binding may limit diffusion of hormone into
the liver. If this was the case, an excess of free hormone would have to be ensured.
However, given that hepatic uptake of F is several times greater than the amount of
free F in plasma and that the uptake from protein-free solutions by the perfused rat
liver is high enough to account for this uptake (i.e. uptake of protein-bound F is not
necessary) (Mendel et al., 1989), protein-binding in the perfusate may not be such a
problem.
However, the binding capacity of CBG and GR is finite, and although the
proportion of steroid recovered increased slightly over the first few minutes of a
perfusion, the majority continued to be removed from the perfusate for the length of
the experiment. There are two other likely possibilities for the fate of the large
quantities of glucocorticoid unaccounted for. Sequestration of steroids into the
biliary system may be considerable, and in vivo, they would enter the enterohepatic
circulation, and return to the liver in the portal blood following intestinal
reabsorption. Cannulation of the major bile ducts or of the duodenum may allow
some estimation of steroid entering this pathway. The majority of steroid however,
is likely to be present in the perfusion effluent. Following hepatic metabolism (the
main pathways of which are outlined in Fig. 1.4), a large proportion of
glucocorticoid metabolites undergo conjugation with glucuronic acid or sulphate in
order to render them more water soluble and aid excretion (Orth et al., 1992).
Glucuronidation predominates and is catalysed by isozymes of UDP glucuronosyl
transferase in the endoplasmic reticulum (Siest et al., 1987) and most 3cc5G-
tetrahydro metabolites are excreted as glucuronides (Orth et al., 1992). Most SB-
hydroxysteroids undergo sulphation in the cytosol (Orth et al., 1992). All such
conjugated products, being water soluble, are not recovered by the methods
employed in these experiments. Hydrolysis of conjugated products in the samples,
followed by non-polar solvent extraction with ethyl acetate will yield information on
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the proportion of steroid in this fraction, and the nature of the products of the hepatic
metabolism.
The other products of A and B metabolism detected by HPLC analysis were
not identified. They were not the major dihydro- or tetrahydro- metabolites of
corticosterone. The proportion of these products did not vary with alterations in 1113-
HSD-1 activity suggesting they are not dependent on the production of
corticosterone, and so are likely to be the result of alternative pathways of A
metabolism. Glucocorticoids are subject to hepatic metabolism via a number of
pathways (section 1.1.5 and Fig. 1.4), which are not distinct, and so the ultimate fate
of an intermediate metabolite is indeterminate. Determination of the identity of the
other products of A and B metabolism will form the basis for further studies.
Notwithstanding these problems, these preliminary experiments have
provided useful information regarding the nature of hepatic 11B-HSD-1, and with
further refinement the liver perfusion model will prove an extremely useful tool in
investigation of the function of 118-HSD-l by virtue of its ability to permit access to
the isolated liver. This will mean more convenient sampling and easier manipulation
of the hepatic environment than has previously been possible and therefore allow
more detailed investigations into the physiology of hepatic 11B-HSD-1.
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CHAPTER 6




The majority of studies on hormonal regulation of 116-HSD have focused on
measuring changes in enzyme activity, and the methods employed do not necessarily
distinguish the effects of 11B-HSD-1 and 11B-HSD-2. Therefore, this should be kept
in mind when drawing conclusions from any studies on tissues which may contain
both isozymes. However the liver does not express 11B-HSD-2 (Brown et al., 1993;
Albiston et al., 1994; Brown et al., 1996), and to date 11B-HSD-2 has not been
demonstrated to be present in the adult hippocampus, and so data from studies on
these tissues as described in this chapter are likely to pertain to the type 1 isozyme.
11B-HSD-1 is regulated in vivo by various hormones, including glucocorticoids,
insulin, sex steroids, GH and T3, in a tissue- and developmentally-specific manner
(section 1.3.4). The experiments described in this chapter pertain to the hormonal
regulation of 11B-HSD-1 in the liver and the hippocampus in vivo, and are in the
main preliminary studies aimed towards further unravelling the complex hormonal
control of this enzyme.
11B-HSD regulation by T3 has been reported to differ between species as
well as the sexes, with raised T3 levels increasing the conversion of F to E in humans
and thyroidectomy reversing this effect (Gordon & Southren 1977; Zumoff et al.,
1983). However, indirect estimation of enzyme activity in humans by the
measurement of plasma or urinary metabolites do not take account of 11B-HSD-2
activity, and, in contrast, thyroid hormone decreases enzyme activity in rat liver
(Whorwood et al., 1993a), whilst thyroidectomy increases activity in female rat liver
but decreases it in the male rat (Lax et al., 1979; Whorwood et al., 1993a). Thus the
studies are inconclusive and contradictory. One of the problems with studies of T3
regulation in the rat, is that GH secretion is almost totally dependent on T3 (Evans et
al., 1992; Spindler et al., 1992; Peake at al., 1973; Hervas et al., 1975; Coiro et al.,
1979). Therefore the sexually dimorphic effects of T3 on 11B-HSD-1 in rat liver may
be mediated indirectly via GH, whilst an additional direct effect of T3 may or may
not be operating simultaneously. Studies employing thyroidectomy to model T3
deficiency in the rat are complicated by loss of the parathyroid and thyroid C-cells in
addition to the thyroid follicle cells, whilst studies employing antithyroid drugs such
as methimazole and propylthiouracil inhibit T3 production from T4 inconsistently,
and may be associated with side-effects (Horvath et al., 1989; Rutgers et al., 1990;
Chiba et al., 1990).
An elegant mouse model has been created in which the T3 producing thyroid
follicle cells have been specifically and completely ablated, to provide a model of
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selective and complete T3 deficiency (Wallace et al., 1991). In these mice, the
coding region of the herpes simplex type 1 virus thymidine kinase gene coupled to
the promoter of the bovine thyroglobulin gene was introduced into the mouse
genome. As the viral thyroglobulin promoter directed expression of the thymidine
kinase gene mainly in the thyroid gland and the testes (Al Shawi et al., 1991), this
meant that administration of the antiviral agent ganciclovir effectively ablated
thyroid follicle cells whilst leaving the parathyroid gland and the C-cells of the
thyroid intact. This completely deprived the mice of T3 (Wallace et al., 1991). I have
investigated the T3 regulation of 11B-HSD-1 in these mice, thus avoiding the
complications of surgical thyroidectomy and hypothyroidism achieved by drug
administration.
Hepatic 11B-HSD-1 is sexually dimorphic in rats, with females showing
approximately half the activity of males (Lax et al., 1978; Low et al., 1993) due to
suppression of activity in the female by the sexually dimorphic pattern of GH
secretion (Low et al., 1994b). Whether hepatic 11B-HSD-1 is sexually dimorphic in
other species is unknown, but hepatic steroid and drug metabolism shows less
pronounced sexual dimorphism in humans than in rodents (Pfaffenberg & Horning,
1977; MacLeod et al., 1979). Therefore I have measured 11B-HSD-1 activity in the
tissues of male and female mice in order to ascertain whether 11B-HSD-1 is sexually
dimorphic, clearly an important factor to be taken into consideration when
interpreting results from the thyroid-ablated mice.
Previous studies have reported glucocorticoid induction of 11B-HSD activity,
both in the liver in vivo (Low et al., 1994; Walker at al., 1994) and in cell culture in
vitro (Hammami & Siiteri, 1991 and Chapter 3). It has been shown that ADX of rats
attenuates hepatic 11B-HSD-1 enzyme activity and also attenuates reactivation of E
to F (presumably mediated by hepatic 11B-HSD-1) (Nicholas & Lugg, 1982) whilst
administration of glucocorticoids to ADX rats increases hepatic 11B-HSD-1 activity
and mRNA (Low et al., 1994c). However in Chapter 4 (section 4.2.1.3) I showed
that ADX increased 116-HSD-l activity and mRNA expression with respect to sham
ADX controls, an observation repeated on four separate occasions. In addition,
glucocorticoid regulation of 11B-HSD-1 appears to be tissue-specific, since neither
ADX, nor glucocorticoid administration affect 11B-HSD-1 mRNA levels, or enzyme
bioactivity in the rat kidney (Moisan et al., 1990c; Smith & Funder, 1991). Chronic
glucocorticoid excess or stress increase 11B-HSD-1 mRNA and enzyme bioactivity
in the hippocampus (Moisan et al., 1990c; Low et al., 1994c). However, the reasons
for this are unclear, as chronic glucocorticoid excess is detrimental to neuronal
function and survival (Landfield et al., 1978; Sapolsky et al., 1985, 1986; Sapolsky,
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1992), and this would potentiate their neurotoxicity. Therefore I have further
investigated glucocorticoid control of 11B-HSD by examining the effects of ADX
and glucocorticoid replacement over a time-course of 21 days in liver, kidney and
hippocampus in the rat.
Various experimental manipulations of circulating glucocorticoid levels,
including exogenous corticosteroid administration and a range of stressors, have
demonstrated deleterious effects on neuronal morphology and survival (Kerr et al.,
1991; Landfield & Eldridge, 1994; Mizoguchi et al., 1992; Watanabe et al., 1992).
Most of the studies on the effects of stress in the hippocampus have employed
noxious stressors or physical restraint, but not all stressors have the same
physiological effects. For example, Komesaroff and Funder (1994) have
demonstrated that plasma adrenaline levels rise in fear-induced stress but not in
hypoglycaemic stress. Psychological, or emotional stress is of particular interest as it
considered to be an important element in the development of various
neuropsychiatric diseases such as insomnia, anxiety disorders and depression
(Checkley, 1992; Paykel, 1978) and studies on prolonged social stress in monkeys
have provided evidence for a link between the degree of stress experienced and the
extent of hippocampal pyramidal neuron damage (Uno et al., 1989).
One well-characterised experimental model for studying the effects of
psychosocial stress is the tree-shrew (Fliigge et al., 1992; Fuchs & Fliigge, 1995;
Fuchs et al., 1993; Johren et al., 1994). Male tree shrews establish stable dominant/
subordinate relations in the laboratory, and stress is only experienced by the
subordinate animal (von Hoist, 1977) with no negative physiological effects on the
dominant individual (Fuchs et al., 1993; von Hoist, et al., 1983). Stress in the
subordinate animal results from the cognitive interpretation of the continuous visual
presence of the dominant individual, not from physical interactions and exertions
during fighting (von Hoist, 1977; von Hoist et al., 1983; Rabb & Stortz, 1976)
making it a suitable model for studying the neuroendocrine responses to
psychosocial stress. Subordinate tree-shrews exhibit disturbed feeding patterns,
sleeping disturbances, alterations in circadian rhythm and clear behavioural
depression. Endocrine responses include constant hyperactivity of the HPA axis and
the sympathoadrenal system (Fuchs, 1984; Fuchs et al., 1992, 1993; von Hoist,
1977), whilst in the hippocampus, a2-adrenoreceptors, GR mRNA and CRH-binding
sites are decreased (Fliigge et al., 1992; Fuchs & Fltigge, 1995). Many of these
reactions are comparable to the symptoms observed in clinically depressed patients.
Therefore, I have examined the regulation of 11B-HSD-1 activity in the
hippocampus by psychosocial stress, glucocorticoids and growth hormone, in this
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model, in order to see if there are changes in the enzyme's activity, thus indicating a
role for hippocampal 11B-HSD-1 in psychosocial stress.
6.2 Results
6.2.1 Thyroid Hormone Regulation of Hepatic 116-HSD-l in the Mouse
RNA used in these experiments was donated by Dr. Helen Wallace of the
Institute of Cell and Population Biology, University of Edinburgh (Wallace et al.,
1991). 11B-HSD-1 was quantitated in the livers of transgenic mice in which the
thyroid follicle cells had been specifically ablated. The vehicle for ganciclovir
(administration of which effectively ablated the thyroid follicle cells) was PBS.
Some thyroid ablated mice received daily T4 replacement injections (250(ig/kg) and
some received 12 hourly GH injections (5 mg/kg). Controls were mice equivalent to
the transgenic mice in background (Wallace et al., 1991).
I quantified 11B-HSD-1 mRNA expression in these transgenic mice (Fig.
6.1). In female mice, thyroid ablation did not alter 11B-HSD-1 mRNA expression,
and GH replacement had no effect. However T4 replacement significantly reduced
11B-HSD-1 expression when compared to controls and to thyroid ablated mice (Fig
6.1). In male mice, 11B-HSD-1 mRNA expression followed the same pattern, but
numbers were not large enough to allow statistical analysis (data not shown).
6.2.2 Sexual Dimorphism of 11B-HSD-1 Activity in the Mouse
Measurement of 11B-HSD activity in the liver, hippocampus and kidney of
male and female CBA/B6 F1 mice (section 2.2.1) showed no differences between

























Figure 6.1; Thyroid hormone regulation of hepatic 11B-HSD-1 in the mouse.
Quantification by northern analyses of 11B-HSD-1 mRNA levels from the livers of
female non-transgenic (Control+GCV) and transgenic female mice following
thyroid ablation (Transgenic+GCV) ± T4 or GH replacement or sham ablation
(Transgenic+PBS). Data are expressed as a percentage of mRNA levels (±SEM for
females, n=3-5) in control animals. GCV=glanciclovir, PBS=phosphate buffered
saline (vehicle), T4=thyroxine, GH=growth hormone.























Figure 6.2: Lack of Sexual dimorphism of 11B-HSD activity in mice.
11B-HSD-1 activity was assayed in homogenates of tissues from male and female
mice. Data are expressed as mean±SEM. n=9-10.
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6.2.3 The Effects of Adrenalectomy and Glucocorticoid Replacement Upon 116-
HSD-1
The experiments described in section 4.2.1.3 reproducibly showed an
increase in hepatic 11B-HSD-1 activity in ADX animals when compared to sham
ADX controls in contrast to previous studies reporting glucocorticoid induction of
11B-HSD-1 in the liver in vivo (Low et al., 1994; Walker at al., 1994) and in cell
culture in vitro (Hammami & Siiteri, 1991 and Chapter 3). A possible reason for this
discrepancy is the longer time course of adrenal manipulations in the experiments in
section 4.2.1.3 (21 d as opposed to 1-10 d in previous studies). Therefore the time
course of the effects of adrenal manipulations upon 11B-HSD activity and 11B-HSD-
1 mRNA expression in rat liver, hippocampus and kidney was examined in more
detail. Male rats were either adrenalectomised or sham-operated and some ADX
animals received glucocorticoid replacement in the form of high dose DEX. 11B-
HSD activity and 11B-HSD-1 mRNA expression were measured 2, 5, 9, 15 or 21 d
after surgery. Untouched animals served as controls. A representative northern blot
is shown in Fig. 6.3.
Sham ADX resulted in a continuing decrease in both 11B-HSD-1 activity and
mRNA expression in the liver over 21d (Fig. 6.3 and Fig. 6.4). The decrease in 116-
HSD-1 mRNA levels preceded the decrease in activity. There was no recovery in
11B-HSD-1 activity or mRNA levels over this time period. ADX resulted in a
quicker decrease in 11B-HSD-1 activity and mRNA than did sham ADX, such that
both were minimal and significantly less than control levels at 2 d (Fig. 6.4). 11B-
HSD-1 activity then recovered, reaching control levels by 9 d, whereas mRNA
levels remained at approximately 50% of control levels over the time course
examined, confirming the observations in section 4.2.1.3. ADX together with DEX
also resulted in a significant decrease in hepatic 11B-HSD-1 levels apparent by 2 d
(Fig. 6.4). There was no recovery in mRNA levels over 21 d. 11B-HSD-1 activity
however did not alter, except perhaps for a fall in the ADX with DEX group at the
end of the time course, with activity at 21 d less than that at 5 d. At 21 d, hepatic
11B-HSD-1 activity is less following DEX treatment than after ADX alone, and
sham ADX animals have lower activity and mRNA expression than either of the
other two groups.
Flippocampal 11B-HSD-1 activity fell following sham ADX, and remained
significantly lower than control until at least 9 d (Fig. 6.5). ADX resulted in changes
in 11B-HSD-1 activity in the hippocampus which were significant between each
sequential time point. Activity fell following ADX, reaching a low point at 9 d, and
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Figure 6.3: Time course of the effect of sham adrenalectomy upon hepatic 1113-
HSD-1 mRNA expression.
Autoradiograph of northern blots of RNA from the livers of male rats at various time
points following sham ADX. Controls are untouched animals. Hybridised to 116-
HSD-1 and 7S cDNAs.
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then recovering, but were still significantly less than control at 21 d. ADX followed
by DEX led to a slow decline in hippocampal 11B-HSD-1 reaching significance at
15 d. There was no difference in activity between the groups at any time point.
Neither was there any difference in 11B-HSD-1 mRNA levels between or within
treatments (Fig. 6.5), probably owing to large standard errors, but there was a trend
for 11B-HSD-1 in the hippocampus to fall following all manipulations and then to
recover over the time course.
11B-HSD activity in the kidney (reflecting the presence of both 11B-HSD-1
and 116-HSD-2 activities) was unaffected by sham ADX (Fig. 6.6). There was,
however, a small but significant decrease in renal 11B-HSD activity following ADX,
with the lowest level at 5 d. Levels were back to control values by 9 d. Likewise,
ADX followed by DEX showed a small drop in activity at 2 d. At 21 d, both ADX
and ADX followed by DEX resulted in 11B-HSD activity levels less than in the
control group. In contrast, both sham ADX and ADX resulted in a dramatic decrease
in renal 11B-HSD-1 mRNA expression (Fig. 6.6) which did not recover over the
time courses examined.
6.2.4 The Effects of Chronic Stress and Glucocorticoid Administration Upon 11B-
HSD Activity in the Tree-Shrew
I examined alterations in 11B-HSD activity in the hippocampus, liver and
kidney in a well-documented model of chronic psychosocial stress in the tree-shrew,
a species close to the primate lineage. All the in vivo manipulations in tree-shrews
were carried out at the German Primate Centre (Gottingen, Germany). Details of the
experimental design of this model are described by Fuchs et al. (1992). Briefly, the
opaque partition between the cages of pairs of male tree-shrews unknown to each
other were removed leading to territorial competition. Once stable
dominant/subordinate relationships had been established, the partitions were
replaced by transparent wire mesh, so that although each animal in a pair was caged
separately, the subordinate males were subjected to a continuing psychosocial stress.
The dominant male served as a control. Additional tree-shrews received excess F
(~6 mg/day) in the drinking water. After 28 d the animals were killed and 11B-HSD
activity was assayed in tissue homogenates of liver, hippocampus and kidney (Fig.
6.7). In the hippocampus, chronic psychosocial stress led to an attenuation of 11B-
HSD-1 activity whereas excess Cortisol alone had no effect. In contrast, both chronic
stress and Cortisol alone decreased hepatic 11B-HSD-1 activity. No changes in 11B-









































Figure 6.4: Time course of the effect of adrenalectomy and dexamethasone
replacement upon hepatic 11B-HSD-1.
(a) 11B-HSD-1 activity and (b) 11B-HSD-1 mRNA levels were quantified from the
livers of male rats at various time points following ADX, ADX with DEX or sham
ADX. Controls are untouched animals and are represented by the values on the y-
axis at the 0 d time point. Data are expressed as (a) % conversion B to A (±SEM) or
(b) percentage of mRNA levels (±SEM) in untouched control animals. n=5.







Figure 6.5: Time course of the effect of adrenalectomy and dexamethasone
replacement upon hippocampal 11B-HSD-1.
(a) 11B-HSD-1 activity and (b) 11B-HSD-1 mRNA levels were quantified from the
hippocampi of male rats at various time points following ADX. ADX with DEX or
sham ADX. Controls are untouched animals and are represented by the values on the
y-axis at the 0 d time point. Data are expressed as (a) % conversion B to A (+SEM)
or (b) percentage of mRNA levels (+SEM) in untouched control animals. n=5.







Figure 6.6: Time course of the effect of adrenalectomy and dexamethasone
replacement upon renal 11B-HSD.
(a) 11B-HSD activity and (b) 11B-HSD-1 mRNA levels were quantified from the
kidneys of male rats at various time points following ADX, ADX with DEX or sham
ADX. Controls are untouched animals and are represented by the values on the y-
axis at the 0 d time point. Data are expressed as (a) % conversion B to A (±SEM) or
(b) percentage of mRNA levels (±SEM) in untouched control animals. n=5.
*P<0.001 compared with control; +P<0.001 compared with control.
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Figure 6.7: The effects of chronic stress and glucocorticoid administration upon
1113-HSD activity in the tree-shrew.
11B-HSD activity was assayed in homogenates of hippocampus, liver and kidney
from male tree-shrews following 28 days psychosocial stress or F administration.
Data are expressed as % conversion B to A (±SEM). n=4-8.
*P<0.01 compared with control; tP<0.01 compared with stress. §P<0.05 compared
with control.
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6.2.5 Effect of Introcerebroventricular Administration of Growth Hormone on 11B-
HSD-1 mRNA Expression in the Brain
Hippocampal 11B-HSD-1 is not sexually dimorphic in rats, nor can it be
altered with sex steroid or GH manipulations (Low et al., 1993; Low et al., 1994b),
and it was proposed that this was due to the failure of GH to cross the blood-brain-
barrier, which is impervious to most small peptides. In order to test this hypothesis,
GH was continuously infused into the lateral ventricle of the brains of male rats for 5
days (section 2.6.5) This had no effect upon 11G-HSD-1 mRNA expression in the
hippocampus, cerebellum or cerebral cortex (Fig. 6.8). It did however significantly









Hippocampus Cerebellum Cerebrum Liver Kidney
Figure 6.8: Effect of introcerebroventricular administration of growth hormone
upon 11B-HSD-1 mRNA in brain.
116-HSD activity was assayed in homogenates of brain regions, liver and kidney of
male rats following 5 days continuous ICV infusion of growth hormone. Data are
expressed as % of control levels±SEM. n=4-5.
*P<0.05 compared with control; |P<0.001 compared with control.
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6.3 Discussion
116-HSD-l activity has previously been described in several mouse tissues
(Burton & Tufnell, 1967), and the recent creation of a transgenic 116-HSD-l
"knock-out" mouse (Kotelevtsev et ah, 1996) means that the regulation of 11B-HSD-
1 in mouse is of interest, particularly in the liver, as preliminary data from these
mice show a decrease in fasting levels of glucose and a lack of induction of hepatic
PEPCK and G-6-Pase in response to starvation (YV Kotelevtsev et ah, personal
communication). Measurement of murine hepatic 116-HSD-l activity revealed that
in contrast to the rat (Lax et ah, 1978; Low et ah, 1993), there is no sexual
dimorphism. In addition, there is no sexual dimorphism in hepatic 116-HSD-l
mRNA expression as quantified by northern analysis (Rajan et ah, 1995a). Sexually
dimorphic expression of 116-HSD-l in the rat is mediated by sex-dependent patterns
of GH secretion (Low et ah, 1994b). The GH-mediated sexual differentiation of the
liver (Gustafsson et ah, 1983a; Gustafsson et ah, 1983b; Roy & Chatterjee, 1983;
Mode, 1993) is not peculiar to the rat and operates in mice also (Norstedt &
Palmiter, 1984). Although some differences are smaller than in the rat, they are still
large (Norstedt & Palmiter, 1984), suggesting that sexual-dimorphism of hepatic
116-HSD-l in mice, if present, would be detectable by the 116-HSD-l bioassay.
Nevertheless, it is possible that blunting of a sexual-dimorphism of hepatic 116-
HSD-l in mice may render it undetectable. That these effects of GH are due to a
direct action on the hepatocyte has been demonstrated by studies in primary rat
hepatocyte cultures (Guzelian et ah, 1988; Toilet et ah, Liddle et ah, 1992) and gene
expression is controlled at the transcriptional level (Legraverend et ah, 1992;
Sundseth et ah, 1992). Whether there is a GH-responsive element on the 116-HSD-l
gene is not known, but as there is sexually dimorphic expression of 116-HSD-l
mRNA in the mouse kidney (less than 50% in females compared with males) (Rajan
et ah, 1995a), it is unlikely the differences in the pattern of expression of rat and
mouse 116-HSD-l in liver is due to differences in gene structure, but rather due to
tissue-specific differences in regulation of gene transcription. Possible explanations
include specificity of response conferred by the existence of subpopulations of the
GH receptor, as suggested by the existence of several mRNA species, epitope
mapping studies and possible receptor-membrane proteins interactions (Smith et ah,
1989; Barnard et ah, 1985; Stred et ah, 1990), or differences in the intracellular
signalling pathways of GH action which involve a cascade of reactions and complex
interactions (reviewed by Postel-Vinay & Kelly, 1996; Postel-Vinay & Finadori,
1996).
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This species-specificity of sexually dimorphic hepatic 11B-HSD-1 expression
raises the question of whether it is sexually dimorphic in humans, where differences
in steroid metabolism may have implications for disease as discussed in Chapter 4.
Hepatic steroid and drug metabolism shows less pronounced sexual dimorphism in
humans than in rodents (Pfaffenberg & Horning, 1977; MacLeod et al., 1979;
Schmucker et al., 1991), probably due, at least in part, to there being only subtle sex
differences in patterns of GH secretion (Ho et al., 1987). However GH
administration to GH-deficient children does alter hepatic drug metabolism
(Redmond et al., 1980). Therefore direct extrapolation of data obtained in animal
studies to humans is not possible, and it is likely that sexual dimorphism of 11B-
HSD-1 will be of a lesser magnitude, if not absent, in humans. Until hepatic 11B-
HSD-1 expression has been measured in humans, the significance of sexually
dimorphic expression in general mammalian biology must remain questionable.
The complete absence of T3, achieved by the specific ablation of thyroid
follicle cells in transgenic mice, had no effect on hepatic 11B-HSD-1 mRNA
expression and it can be concluded that T3 does not regulate 116-HSD-l in mouse
liver. T3 stimulates transcription of the GH gene (Evans et al., 1992; Spindler et al.,
1992) and in hypothyroidism, GH secretion is almost totally abolished (Spindler et
al., 1992; Hervas et al., 1975). As discussed in Chapter 4, the failure of T3 to
regulate 118-HSD-l in primary rat hepatocyte cultures is likely to reflect an indirect
nature of action, possibly via its effects on GH secretion, and this is supported by
previous studies in rats reporting sexually dimorphic effects of T3 on the liver, with
thyroidectomy increasing 118-HSD activity in females, but decreasing activity in
males (Lax et al., 1979; Whorwood et al., 1993a). In the light of the lack of GH-
mediated sexual dimorphism of 11B-HSD-1 in mouse liver, the absence of T3
regulation in mice is consistent with the idea that it is GH-mediated. T3 replacement
in thyroid-ablated mice down-regulated 11B-HSD-1 mRNA for reasons that are not
clear, but the circulating T4 levels achieved by replacement are approximately 50%
higher than in control mice (although T3 levels were not higher than controls)
(Wallace et al., 1991). Excess T3 may attenuate 11B-HSD-1 expression via a
"threshold" mechanism, whereby under normal physiological conditions T3 levels
do not affect 11B-HSD-1 expression, but upon exogenous administration of T3, an
excess of hormone is repressive. This may be akin to the E2 repression of hepatic
11B-HSD-1 in the rat, where exogenous E2 administration results in a dramatic
decrease in enzyme levels far in excess of that seen in normal females (Low et al.,
1993). It is interesting to note that there are sequences resembling a T3 response
element/E2 response element half-site, which are found within the 11B-HSD-1 gene
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promoter (Moisan et al., 1992), and to speculate that T3 and E2 may perhaps exert
their effects by repression through these sequences.
Previous studies have reported glucocorticoid induction of 11G-HSD activity
in the liver (Low et al., 1994c; Walker et al., 1994), hippocampus (Moisan et al.,
1990c; Low et al., 1994c, Walker et al., 1994), testis (Gao et al., 1996) and in cell
culture (Chapter 3; Takeda et al., 1995; Hammami & Siiteri), whilst ADX decreases
enzyme activity and mRNA expression. In contrast, the data in Chapter 4, section
4.2.1.3 demonstrated a marked increase in hepatic 11B-HSD-1 activity and mRNA
expression following ADX with respect to sham ADX controls 21 days post¬
operatively, and this observation was reproduced on several occasions. Previous
studies examined changes in hepatic 11G-HSD activity and mRNA expression over
1-10 days (Low et al., 1994c; Walker et al., 1994). That the discrepancy might
reflect the longer duration of ADX was considered a possible explanation, and
prompted the closer examination of the time course of the control of 11G-HSD-1
gene expression by glucocorticoids.
All of the treatments showed changes in hepatic 11G-HSD-1 activity of a
lesser magnitude than in the encoding mRNA, but following approximately the same
pattern, presumably reflecting the slower turnover of the 11G-HSD-1 protein, as
previously reported (Low et al., 1994c). ADX resulted in an initial decrease in 1113-
HSD-1 activity, returning to control levels over approximately 10 days, which is in
accordance with the findings in previous studies (Low et al., 1994c; Walker et al.,
1994). What is interesting, is that the discrepancy between 11I3-HSD-1 activity and
mRNA at 21 days observed in the experiments in Chapter 4, and confirmed in these
experiments, is in fact due to the marked down-regulation of 11 G-HSD-1 in sham-
operated animals. DEX administration to ADX animals resulted in a slow decline in
11G-HSD-1 activity, such that at 21 days it is less than in ADX animals receiving
vehicle. These effects are complicated, but may be partially explained by the
proposal that the response of 11 G-HSD-1 gene expression to removal of
glucocorticoids is an initial decrease of mRNA transcription followed by a
compensatory up-regulation to restore levels towards normal, mediated by a distinct
mechanism consequent upon glucocorticoid depletion. ADX-associated induction of
hepatic 11G-HSD-1 is perhaps more in accordance with its proposed role to
regenerate active glucocorticoids. Thus in chronically-ADX animals, the increase in
1 lG-reductase may be an attempt to compensate for the lack of intrahepatic
glucocorticoid to sustain crucial glucocorticoid-regulated functions. Long-term DEX
administration will obviate the need for 11G-HSD-1 generation of glucocorticoid,
which may explain the decline in activity. Alternatively, the opposing effects of
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ADX and ADX with DEX could be mediated via their opposing effects on ACTH
secretion. ADX increases ACTH levels, whilst DEX administration inhibits
secretion. The decrease in 11B-HSD-1 activity and mRNA (also observed in the
kidney) resultant upon sham ADX remains to be explained, but does not appear to be
directly mediated by glucocorticoid hormone action.
Neither ADX, nor glucocorticoid administration affect 11B-HSD bioactivity
in the rat kidney (Moisan et al., 1990c; Smith & Funder, 1991 and this data). This is
due to the presence of the 11B-HSD-2 isozyme whose glucocorticoid regulation is
distinct from that of 11B-HSD-1 in this tissue, since 11B-HSD-1 mRNA levels are
dramatically attenuated upon glucocorticoid depletion.
In contrast with previous short- to medium-term studies (Moisan et al.,
1990c; Low et al., 1994c, Walker et al., 1994), chronic glucocorticoid excess did not
increase 11B-HSD-1 bioactivity in the hippocampus. Again, 11B-HSD-1 activity fell
following ADX and then levels returned towards normal, whilst with DEX
administration to ADX animals, activity stayed repressed, indicating a similar
pattern of glucocorticoid regulation to that in liver. The glucocorticoid regulation of
11B-HSD-1 in the hippocampus is worthy of special consideration for two reasons.
Firstly, the hippocampus has a crucial role in the HPA axis stress response feedback
by inhibiting CRH neurosecretion and modulating the circadian rhythm of
glucocorticoid secretion (reviewed by Jacobson & Sapolsky, 1991; Whitnall, 1993)
and secondly, hippocampal neurones are extremely sensitive to changes in
glucocorticoid concentrations. The hippocampus is rich in both MR and GR
(McEwan et al., 1986; Reul & De Kloet, 1985) and so 11B-HSD-1 has the potential
to play a major role in modulating glucocorticoid action in this tissue (Moisan et al.,
1990a; Lakshmi et al., 1991). Glucocorticoid excess compromises hippocampal cell
function and survival and results in pyramidal neuronal loss (Landfield et al., 1978;
Sapolsky et al., 1985, 1986; Sapolsky 1985, 1992; Landfield & Eldridge, 1991).
Therefore reasons for regeneration of glucocorticoid by 11B-HSD-1 reductase
activity (Rajan et al., 1995b) are not clear. However, chronic glucocorticoid
depletion following ADX also leads to neuronal dysfunction and possibly death in
the dentate gyrus granule cells (Sloviter et al., 1989; Gould et al., 1991) and it may
be that the function of hippocampal 11B-HSD-1 is to ensure the provision of the
optimal level of active glucocorticoid required for maintenance of essential neuronal
functions from the pool of circulating A when glucocorticoid levels are low (e.g.
during the diurnal nadir), whilst negative-feedback provides rapid responses to avoid
over-exposure to glucocorticoids under normal circumstances. Glucocorticoid-
mediated regulation of hippocampal 11B-HSD-1 may help to ensure this protection
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of neurones. This situation is analogous to that proposed in the liver and would
explain the similarities in the patterns of glucocorticoid regulation observed in these
tissues.
11B-HSD-1 activity in the hippocampus of tree-shrews is down-regulated by
psychosocial stress to approximately 50% of control levels. In contrast, excess
Cortisol administration has no effect on levels of activity. The increase in
hippocampal 11B-HSD-1 in rats by arthritic stress appears to depend in part on an
adrenal product (Low et al., 1994c) and the induction of 11B-HSD-1 in primary rat
hippocampal cultures by dexamethasone (Rajan et al., 1995b) provides evidence for
direct glucocorticoid induction. This is supported by the presence of sequences
resembling the GRE which have been reported in both human (Tannin et al., 1991)
and rat (Moisan et al., 1992b) 11B-HSD-1 genes, and data from transfection
experiments of HepG2 cells with plasmids in which 11B-HSD-1 promoter DNA is
fused to a reporter gene suggest a GRE lies within 1800 base pairs of the
transcription start of rat 116-HSD-l (Voice et al., 1996). However, differences in the
effects of stress and of exogenous glucocorticoid administration on hippocampal
neuronal morphology have been previously observed in rats (Stein-Behrens et al.,
1994), and prolonged (28 days) psychosocial stress in tree-shrews results in an
increase in the optical density of the nucleoplasm in pyramidal neurons (indicating a
change in the chromatin structure), and a reduction in the number of branch points
and dendritic length of neurones, but no reduction in pyramidal neuron density or
evidence of histopathological changes (Fuchs et al., 1995). This is in contrast with
previous studies in rats and suggests that stress per se may exert effects on the
hippocampus via mechanisms distinct from glucocorticoids which may explain why
hippocampal damage similar to that observed in rats is not observed in humans on
long-term glucocorticoid therapy (Hall, 1990). These differential effects may
include the regulation of 118-HSD-l, such that the effects of glucocorticoids may
depend on other neuroendocrine factors (such as sympathoadrenal activity or the
expression of CRH-binding sites) which are wide open to speculation at present.
In the liver, both stress and glucocorticoid administration attenuate 11B-
HSD-1 activity, implying there is a direct negative regulation by glucocorticoids in
this tissue. The regulation in both liver and hippocampus are in agreement with the
proposed role of 11B-HSD-1 to potentiate glucocorticoid action within the tissues
where it is expressed. The lack of effect of stress or glucocorticoid regulation on
renal 11B-HSD activity again reflects the expression of 11B-HSD-2 in this organ.
Therefore the glucocorticoid regulation of 11B-HSD-1 is complicated and
tissue-specific. Presumably the pattern of regulation within a tissue reflects the
183
function of the enzyme within that tissue. Further information regarding the
regulation of 11B-HSD-1 from molecular studies on the mechanisms governing gene
transcription, coupled with studies on enzyme function, will help to aid the
understanding of these regulatory patterns.
Hippocampal 11B-HSD-1 is not sexually dimorphic in rats, nor can it be
altered with sex steroid or GH manipulations (Low et al., 1993; Low et al., 1994b),
and it was proposed that this was due to the failure of GH to cross the blood-brain-
barrier, which is impervious to most small peptides. Therefore it was a surprise to
find that 11B-HSD-1 mRNA expression was not regulated by GH in the brain. That
the GH used in this experiment was biologically active was confirmed by the
striking down-regulation of 11B-HSD-1 mRNA in the periphery (liver and kidney),
typical of the effects of continuous female-pattern GH secretion on 11B-HSD-1
expression mimicked here by the continuous ICV infusion of GH. This also suggests
that GH has crossed the blood brain barrier. This may be due to the fact that the
levels of GH achieved within the brain by this experiment are likely to be
supraphysiological, and may overcome the capacity of the blood brain barrier to
prevent passage of GH across it. Why the regulation of 118-HSD-l in brain should
be different from the periphery is not clear. It could be analogous to the situation in
the liver, where GH-mediated sexual differentiation is species-specific as discussed
above, or it may be due to the presence of subpopulations of the GH receptor (Smith
et al., 1989; Barnard et al., 1985; Stred et al., 1990). It could be due to differences in
the intracellular signalling pathways of GH action in different cells, or mediated via
the interaction of the GH signalling pathway with a variety of transcription factors
which may regulate 11B-HSD-1 and may be differentially expressed between tissues.
It could also be due to lower expression levels of the GH receptor in neurons in
comparison to hepatocytes, although some specificity of response would still be
expected.
The studies in this chapter have further characterised the hormonal regulation
of 11B-HSD-1. Some of this data is preliminary. They are suggestive rather than
conclusive of the patterns of 11B-HSD-1 regulation by these hormones, and have
emphasised the complexity of this regulation. The widely varying effects of
hormones on 11B-HSD-1 between tissues and between species make interpretation
of the data available on hormonal regulation difficult in some cases. However as the
function of the enzyme becomes better understood, the interpretation of these data





The experiments presented in this thesis were carried out in order to gain an
insight into the biological role of the enzyme, 11B-HSD-1. This was prompted by the
existence of the large body of knowledge concerning the distribution and modulation
of expression of the enzyme, but a lack of understanding regarding its biological
importance. The co-localisation of 11G-HSD-1 expression with GR in many tissues
throughout the body has led to suggestions that 11B-HSD-1 has a central role in the
regulation of corticosteroid access to GR (Moisan et al., 1990b; Teelucksingh et al.,
1990; Whorwood et al., 1991) and possibly to MR in the brain (where glucocorticoid
is the physiological ligand (McEwan et al., 1986; de Kloet, 1991; Seckl & Olsson,
1995)). Thus 11G-HSD-1 would mediate the expression of glucocorticoid functions
in tissues where it is co-localised with GR. As the highest expression of 11B-HSD-1
is in the liver (Monder & Shackleton, 1984), which is also a major target for
glucocorticoid action, the studies in this thesis concentrated predominantly on this
organ.
The experiments described in Chapter 3 were designed to examine 11B-HSD-
1 activity and expression in cell culture and addressed some fundamental aspects of
11B-HSD-1 function. The enzyme functions predominantly as a 1 lB-reductase in
intact hepatocytes. That this was relevant to intact liver was confirmed by the
examination of 11B-HSD-1 activity in the perfused liver as described in Chapter 5.
Previously, interpretation of studies on 11B-HSD-1 were based on the premise that
the enzyme activity is reversible (Agarwal et al., 1989; Monder & White, 1993), and
that different tissues may exhibit either predominantly 116-reductase activity or 11B-
dehydrogenase activity, depending on their specific requirements for low or for high
glucocorticoid levels, or, alternatively that 11B-HSD-1 was capable of rapid shifts in
reaction direction as required, in order to maintain a constant intracellular
glucocorticoid concentration in the face of fluctuations in the circulating levels of
hormone. In fact, enzyme direction in intact hepatocytes proved refractory to a wide
range of physiological and physiochemical manipulations designed to favour 11B-
dehydrogenation, and taken together with other recent studies on enzyme function in
intact cells and organs (Stewart et al., 1990; Leckie & Seckl, 1996; Hammami &
Siiteri, 1991; Brem et al., 1995; Rajan et al., 1996), it is looking increasingly likely
that 11B-HSD-1 functions largely as an 1 lB-reductase in vivo, and so we must
review our understanding of the proposed physiological actions of 11B-HSD-1.
On the basis of the evidence that hepatic 11B-HSD-1 is an 1 lB-reductase
(thus generating active glucocorticoids within the liver), I examined the possibility
that 11B-HSD-1 modulates glucocorticoid actions within the liver in the experiments
described in Chapter 4. The results point strongly towards 11B-HSD-1 activity
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playing a fundamental role in maintaining hepatic glucocorticoid-regulated
functions, in particular glucose homeostasis, as evidenced by the effects on hepatic
gene expression of metabolic enzymes whose expression is known to be
glucocorticoid-modulated. The data are also suggestive of an ability of enzyme
activity to modulate hepatic insulin sensitivity. The study by Walker et al., (1995)
demonstrating an increase in insulin sensitivity upon CBX inhibition of 116-HSD in
humans, reinforces the hypothesis that reduced intrahepatic glucocorticoid
regeneration by inhibition of 116-HSD-1 activity may increase insulin sensitivity in
vivo.
Obviously this is a target for further studies. The primary hepatocyte culture
system for study of 11B-HSD-1 described in Chapter 3 will be a useful model for
exploring these ideas. It provides a system for easy manipulation of 116-HSD-1 and
for examination of parameters of hepatic insulin sensitivity including glucose uptake
and net glycogen synthesis, as well as measurements of glucocorticoid-sensitive
gene transcription. Likewise, the liver perfusion system (Chapter 5) provides a
model in which to examine these indicators of insulin sensitivity and will permit
manipulation of physiological conditions in vivo, whilst allowing examination of the
effects of manipulations in the isolated organ of interest.
Clearly a method of down-regulation of hepatic 11B-HSD-1 or inhibition of
enzyme activity is crucial in furthering these investigations. The oestradiol
attenuation of 116-HSD-1 expression employed in the experiments in Chapter 4 is
extremely effective, but subject to criticism as E2, in common with most hormones,
has many effects on a wide range of physiological functions including regulation of
other enzymes involved in glucocorticoid metabolism (Leblanc & Waxman, 1988).
Therefore a more specific manipulation is required. At the moment, the most
effective pharmacological inhibitor of 11B-HSD-1 available is CBX. However, as
demonstrated by its poor efficacy of inhibition in intact hepatocytes and in perfused
liver, it is far from adequate in this respect, and also lacks specificity of action as it
inhibits other enzyme activities, most notably 11B-HSD-2 and 5a-reductase (Walker
& Edwards, 1994; Latif et al., 1990). Hopefully a more specific and more effective
inhibitor will be found. Other compounds are known to inhibit 11B-HSD activity,
including a number of endogenous compounds (Hierholzer et al., 1991; Biihler et al.,
1994) which may direct us towards suitable candidates.
A specific 11B-HSD-1 inhibitor would be a invaluable tool in investigations
of the enzyme's physiological role not only in liver, but in all the organs where it is
expressed. However the creation of an 11B-HSD-1 "knockout" mouse (Kotelevtsev
et al., 1996) has provided us with a model of complete enzyme inhibition. Studies
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regarding the status of these animals with respect to glucose tolerance, insulin
sensitivity and the effects of dietary and glucocorticoid manipulations upon these
functions are already in progress.
The physicochemical and hormonal manipulations of 11B-HSD-1 in
hepatocyte cultures and hormonal manipulations in vivo (Chapter 6) indicated that
alterations in the biological activity of the enzyme are probably mediated primarily
via down-regulation at the transcriptional level and not through alterations in protein
activity or degradation. This results in a slow decline in 116-HSD-l activity when it
is down-regulated as evidenced by these experiments and those of Low et al. (1993,
1994b, 1994c). Presumably this is due to the long half-life of the protein which
appears to be in the order of days. There is however, the potential for a rapid
increase in activity when transcription and hence protein synthesis is stimulated.
This coupled with the function of 116-HSD-l to generate active glucocorticoids by
its 116-reductase activity, points towards a crucial role for the enzyme in the
maintenance of glucocorticoid levels within a given tissue to above a minimum level
required for optimal tissue function. It is unlikely to be concerned with acute
adaptations to glucocorticoid excess. This is in accordance with the role, proposed
here, for hepatic 116-HSD-l to maintain glucocorticoid-regulated functions in the
liver during times of low glucocorticoid availability. The precise role of 11B-HSD-1
in the brain (and indeed in the wide variety of other tissues in which it is expressed
but which have not been considered in this thesis), is yet to be determined, but a
similar function to protect neurons from the adverse effects of relative glucocorticoid
deficiency is conceivable. The long-term stress and/or glucocorticoid-mediated
regulation of 11B-HSD-1 in liver and in hippocampus are in accordance with this
hypothesis.
The hormonal regulation of 11B-HSD-1 expression is obviously extremely
complex. It is species- and tissue-specific, and, at least in the case of hippocampal
11B-HSD-1, modulated by factors that are as yet unknown. Further understanding of
the mechanisms governing regulation of 11B-HSD-1 expression is most likely to
come from molecular studies on the cloned 11B-HSD-1 gene (Agarwal et al., 1989).
Studies on the 11B-HSD-1 promoter to identify DNA sequences required for
responses to regulatory hormones and proteins and perhaps sequences associated
with tissue-specific factors, will yield information on the regulation of the gene.
Tissue-specific intracellular messenger signalling systems could provide an
additional level of control and studies concentrating on these aspects of 11B-HSD-1
biology, alongside physiological studies both in vivo and in cell culture, will help to
further understanding of the biological functions of this enzyme.
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ABSTRACT
11/3-Hydroxysteroid dehydrogenase (11/3HSD) catalyzes the con¬
version of corticosterone to inert 11-dehydrocorticosterone, thus reg¬
ulating glucocorticoid access to intracellular receptors. The type 1
isoform (11 /3HSD-1) is a bidirectional NADP(H)-dependent enzyme in
'jitro and is highly expressed in liver, where it is regulated by glu¬
cocorticoids, thyroid hormones, estrogen, and GH in vivo. In humans
in vivo, enzyme inhibition alters glucose homeostasis, an effect
thought to be mediated in the liver. However, detailed investigation
of the biology of 11/3HSD-1 in liver, its function, regulation, and
indeed even reaction direction, has been hampered by the lack of
clonal hepatic cell lines that express 110HSD-1. Studies ofnonhepatic
cell lines have suggested that 11/3HSD-1 is directly regulated by
hormones, and transfection of nonhepatic cell lines has shown that
reaction direction varies between cell types, possibly reflecting in¬
tracellular cosubstrate (NADP+/NADPH) ratios or pH.
To investigate reaction direction and gene regulation of 11/3HSD-1
in hepatocytes, we defined conditions for primary culture of adult rat
hepatocytes that maintain high 11/3HSD-1 messenger RNA expres¬
sion. In intact primary hepatocytes over a wide range of steroid con¬
centrations (2.5-250 nM), 11/3-reduction was the predominant reac¬
tion direction [33.5 ± 0.5% conversion of 11-dehydrocorticosterone (25
nM) to corticosterone after 30 min], with undetectable 11/3-dehydro-
genation. However, homogenates ofhepatocyte cultures showed plen¬
tiful 110-dehydrogenase activity. Treatment of hepatocyte cultures
with the metabolic inhibitors sodium azide (5 mM) and KCN (1 mM)
altered cellularNADP+/NADPH ratios from 0.244 ± 0.042 in controls
to 0.020 ± 0.001 and 0.152 ± 0.009, respectively, but had no effect on
11/3-reductase or 110-dehydrogenase activity. High concentrations of
KCN (10 mM) modestly increased 11/3-reductase activity (32.4 ± 1.7%
to 48.8 ± 0.5%), whereas 11/3-dehydrogenation remained at the limit
of detection. Manipulation of culture medium pH (6.2-8.0) had no
effect on enzyme activity. Dexamethasone (1(D7 M) induced hepato¬
cyte 11/3-reductase activity from 23.4 ± 0.7% to 35.5 ± 1.5% and
11/3HSD-1 messenger RNA expression (207% rise), an action inhib¬
ited by insulin (10~7 M). GH, estradiol, and T3 had no effect.
These results demonstrate that 11/3HSD-1 functions as an 11/3-
reductase in intact rat hepatocytes in culture. The cosubstrate ratio
only weakly affects reaction direction. Glucocorticoid and insulin reg¬
ulation ofhepatic 11/3HSD-1 is directly mediated, but other hormonal
controls are either lost in culture ormediated indirectly. This primary
hepatocyte culture system will allow investigation of the control of
11/3-reductase activity and its implications for glucocorticoid-regu-
lated hepatic functions. (Endocrinology 136: 4754-4761, 1995)
The 11/3-HYDROXYSTEROID dehydrogenase (11/3HSD)catalyzes the reversible conversion of physiologically
active corticosteroids [Cortisol in humans and corticosterone
(B) in rats] to inactive 11-dehydro forms [cortisone and 11-
dehydrocorticosterone (A)], thus acting as a tissue-specific
regulator of glucocorticoid access to intracellular corticoste¬
roid receptors (1, 2). At least two distinct isoforms exist,
11/3HSD-1, originally purified from liver (3), and 11/3HSD-2,
recently characterized in kidney and placenta (4, 5). The
best-documented physiological role for 11/3HSD is found in
the distal nephron, where the enzyme ensures aldosterone-
selective access in vivo to otherwise nonspecific mineralo-
corticoid receptors by rapidly inactivating glucocorticoids (6,
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7). The isoform responsible, I1/3HSD-2, is a high affinity,
NAD-dependent, exclusive 11/3-dehydrogenase (5, 8) whose
expression is restricted to mineralocorticoid target tissues,
placenta, and a limited number of other tissues. Congenital
deficiency of this enzyme or inhibition by licorice or its de¬
rivatives allows illicit occupation of mineralocorticoid re¬
ceptors in the distal nephron by glucocorticoids, producing
sodium retention and hypertension (9, 10).
By contrast, 11/3HSD-1 is widely distributed, with the
highest levels in liver and proximal tubules of kidney [al¬
though it is absent from the distal nephron (6)], tissues that
also express high levels of glucocorticoid receptors. It has
been proposed that the role of 11/3HSD-1 is to modulate
glucocorticoid access to these sites (11-13). 11/3HSD-1 has
been purified from rat liver, antisera raised, and an encoding
complementary DNA (cDNA) isolated (3, 14, 15). The hu¬
man, monkey, sheep, and mouse homologs have also been
cloned (16-19). 11/3HSD-1 has a lower affinity for steroid
substrates (Km, 2 /am for corticosterone) than the type 2 iso¬
form, is NADP(H) dependent, and is bidirectional in tissue
homogenates and purified microsomal fractions (3). How¬
ever, transfection studies have indicated that the reaction
direction of 11/3HSD-1 varies between clonal cell types, with
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bidirectional activity in some cells [e.g. Chinese hamster
ovary cells (15)], but predominant 11/3-reduction (reactiva¬
tion of inert 11-keto metabolites) in others [e.g. TBM and
COS-7 (20, 21)]. Reaction direction has been proposed to
reflect cosubstrate (NADP+/NADPH) ratios, with NADP+
favoring 11/3-dehydrogenase activity, and NADPH favoring
11/3-reduction (22). Glycosylation status and pH have also
been implicated in the control of direction (22,23). However,
changes in glycosylation cannot explain exclusive 11 ^-re¬
duction in intact COS-7 cells transfected with 11/3HSD-1
cDNA, which nonetheless shows 11/3-dehydrogenation
when the enzyme is assayed in homogenates of the same
transfected cells (21). Clearly, cell context is crucial to the
direction of 11/3HSD-1 enzyme activity.
The reaction direction of 11/3HSD-1 in liver [which highly
expresses this isoform without detectable 11/3HSD-2 (4)] is
unknown, although indirect evidence suggests that in liver,
11 /3-reductase predominates. Thus, the effluent of perfused
cat liver has a high Cortisol to cortisone ratio (24). Moreover,
after oral administration of cortisone in humans, peripheral
plasma levels of Cortisol, but not cortisone, rise (25), sug¬
gesting that cortisone is activated by 11 /3-reductase on its first
pass through the liver. However, the reaction direction of
11/3HSD-1 in hepatocytes has not been directly addressed.
11/3HSD-1 is regulated in vivo by various hormones, in¬
cluding glucocorticoids, insulin, thyroid hormone (T3), GH,
and sex steroids, in a tissue- and developmentally specific
manner. Hepatic 11/3HSD-1 is sexually dimorphic in rats,
with females showing lower activity than males (26,27). This
is due to suppression of activity in the female by estradiol
(E2), an effect largelymediated indirectly via the effects of sex
steroids on the pattern of pituitary GH secretion (26-28). In
rat liver and cultured human skin fibroblasts, glucocorticoids
up-regulate enzyme activity, an effect that may be antago¬
nized by insulin, at least in cultured fibroblasts (29, 30).
Thyroid hormone has been reported to decrease enzyme
activity in rat liver, whereas thyroidectomy increases activity
in female rat liver, but decreases it in that of the male rat (31,
32). Whether any of these hormonal effects are mediated
directly upon hepatocytes remains unknown, and such stud¬
ies have been hampered by the absence of liver-derived
clonal cell systems that express 11/3HSD-1.
The aims of this study were, therefore, 1) to establish
primary hepatocyte cell cultures optimal for themaintenance
of 11/3HSD-1 activity and messenger RNA (mRNA) expres¬
sion, 2) to determine whether the direction of 11|3HSD-1
enzyme activity in hepatocytes can be manipulated by al¬
terations in NADP/NADPH ratios or pH, and 3) to examine
the hormonal regulation of 11/3HSD-1 in cell culture.
Materials and Methods
Hepatocyte isolation
Male Han Wistar rats were anesthetized with pentabarbitone (60
mg/kg), and their livers were perfused in situ with collagenase, essen¬
tially as described by Seglen (33). The liver was perfused in situ with a
calcium-free buffer, followed by a solution containing 0.0275% collag¬
enase type IV (Sigma Chemical Co., Poole, UK) in 5 mM CaCl2, 30 ium
HEPES, 10 mM glucose, 0.05% KC1, 0.001% phenol red, and 0.9% NaCl.
The dissociated liver was removed, and hepatocytes were isolated by
filtration through a 60-pm filtermesh. Parenchymal cells were separated
from nonparenchymal and dead hepatocytes by repeated low speed
centrifugation. Yields of 5-10 X 10s cells/liver with 70-75% viability, as
determined by trypan blue exclusion, were routinely obtained.
Cell culture conditions and hormonal manipulations
Hepatocytes were plated on dishes coated with Matrigel (Collabo¬
rative Biomedical Products, Bedford, MA) in Dulbecco's Modified Ea¬
gle's Medium-Ham's F-12 medium (GIBCO, Paisley, UK) containing 5%;
Nu-serum (Collaborative Biomedical Products), 100U/ml penicillin, 100
pg/ml streptomycin, 200 mM i-glutamine, 25 yu-g/ml gentamycin sul¬
fate, 0.7 pg/ml amphotericin B (all from GIBCO), 5 pg/ml insulin
(Sigma), and 0.1 pM dexamethasone (Sigma). Cells were plated at a
density of 1 X 106/35-mm dish in 2 ml medium (for 11/3HSD assays) or
3 X 106 ceIls/60-mm dish in 4 ml medium (for NADP+/NADPH quan¬
titation). The medium was replaced every 24 h after cells were placed
in culture. Cultures weremaintained at 37 C in a humidified atmosphere
containing 5% C02 and 95% air. Test hormones or antagonists were
added to hepatocytes in freshmedium 48 h after plating at the following
concentrations; E2,10~8 m (Sigma); T3,10~8 m (Sigma); GH, 0.05 IU/ml
(Eli Lilly Co., Basingstoke, UK); RU38486, 10~6 m (gift from Roussel-
UCLAF, Romaineville, France); and tamoxifen, 10~6 M (Sigma). In some
experiments, 48 h after being placed into culture hepatocytes were
transferred to medium containing charcoal-stripped Nu-serum, pre¬
pared as previously described (34), and analyzed for steroid hormones
to check the efficiency of the procedure. Stripping reduced Nu-serum
levels of Cortisol, E2, progesterone, T3, and T4 to below detection limits.
Cells were cultured in medium containing stripped Nu-serum supple¬
mented with dexamethasone (10~7 m) reflecting the level of glucocor¬
ticoid in control medium, insulin (1.3 X 10~7 m), and hormones, as
described above, where stated. The medium was changed daily, and
fresh hormones were added. All hormones were added to the medium
at a concentration chosen to be close to physiological levels, and an¬
tagonists were employed at concentrations sufficient to block the effects
of the hormone present. Twelve days after the addition of hormones, the
cells were harvested for mRNA extraction.
Quantitation of llfiHSD activity
In intact cells. Cells were first assayed for enzyme activity 48 h after being
placed into culture and then every 3-4 days thereafter. Medium was
aspirated and replaced by 2ml fresh medium containing 2 nM [3H]B (SA,
84 Ci/mmol; Amersham International, Aylesbury, UK) and a quantity
of unlabeled B appropriate for the concentration of B required or 2 nM
[3H]A made as previously described (4), and unlabeled A as required.
In most experiments, 23 nM unlabeled A or B was added to the medium,
giving a final concentration of 25 nM A or B. This concentration was
chosen as to reflect moderate to high physiological free steroid levels.
[3H]A was at least 97% pure, as estimated by HPLC, and was resus-
pended to give the same specific activity as [3H]B. In most experiments,
1-ml aliquots of medium were removed from the culture medium after
30 and 60 min of incubation. In the experiment shown in Fig. 3b, the
determination of product formation with time, 100-pl aliquots of me¬
dium containing 25 nM [3H]B or 25 nM [3H]A were removed after 15,30,
60, 90, and 120 min incubation. Steroids were extracted with ethyl
acetate, dried, resuspended in ethanol, separated by TLC, and estimated
by scintillation counting. Enzyme activity in each direction was ex¬
pressed as the percent conversion to product. Cells were washed twice
in fresh medium after each assay. Assays were repeated at intervals from
4 h to 28 days after plating.
In cell homogenates. Seven days after being placed in culture, cells were
harvested from culture dishes by dissolution ofMatrigel basementmem¬
brane. One milliliter of CR-Dispase (Collaborative Biomedical Products)
was added to each 35-mm culture dish after aspiration of the medium
and incubated for 2 h at 37 C to yield a cell suspension. Cells were
sedimented by centrifugation at 50 X g for 2 min, and the supernatant
was discarded. The pellet was resuspended in 100 pi TM Triton [0.1%
Triton X-100 in 20 mM Tris-HCl (pH 7.5), and 2 mM MgCl2], and the total
protein concentration of the suspension was estimated colorimetrically
(Bio-Rad protein assay kit, Hemel Hampstead, UK). Twenty-five mi¬
crograms of cell homogenate were incubated with 200 p.M NADP and
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12 ran [3H]B or with 200 p.m NADPH and 12 nM [3H]A in a total volume
of 250 yu.1 with Krebs-Ringer buffer supplemented with 0.2% glucose and
0.2% BSA for 10 or 60 min at 37 C. Steroids were extracted with ethyl
acetate and separated by HPLC. Enzyme activity in each direction was
expressed as the percent conversion to product.
Metabolic inhibition and pH manipulation
Medium was aspirated and replaced with fresh medium containing
5 mm sodium azide (Sigma) or KCN (Aldrich, Gillingham, UK) at either
1 or 10 mm or with medium of the appropriate pH. The concentrations
of metabolic poisons employed are well recognized to cause inhibition
of oxidative phosphorylation in cell culture systems. For pH manipu¬
lations, medium with the appropriate pH was prepared by adjustment
of the quantity of sodium bicarbonate (GIBCO) added to the medium
upon preparation or by addition of HC1 to achieve a medium of pH 6.2.
Cells were preincubated for 4 h before assaying 11/3HSD activity, as
described above, or quantitation of NADP+/NADPH.
NADP+ and NADPH extraction and quantitation
Quantitation of NADP+ and NADPH was carried out according to
the enzymatic cycling method, as described by Blomquist and Hakanson
(35). For NADP+, cells were harvested in 1.5 ml ice-cold 500 mm per¬
chloric acid, sonicated for 4 min on ice, left on ice for 15 min, and pelleted
(5000 rpm; 10 min). For NADPH, cells were harvested in 1.5 ml 250 mM
sodium hydroxide, heated to 60 C for 5 min, and centrifuged. Bicine (0.3
ml 1 m; Sigma), pH 8, was added to the supernatant of each sample and
titrated to pH 8. Reagent blank (100 mm bicine, pH 8), standard, or
sample was added to 1.0 ml cycling reagent (10 mm isocitric acid, 10 mm
magnesium chloride, 500 jum dithiothreitol, 2mm phenazine ethosulfate,
and 1.0 g/liter BSA in 100 mm bicine, pH 8). Cycling was started by the
addition of 0.2 ml isocitrate dehydrogenase (1.25mg protein/ml; Sigma).
Samples were incubated at room temperature in the dark for 60 min,
absorbance at 570 nm was measured, and NADP+ and NADPH were
estimated from standard curves. Standards were 0.5-2.5 x 10~7 m
NADP+ or NADPH in 100 mm bicine, pH 8. The detection limit was 1
x 1CT8 m for both NADP and NADPH.
Extraction and analysis of mRNA
mRNA was extracted from freshly isolated (uncultured) hepatocytes
and from hepatocytes at varying time points after being placed into
culture. Cells were harvested from culture dishes as described above,
and total RNA was extracted from cells by the guanidinium thiocyanate
method, as described by Chomczynski and Sacchi (36), and separated on
a 1.2% agarose gel containing 2% formaldehyde. RNA was blotted onto
nitrocellulose membranes (Hybond-N, Amersham International); pre-
hybridized in 6 ml phosphate buffer (0.2 m NaH2P04, 0.6 m Na2HP04,
and 5 mm EDTA), 3 ml 20% sodium dodecyl sulfate (SDS), and 100 pg
denatured herring testicularDNA (Sigma) for 2 h at 55 C; and hybridized
at 55 C overnight in the same solution containing rat 11/3HSD-1 cDNA
labeled with [ P]deoxy-CTP using a random primed DNA labeling kit
(Boehringer Mannheim UK, Lewes, UK). Three 20-min washes were
carried out at room temperature in 1 x SSC (0.3 m NaCI and 0.03 m
sodium citrate)-0.1% SDS followed by a stringentwash at 55 C for 30 min
in 0.3 x SSC-0.1% SDS. Filters were exposed to autoradiographic film for
1-4 days (adjusted to ensure that the signal density was within the linear
1113-HSD-1
range). Filters were rehybridized with similarly labeled 7S RNA cDNA
probes to control for loading, as previously described (27, 28). Optical
density was determined using a computer-driven image analysis system
(Seescan, Cambs, UK).
Statistics
Experimental points are the mean ± sem of three to seven replicates
from the same culture preparation or different cultures, as indicated in
the figure legends. Data were compared by analysis of variance and
Newman-Keuls post-hoc tests, as appropriate. Significance was set at P
< 0.05. Data are the mean ± sem.
Results
Measurement of enzyme direction and maintenance of
11 filiSD activity
In preliminary experiments, most cell culture conditions,
using several different media and either plastic culture
dishes or collagen-coated dishes, were associated with either
variable cell viability or the loss of 11/3HSD-1 activity and
mRNA expression from otherwise viable primary hepato-
cyte cultures (data not shown). However, maintenance of
11/3HSD-1 mRNA expression over an extended period of
time up to 35 days was achieved by culturing hepatocytes on
Matrigel (a gel matrix extracted from the Englebreth-Holm-
Swarmmouse tumor; Fig. 1 and data not shown). Toward the
end of this time, some cell loss became apparent. Measure¬
ment of enzyme activity in intact cells over this time dem¬
onstrated that the predominant reaction direction was 11/3-
reduction (Fig. 2). This held over a wide range of
physiologically relevant substrate concentrations (Fig. 3a).
Product formation was linear with incubation time over at
least 1 h (Fig. 3b). 11 /3-Dehydrogenase activity was below the
limit of detection, except for low levels over the first 2-3 days
after plating and after cells had been cultured for more than
28 days (Fig. 2). At both of these time points, but not during
the intervening period, dead and dying cells were present.
Measurement of 11/3HSD activity in cell homogenates
demonstrated that 11 /3-dehydrogenase activity (conver¬
sion of B to A) is readily detectable under these conditions,
with 53.9 ± 0.1% and 93.2 ± 2.4% conversion after 10 and
60 min of incubation, respectively. In contrast, 11/3-reduc-
tase activity (conversion of B to A) appeared to be unstable
in homogenates, as previously documented (27), and was
undetectable after 60 min of incubation.
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Fig. 1. 11/3HSD-1 mRNA expression in primary hepatocyte cultures. Autoradiograph of a representative Northern blot of RNA from freshly
isolated hepatocytes (0 days) and from hepatocytes maintained for up to 14 days in culture, probed with 11/3HSD-1 and 7S RNA cDNAs.
Replicates represent RNA extracted from hepatocytes from separate culture dishes from the same culture preparation. All samples were
electrophoresed on a single Northern gel and treated identically thereafter, and are typical of results obtained from several different culture
preparations.
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Fig. 2. 11/3HSD-1 activity in primary hepatocyte cultures. Hepato-
cytes were plated onMatrigel basementmembranematrix and main¬
tained in Dulbecco's Modified Eagle's Medium-Ham's F-12 medium
with 5% Nu-serum for up to 35 days. 11/3HSD-1 activity was mea¬
sured at intervals. Activity is expressed as the percent conversion
(±sem) ofA to B (11/3-reductase) or B toA (11/3-dehydrogenase) in the
medium overlying the cells after 60 min (n = 2-6). Results are from
three separate culture preparations.
Effect of alteration of intracellular cosubstrate ratio on
lipHSD-l reaction direction in primary hepatocytes in
culture
Treatment of 3-day-old hepatocyte cultures with sodium
azide (5 mm) or KCN (1 mm) did not alter 11/3HSD activity
or direction. Indeed, 11 ^-dehydrogenase activity had a ten¬
dency to fall below detectable limits with both azide and
cyanide treatment. Increasing the KCN to 10 mm increased
llj3-reductase activity, whereas 11/3-dehydrogenation was
undetectable (Fig. 4).
To ascertain that azide and cyanide had altered intracel¬
lular cosubstrate ratios in hepatocytes, NADP+ and NADPH
concentrations were measured after 4-h incubation with ei¬
ther KCN or sodium azide. KCN (1 mm) decreased NADP+
levels compared with those in extracts from untreated cells,
and 5 mm azide decreased NADP+ to levels below the de¬
tection limit (<1 x 10~8 m), demonstrating that the metabolic
inhibitors significantly depleted NADP+ availability, but
had no effect onNADPH levels within the hepatocytes at the
concentrations used (Fig. 5a). This represents a large alter¬
ation in the intracellular cosubstrate ratio (Fig. 5b).
Effect ofpH on reaction direction of llfSHSD-1 in
hepatocytes in culture
11/3HSD activity was measured in primary hepatocytes
cultured in medium adjusted to pH 6.2, pH 7.4, or pH 8.0.
Neither 11/3-reductase activity (conversion of A to B in 30
min) nor 11/3-dehydrogenase activity (conversion of B to A
in 30 min) was altered (Fig. 6).
Hormonal regulation of 11 fiHSD-1 in hepatocytes in culture
11/3-Reductase activity of 11/3HSD-1 was measured in pri¬
mary hepatocytes cultured in the presence of E2, GH, T3, or
a combination of hormones; activity was measured every 3





Fig. 3. 11/3HSD-1 is a predominant reductase in intact hepatocytes.
a, 11/3HSD-1 activity was measured in hepatocytes over a range of
substrate concentrations. Activity is expressed as the percent con¬
version ofA to B (11/3-reductase) or B toA (11/3-dehydrogenase) in the
medium overlying the cells after 30 min (n = 3). b, Conversion of
substrate to product by 11/3HSD-1 activity was measured over a time
course of 120 min. Activity is expressed as the percent conversion of
A to B (11/3-reductase) or B to A (11/3-dehydrogenase) in the medium
overlying the cells.
was observed at any time in cells exposed to 10~8 m E2, 0.05
IU/ml GH, 10~8 m T3, or a combination of E2 and GH (Fig.
7). T3 also did not alter 11/3HSD-1 mRNA expression after 12
days (data not shown). In case the effects of hormones were
obscured by high endogenous levels in the culture medium,
the effects of the estrogen receptor antagonist tamoxifen and
the glucocorticoid receptor antagonist RU38486 (mifepris¬
tone) were examined. Neither antagonist had a consistent
effect on 11/3HSD activity in cultured hepatocytes (either
11/3-reductase or dehydrogenase activities) over 12 days
(data not shown), although there was a trend for RU38486 to
reduce 11/3-reductase activity (not shown).
To examine further the effects of glucocorticoid and in¬
sulin on 11/3HSD-1 activity in hepatocytes, Nu-serum was
charcoal stripped to remove endogenous steroids and small
peptides before addition to the medium (insulin levels were
decreased >5000-fold, and Cortisol became undetectable).
11/3HSD activity was decreased by charcoal stripping of the
Nu-serum from 31.2 ± 3.0% to 23.4 ± 0.7% conversion of A
toB. Dexamethasone (10~7m) and insulin (1.3 x 10~7m)were
added to medium containing the stripped serum, singly and
in combination, to concentrations reflecting those in the stan-





















Fig. 4. Effects of metabolic inhibitors on 11/3HSD-1 activity in hep-
itocyte cultures. Hepatocytes were incubated for 4 h with 5 mM
sodium azide, 1 mM KCN, or 10 mM KCN before 11/3HSD-1 activity
was measured. Values are expressed as the percent conversion of A
to B (llj3-reductase) or B to A (11/3-dehydrogenase) after 30 min (n =
7 for 5 mM azide and 1 mM KCN; n = 3 for 10 mM KCN). *, P < 0.05
ds. control. Results are from three separate culture preparations.
dard maintenance medium. Dexamethasone increased both
11/3HSD activity and 11/3HSD-1 mRNA expression, whereas
insulin decreased 11/3HSD-1 mRNA expression, although
enzyme activity was not significantly altered over the 12-day
period. Insulin also antagonized the increase in 11/3HSD-1
mRNA by dexamethasone when the hormones were added
in combination (Fig. 8). Where effects of hormones or an¬
tagonists in the standard maintenance medium were not
significant but suggested a trend, the experiments were re¬
peated in medium containing charcoal-stripped serum. T3
again had no significant effect in medium containing
stripped Nu-serum (data not shown).
Discussion
We have developed primary rat hepatocyte cultures that
maintain 11 /3HSD-1 gene expression for several weeks. These
cells show exclusively 11/3-reductase activity over a wide
range of substrate concentrations. Reaction direction is little
affected by alterations in the intracellular NADP/NADPH
ratio or pH. 11/3-Reductase activity is increased by dexa¬
methasone, an effect antagonized by insulin, but no direct
effects of estrogen, T3, or GH were detected. These data are
evidence for the predominance of the 11 /3-reductase activity
of 11/3HSD-1 in the intact liver and indicate that unknown
factors, presumably related to cell type and possibly intra¬
cellular localization, determine the predominant reaction di¬
rection of 11/3HSD-1 in vivo.
Most cell culture conditions are associated with the rapid
loss of differentiated functions in primary hepatocyte cul¬
tures (37, 38), including the loss of 11/3HSD-1 mRNA
expression and enzyme activity. Presumably, when hepa¬




















Fig. 5. Effect of metabolic inhibitors on NADP+/NADPH levels (a)
and NADP+/NADPH ratios (b) in hepatocyte cultures. Hepatocytes
were incubated for 4 h with 5 mM sodium azide or 1 mM KCN before
extraction and quantitation of NADP+ and NADPH by enzymatic
cycling. Values are expressed as the concentration of cosubstrate (a)
and the NADP+/NADPH ratio (b) in sample extract. *, P < 0.05 vs.
control.
ferentiated functions and begin to divide, a process per¬
haps akin to hepatic "regeneration" (39, 40). Maintenance
on a gel matrix in medium containing high levels of glu¬
cocorticoids, insulin, and other peptides, presumably
more closely resembles the milieu of the intact liver and its
portal circulation and, thus, allows isolated cells to main¬
tain differentiated functions, including expression of
11/3HSD-1.
11 /3-Reduction is the primary activity of 11/3HSD-1 in
intact hepatocytes, with 11/3-dehydrogenase activity unde¬
tectable or barely detectable. Likewise, intactCOS7 cells tran¬
siently transfected with 11/3HSD-1 cDNA show only
llj3-reduction. However, in homogenates of liver, primary
cultures of hepatocytes, or 11 /3HSD-1 -transfected COS7 cells,
11/3-dehydrogenase activity is readily detectable (21, 26, 27).
In contrast, intact Chinese hamster ovary cells transiently
transfected with 11/3HSD-1 cDNA show both dehydrogena-
tion and reduction (15). The determination of enzyme direc¬
tion in vivo is unlikely to be due to glycosylation or other
posttranslational modifications, as 11/3-dehydrogenase ac¬
tivity in all cases is readily detectable in homogenates,












Fig. 6. Effect of pH on 11/3HSD-1 activity in hepatocyte cultures.
Hepatocytes were incubated with culture medium of pH 6.2, pH 7.4,
or pH 8.0 for 4 h before 11/3HSD-1 activity was measured. Values are
expressed as the percent conversion ofA to B (11/3-reductase) or B to
A (llj3-dehydrogenase) after 30 min.
Fig. 7. Effects ofaddition ofE2, GH, and T3 to hepatocyte cultures on
11/3HSD-1 activity. Hepatocytes were maintained in medium with E2
(10~8 m), GH (0.05 IU/ml), or T3 (1CTS m) added. Activity was mea¬
sured after 12 days. Values are expressed as the percent conversion
of A to B (11/3-reductase) after 30 min. Results are from two (T3) or
three (GH and E2) separate culture preparations.
whereas the equilibrium shifts to favor reduction in most
intact cells (this work and Refs. 15 and 21). Therefore, the
direction in vivo is likely to reflect some aspect of the cellular
environment of the protein. In principle, cosubstrate avail¬
ability might determine reaction direction, as indeed it does
in homogenates, with NADP+ favoring dehydrogenation
and NADPH favoring reduction. Although treatment with
very high concentrations of cyanide (10 mm) did increase
11/3-reductase activity, in keeping with the theory that a
relative increase in NADPH will favor 11 /^-reduction, the
large changes in NADP+/NADPH ratios achieved with the
metabolic poisons used here had remarkably little effect on
reaction direction. These data suggest that neither the ratio
of NADP+/NADPH nor the availability of NADP' deter¬
mines the reaction direction in vivo (23). However, it remains
to be determined whether limiting the availability of
NADPH, particularly in the specific subcompartment con¬
taining 11/3HSD-1, could shift the reaction direction in intact
cells toward 11/3-dehydrogenation. Similarly, although in













Fig. 8. Regulation of 11/3-OHSD-l activity (a) and mRNA expressior
(b) in hepatocyte cultures by dexamethasone and insulin. Hepatocytes
were maintained in standard medium (5% Nu-serum) or mediuir
containing 5% charcoal-stripped Nu-serum to which dexamethasone
(10"7m) and/or insulin (1.3 x 10~7m) were added. Activity and mRNil
were quantified after 12 days. Activity is expressed as the percent
conversion of A to B (11/3-reductase) after 30 min. mRNA levels are
expressed as a percentage of control levels normalized for loading. *
P < 0.05 vs. control; t, P < 0.05 vs. dexamethasone.
11/3HSD-1 [reduction is favored at acid pH and dehydroge¬
nation at alkaline pH in vitro (22)], there was no alteration ir
enzyme direction or activity in intact hepatocytes over I
range of extracellular pH values. Thus, it is unlikely thai
variations in pH determine 11/3HSD-1 reaction direction
although it remains possible that within a subcellular com¬
partment pH may be very different from that within the eel
as a whole. 11/3HSD-1 is a membrane-associated protein thai
shows a microsomal location (1); 11/3HSD-2, which is ar
exclusive dehydrogenase, is also a membrane-associatec
protein, but shows a different intracellular distribution tc
11/3HSD-1 (4). The key determinants of reaction directior
probably reflect more than the mere presence of membrane
(as this is also present in homogenates) and may be con¬
trolled by the suborganelle microenvironment generated, foi
example, by neighboring enzymes. The precise intracellulai
localization of both isoforms of 11/3HSD awaits the devel¬
opment of highly specific antisera suitable for electron mi¬
croscopic studies.
Previous studies have shown that 11/3HSD-1 is sexualty
dimorphic in the liver, with lower levels in females thar
males. E2 markedly attenuates hepatic 11/3HSD-1 activity
and mRNA expression in vivo, an effect that is in part me¬
diated by GH (28). In primary hepatocyte cultures, neither E;
nor GH affected 11/3HSD-1 enzyme activity. The failure o
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GH to regulate 11/3HSD-1 in primary hepatocytes in culture
might reflect an indirect mechanism of action or may be due
to a reduction in the number of GH receptors on the cells in
culture. The absence of effects of E2 and T3 presumably
reflects the indirect nature of their effects on hepatic
11 /3HSD-1, as loss of their receptors is unlikely, and these
receptors act directly on target DNA. Although, sequences
resembling estrogen or thyroid hormone response elements
are found within the 11/3HSD-1 gene promoter (41), the data
presented here support in vivo evidence that the regulation
of 11/3HSD-1 expression by sex steroids, and presumably
thyroid hormones, is mediated indirectly. Indeed, the latter
contention is supported by the sexually dimorphic effects of
thyroid hormones on rat liver, with thyroidectomy increas¬
ing 11/3HSD activity in females, but decreasing activity in
males (31).
In contrast, dexamethasone and insulin clearly regulate
11/3HSD-1 in hepatocyte cultures. Previous studies have
shown that adrenalectomy of rats attenuates hepatic 11 /3ITSD
enzyme activity as well as reactivation of cortisone to Cortisol
(presumably mediated by hepatic 11/3HSD-1); administra¬
tion of glucocorticoids to adrenalectomized rats increased
hepatic 11/3HSD-1 activity and mRNA (29). This appears to
be a direct effect on hepatocytes, as dexamethasone increased
11/3HSD-1 activity and mRNA expression in hepatocyte cul¬
tures. The molecular mechanism is unknown, but prelimi¬
nary data from transfection experiments of HepG2 cells with
plasmids in which 11/3HSD-1 promoter DNA is fused to a
reporter gene suggest that a glucocorticoid response element
lies within 3700 base pairs of the transcription start of
11/3HSD-1 (Chapman, K. E., M. Voice, R. Wallace, and V.
Lyons, unpublished data). The antagonism by insulin of dex-
amethasone-induced 11/3HSD-1 activity and mRNA expres¬
sion in cultured hepatocytes reflects similar regulation in
cultures of human fibroblasts (30). Many key metabolic en¬
zymes in the liver are antagonistically regulated by insulin
and glucocorticoids, and the data presented here suggest that
similar controls apply to hepatic 11/3HSD-1.
Intriguingly, many hepatic enzymes involved in carbohy¬
drate and fat metabolism are controlled by glucocorticoids,
including phosphoenolpyruvate carboxykinase, the rate-lim¬
iting enzyme in gluconeogenesis. 11/3-Reduction of A or cor¬
tisone in liver will increase local concentrations of active
glucocorticoids, potentiating glucocorticoid action regard¬
less of circulating Cortisol or B levels (the latter will be de¬
termined by the activity of the hypothalamic-pituitary-ad-
renal axis). In this regard, it is interesting that Cortisol shows
a pronounced diurnal variation, whereas cortisone levels
vary little and are similar to free Cortisol concentrations (25).
Thus, activation of inert cortisone or A may allow hepato¬
cytes to maintain crucial glucocorticoid-regulated metabolic
functions during the daily Cortisol nadir. The implications of
abnormal 11/3-reductase activity for disease are unknown,
but in principle, excess activity may increase gluconeogen¬
esis and attenuate insulin sensitivity, producing insulin re¬
sistance/noninsulin-dependent diabetes mellitus. Indeed,
recent data suggest that 11 /3HSD inhibitors increase central
(hepatic) insulin sensitivity in humans, presumably by at¬
tenuating glucocorticoid regeneration in the liver (42). The
primary hepatocyte system described here will assist further
examination of these ideas.
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